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ABSTRACT 
Magnetic nanocarriers are widely explored for improved treatment of diseases like cancer. 
Their magnetic properties allow for magnetic targeting upon external magnetic field 
exposure, and in parallel, the nanocarriers can be monitored non-invasively in vivo via 
magnetic resonance imaging (MRI). 
Nanocarrier formulations can be tailored regarding application-specific needs. In pre-clinical 
studies, various viral and non-viral vector systems were already successfully functionalized 
with target tissue-specific binding moieties, and (co-)loaded with for example nucleic acids or 
chemotherapeutic drugs. Such active targeting approaches, and the stabilizing and shielding 
properties of assembled and functionalized complexes help to overcome low delivery rates 
and reduce unspecific cell uptake compared to conventional therapies. 
 
Nanocarrier systems examined in this study were magnetic complexes with oncolytic 
viruses, magnetic small interfering ribonucleic acid (siRNA) complexes, and magnetic 
liposomes. 
Core component of all investigated nanocarrier formulations were selected core-shell type 
magnetic nanoparticles (MNPs). The MNPs assembled with virus particles and siRNA were 
cationic, the MNPs encapsulated in the magnetic liposomes anionic, enabling electrostatic 
interactions. 
The different magnetic nanocarrier formulations were analyzed regarding their physico-
chemical properties such as hydrodynamic diameter, electrokinetic (or zeta) potential, 
magnetophoretic mobility (magnetic responsiveness) and the stability in the presence of 
serum. In all regards, they were comparable to formulations presented by other groups. 
 
Transmission electron microscopy (TEM) was used to elucidate the structure of magnetic 
viral complexes and their intracellular compartmentalization. We proved the assumed 
layering of MNPs around the virus particles as well as endosomal cell uptake. Based on 
promising oncolytic potential in vitro, especially in the presence of serum and an external 
magnetic field, we tested the viral complexes in a proof-of-principle in vivo study in a rodent 
model and could show successful magnetic targeting within an orthotopic tumor lesion and 
efficient virus replication. 
With regard to clinical application of such formulations and to identify the influence of 
compartmentalization on the MRI contrast properties quantitatively, MNPs and magnetic 
complexes were examined in vitro using tissue-mimicking agarose gel phantoms. The 
chosen MNPs possessed high r2 und r2* relaxivities, and could be detected over the liver-
mimicking background even at very low concentrations of 1 µM iron (104 cells labeled at 5 pg 
Fe/cell) with field-independent (1.5 T and 3.0 T) linear dependency of relaxation rate and 
iron concentration. 
 
  XV 
Self-assemblies of siRNA and MNPs were analyzed in a proof-of-concept gene-silencing 
set-up. Gastro-intestinal cancer cell lines were stably transduced with a luciferase-GFP 
construct as reporter genes and their down-regulation after magnetofection with magnetic 
complexes carrying anti-luciferase or anti-GFP siRNA was validated. 
On this basis, in future approaches, such siRNA complexes could be used for the knock-
down of for example oncogenes. 
 
In in vitro experiments such as cell labeling and cell viability evaluation, the MNPs chosen 
for liposome synthesis performed well. To attest their biocompatibility, we evaluated the 
toxicity of the MNPs in vivo in mice. No negative changes hindering further approaches 
could be detected. 
Hence, we assessed different liposome synthesis protocols and compared the resulting 
magnetic liposomes regarding their physico-chemical characteristics. Thin film hydration and 
injection method emerged as methods of choice. First in vivo experiments in wildtype and 
tumor-bearing mice demonstrated the capability of magnetic targeting and provided a 
biodistribution profile with no pathologic alterations due to accumulated liposomes. 
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ZUSAMMENFASSUNG 
Magnetische Nanocarrier sind seit einiger Zeit im Fokus der Forschung, da sie die Lieferung 
von therapeutischen Formulierungen in ein Zielgewebe verbessern können. Ihre 
magnetischen Eigenschaften ermöglichen magnetisches Targeting, sobald ein externes 
Magnetfeld angelegt wird. Gleichzeitig kann der Weg der Nanocarrier in vivo nicht-invasiv 
mittels Magnetresonanztomographie (MRT) verfolgt werden. 
Durch anwendungs-spezifische Modifizierungen können solche Nanocarrier-Formulierungen 
maßgeschneidert werden. Zahlreiche virale und nicht-virale Vektorsysteme wurden in 
präklinischen Studien bereits erfolgreich mit Zielstruktur-spezifischen Bindungsmolekülen 
versehen, und konnten zum Beispiel mit Nukleinsäuren oder Chemotherapeutika beladen 
werden. Ziel solcher aktiven Targeting-Ansätze ist es, die Konzentration der Formulierung 
am Zielgewebe zu erhöhen. Gleichzeitig können so im Vergleich zu konventionellen 
Therapien auch Nebenwirkungen durch unspezifische Aufnahme in Nicht-Zielstrukturen 
verringert werden, auch durch den stabilisierenden und abschirmenden Einfluss der 
Komplex-Bildung. 
 
Die in dieser Studie untersuchten Nanocarrier-Formulierungen waren Magnetpartikel-
Komplexe mit onkolytischen Viren und kleinen eingreifenden (small interfering) 
Ribonukleinsäuren (siRNA), sowie magnetische Liposomen. 
Essentieller Bestandteil aller Formulierungen waren ausgewählte magnetische Kern-Hülle 
Nanopartikel (magnetic nanoparticles MNPs). Die MNPs in den Komplexen mit 
Viruspartikeln und siRNA waren positiv, die in den magnetischen Liposomen negativ 
geladen, das erlaubte die Ausbildung elektrostatischer Wechselwirkungen. 
Die verschiedenen magnetischen Nanocarrier-Formulierungen wurden bezüglich ihrer 
physikalisch-chemischen Eigenschaften wie den hydrodynamischen Durchmessern und 
elektrokinetischen (oder zeta) Potentialen, der magnetophoretischen Mobilität, und der 
Stabilität in Anwesenheit von Serum untersucht. Hierbei zeigten sie vergleichbare 
Eigenschaften wie die Formulierungen anderer Gruppen. 
 
Mittels Transmissions-Elektronenmikroskopie (TEM) wurde die Struktur sowie die 
intrazelluläre Kompartmentalisierung der magnetischen Viruskomplexe untersucht. So 
konnte die Umhüllung der Viruspartikel mit Schichten von MNPs und ihre intrazelluläre 
Akkumulation in Endosomen bestätigt werden. In vitro wiesen sich die Komplexe durch ein 
hohes onkolytisches Potential aus, besonders in der Anwesenheit von Serum und externem 
magnetischen Feld. Daraufhin wurde eine Proof-of-Principle-Studie in vivo in einem 
Nagermodell durchgeführt, und das erfolgreiche magnetische Targeting innerhalb einer 
orthotopen Tumorläsion, sowie die anschließende effiziente Virusreplikation gezeigt. 
Im Hinblick auf die diagnostische Anwendung und um den Einfluss der 
Kompartmentalisierung auf MRT-Kontrasteigenschaften quantitativ zu untersuchen, wurden 
die MNPs und ihre Komplexe in vitro in gewebeähnlichen Agarosegel-Phantomen 
untersucht. Die untersuchten MNPs wiesen hohe r2 und r2* Relaxivitäten auf, und die 
Nachweisgrenze in diesen Lebergewebe-nachahmenden Phantomen lag bei unter 1 µM 
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Eisen (104 Zellen markiert mit 5 pg Fe/Zelle). Die lineare Abhängigkeit von Relaxationsrate 
und Eisenkonzentration war dabei Feldstärken-unabhängig (1.5 und 3.0 T). 
 
In einem Proof-of-Concept-Ansatz wurden selbst-assemblierte MNP-siRNA-Komplexe für 
die Anwendung im Gene-Silencing, der gezielten Abschaltung einzelner Gene, untersucht. 
Gastro-intestinale Zelllinien wurden zunächst mit einem Luciferase-GFP-Konstrukt als 
Reportergene stabil transduziert, um anschließend durch deren Herunter-Regulation die 
erfolgreiche Magnetofection mit anti-Luciferase- oder anti-GFP-siRNA-beladenen 
magnetischen Komplexen nachzuweisen. 
Auf dieser Basis können in zukünftigen Ansätzen solche siRNA-Komplexe zum Beispiel 
genutzt werden für das gezielte Abschalten von Onkogenen. 
 
In in vitro Versuchen wie Zellmarkierung und Vitalitätsprüfung zeigten die ausgewählten 
MNPs gute Ergebnisse. Um auch ihre Biokompatibilität zu bestätigen, wurden sie in vivo in 
Mäusen auf ihre Toxizität hin untersucht und es konnten keine negativen Auswirkungen 
festgestellt werden. 
Daraufhin wurde die MNPs in verschiedenen Liposom-Synthese-Protokollen verwendet und 
diese bezüglich ihrer physikalisch-chemischen Eigenschaften untersucht. Auf dieser Basis 
wurden die Dünnschicht-Hydrierung (thin film hydration) und eine Injektionsmethode als 
Methoden der Wahl ausgewählt. In ersten in vivo Experimenten in Wildtypmäusen und 
Mäusen mit Tumorläsionen zeigten sich die Liposomen als geeignet für magnetisches 
Targeting und es konnten keine pathologischen Gewebeveränderungen nach der 
Liposomenakkumulation festgestellt werden. 
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1 INTRODUCTION 
1.1 Gastro-intestinal cancers 
Among estimated new gastro-intestinal cancer cases and cancer-related deaths for the year 
2017, pancreatic cancer, in most cases pancreatic ductal adenocarcinoma (PDAC), and 
primary liver cancer, predominantly hepatocellular carcinoma (HCC), rank on the positions 2 
and 3, and the incidences are expected to further rise [2, 3]. So it is of upmost urgency to 
improve diagnosis and the existing treatment options. Both tumor types share diagnosis in 
advanced cancer stages, resulting in reduced chance for curative surgical removal of the 
lesions. In palliative approaches both cancers do not respond well to systemically 
administered chemotherapeutics and other therapy approaches are limited. 
Less than 15 % of HCC patients are curable by liver transplantation, surgical tumor 
resection, or ablation [4]. The overall resectability rates in PDAC patients are below 20 % at 
the time of diagnosis [5-7]. Of the as resectable classified PDAC patients, further 30 % 
emerge as non-resectable after staging laparoscopy due to peritoneal carcinosis [8]. The 
German incidence (figure 1A) and mortality rates (figure 1B) for HCC and PDAC as well as 
the survival for ten years after the first diagnosis of liver (figure 1C) and pancreatic cancer 
(figure 1D) are plotted in figure 1 (modified from [9-11]). 
 
Figure 1: HCC and PDAC: Tumor statistics. German age-standardized incidence (A; Saarland) and 
mortality rates (B) (International Agency for Research on Cancer; 2017; [9]). Absolute survival for up 
to ten years after first diagnosis (ICD-10) of HCC (C) or PDAC (D) in Germany (2013-14; [10, 11]). 
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1.1.1  Hepatocellular carcinoma (HCC) 
1.1.1.1 Risk factors and etiology 
A functional liver is necessary for maintenance of a healthy organism. Inter alia, she is 
responsible for bile secretion into the intestines, production of blood clotting factors, and 
break down of alcohol, drugs and toxic wastes for renal and intestinal clearance [12]. Due to 
external influences and intrinsic aspects, many patients suffer from pathologic alterations 
and comprised liver function. There are several risk factors like chronic viral hepatitis (Hep-B 
or Hep-C), alcohol abuse, non-alcoholic fatty liver disease (NAFLD), non-alcoholic 
steatohepatitis (NASH), obesity, type 2 diabetes, aflatoxins (direct exposure or via 
contaminated foods [13]), exposure to chemicals, rare metabolic diseases, anabolic steroids, 
and tobacco which could ultimately result in liver cirrhosis [14]. Additional prevalence 
depends on race or ethnicity (Asian and African roots [15-17]), age (≥	 60 years), and gender 
(3 times higher risk for men [18]). The liver cirrhosis then presents a frequent precondition of 
HCC development, 90 % of all HCC patients were diagnosed cirrhotic before the first tumor 
lesions developed [14]. The etiology of HCC is summarized schematically in figure 2B [17] 
and tabularized by geographical areas in figure 2C [15]. 
 
 
Figure 2: HCC: Pathology and etiology. A: Schematic and CT scan of HCC lesions [17]. B: Risk 
factors [17]. C: Regional etiology (National Cancer Institute at the National Institute of Health, USA; 
[15]). 
1.1.1.2 Tumor diagnosis 
Patients with comprised liver function are often identified during routine screening 
examinations by elevated γGT or GPT serum levels. Later-on, several patients develop liver 
cirrhosis, as cirrhotic diagnosed patients then are monitored more closely depending on the 
grade of their liver dysfunction. [14] 
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As not all patients show clear symptoms upon development of HCC, many liver tumors are 
eventually diagnosed during the periodic routine screening examinations. Diffuse HCC 
symptoms can be unexplained weight loss, loss of appetite, abdominal discomfort or 
distention (enlargement), fluid in the abdomen (ascites), gastro-intestinal hemorrhage (blood 
in the stool), nausea or vomiting, jaundice, weakness or fatigue, pain near the right shoulder 
blade or in the back, persistent itching, easy bruising and bleeding, or fever [12, 19]. After 
suspicious ultrasound (US) findings, HCC lesions can be confirmed by further examinations. 
Additionally, alpha-fetoprotein (AFP), a protein normally only produced by a fetal liver, is 
commonly secreted from liver cancer cells, and therefore can serve as marker of tumor 
progression in HCC patients [14]. 
HCC likely develops from hepatocytes and is a primary cancer originating from and located 
in the liver (figure 2A; [17]). It can occur as unifocal single tumor mass, or as multifocal HCC 
of several smaller, often inter- and intra-tumorally heterogenous cancer nodules in the liver 
[12, 20]. Multifocal nodular HCCs develop mostly in patients with cirrhotic livers [12]. In 
advanced stages, HCC commonly metastasizes to lungs, lymph nodes, adrenal gland, 
bones, and seldom into the brain [21]. 
1.1.1.3 Cancer statistics 
Liver tumors were diagnosed more frequently in the recent years, most probably due to both, 
improved diagnostic tools and the increasing incidence because of growing numbers of 
cirrhotic HCC risk patients. Worldwide, liver cancer was the sixth most frequent cancer 
among the newly diagnosed tumors [22]. The relative numbers of newly diagnosed HCC 
patients in 2014 were 10.7/3.6 per 100,000 (men/women; age adjusted to the European 
standard) in Germany (GEKID-Atlas 2017; figure 3C; [23]). Incidence rates were steadily 
increasing as calculations based on the cancer registry data of the federal states 
demonstrate [23]. The same development could be observed in the United States [2, 3, 24], 
the UK [16], Europe [11] and worldwide [13, 24, 25] (figure 3A [25] and 3D [11]) with male 
predominance and in higher ages [11, 16, 24]. In Germany, 1 in 82 men and 1 in 190 women 
will be diagnosed with liver cancer during their lifetime [11]. The estimated 5-year-survival 
rate is 14/11 % (men/women) (Robert Koch Institute 2017; [10]) in Germany and 18 % in the 
United States [2], the 10-year-survival rate was estimated to be 10/9 % (men/women) [10], 
both getting less optimistic every year [24]. Especially in (South-)East Asia, the incidence 
rates were three to five times higher than in the European Union in 2013 [24].  
Worldwide, liver tumors were the 6th most common cause of cancer related death in 2015/16 
[4, 26, 27] (figure 3B; [28]). For 2017, it was predicted to be fifth most common [2, 3], and by 
2030, liver tumors are projected to become the 3rd leading cause of cancer related death in 
the United States [27]. This upwards tendency was also seen in Germany, with a clear male 
predominance there were 8.2/2.9 victims per 100,000 (male/female; age adjusted to the 
European standard; figure 43A; [24]) [10]. 
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Figure 3: HCC: Incidence and mortality. Estimated worldwide age-standardized incidence (A; [25]) 
and mortality (B; [28]) rates (2012; [29]). C: Absolute number of new cases in Germany (2003-14; 
modified from [23]). D: International incidence and mortality rates (1France: No data on incidence 
available; age-standardized per 100,000 residents; 2013-14; modified from [11]). 
1.1.2 Pancreatic ductal adenocarcinoma (PDAC) 
The pancreas consists of exocrine and endocrine compartments, figure 4 presents its 
structure and localization within the body [30]. Digestive enzymes released from the exocrine 
pancreas are produced in the acini and released through ducts into the small intestine. The 
endocrine pancreas is made up of islets of Langerhans, cell clusters which produce specific 
and important hormones such as for example insulin, glucagon and somatostatin, all of 
which contribute to the regulation of metabolic processes in the body [31]. The pancreas is 
capable to develop either exocrine or endocrine tumors. Exocrine tumors, mostly pancreatic 
adenocarcinomas, are the most common type of exocrine cancers in general. Usually they 
originate from the pancreatic ducts, and hence are called pancreatic ductal 
adenocarcinomas (PDAC). 
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1.1.2.1 Risk factors and etiology 
Risk factors for development of pancreatic 
cancer are age (90 % are older than 55, 
70 % older than 65 years), gender (male 
predominance), race/ethnicity (Black 
people more likely than Asian, Hispanic, 
or White people in the United States [32], 
and White and Black people more likely 
than Asians in the UK [33]), tobacco (2-3 
times higher risk), obesity, alcohol abuse, 
diabetes, family history, rare inherited 
conditions, chronic pancreatitis, exposure 
to chemicals, bacteria (Helicobacter 
pylori), chronic viral hepatitis (Hep-B), and 
liver cirrhosis [32]. 
Figure 4: Structure (magnification) and localization  
of the pancreas within the body (big picture) [30]. 
1.1.2.2 Tumor diagnosis 
PDAC gets often diagnosed at late stage due to the diffuse symptom pattern, and therefore, 
in its early stages is also classified as silent disease. Symptoms and signs of pancreatic 
tumors could be jaundice, pain in the upper abdomen or upper back, thrombosis in an arm or 
leg, burning feeling in stomach or other gastro-intestinal discomforts, stomach bloating, 
floating stools due to bad fat digestion (bad odor, unusual color), weakness, loss of appetite, 
nausea and vomiting, chills, fever, and unexpected weight loss [34]. Also, the tumor marker 
carbohydrate antigen 19-9 (CA19-9) is often elevated in PDAC patients [17]. 
1.1.2.3 Cancer statistics 
The German incidence and mortality rates are calculated based on the cancer registries of 
the federal states (GEKID-Atlas 2017; [23]). Both rates are constantly growing [33], and 
compared to the development in Scandinavia and the United States, this increase happens 
faster in Germany (figure 5C; [23, 24]). In 2014, there were 14.1/10.3 new cancer cases per 
100,000 Germans (male/female patients; age adjusted to the European standard; figure 5C) 
[23]. Those numbers represent the European, United Statesʼ and worldwide situation for 
PDAC: it ranks on the 12th position among the newly diagnosed tumors (figure 5A [35] and 
5D, [2, 3, 11, 22, 28, 33]. Worldwide there is a slight male predominance (12th versus 11th) 
[13], whereas in the European countries the predominance is female (9th versus 12th) [23, 
33]. The incidence to develop PDAC is higher in the economically developed countries [24], 
besides other factors this might be due to the increasing numbers of adipose patients and 
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life expectancies. The latest life time risk estimation to develop PDAC predicts 1 in 57 men 
and 1 in 59 women (Robert Koch Institute 2017; [10, 11]), this is an increase of about 20 % 
in the last 10 years [36]. The estimated the 5-year-survival rate in Germany is 8.9/8.8 % 
(men/women) [11] and 8 % in the United States [2], the 10-year-survival rate is 10.9/11.0 % 
in Germany [11]. The estimation of Gudjonsson is devastating, as after correcting the 
numbers for repetitions and the life table percentage, his calculations result in a 5-year-
survival rate of hardly more than 0.3 % [37]. 
In 2016, PDAC was the fourth leading cause of cancer death worldwide (figure 5B; [31, 38]) 
with rising tendency [2, 22, 36]. In Germany, the tendency for PDAC-related death was 
significantly rising (13.2/9.8 victims (male/female) per 100,000 in 2015; age adjusted to the 
European standard; figure 43B; [24]) compared to the previous years [10, 24, 36, 39]. For 
2017, PDAC was estimated to be the third most common reason [2, 3], and by 2030 
pancreatic cancer was projected to become the second leading cause, all in the United 
States with a clear male predominance [2, 27, 37, 40]. The average age at cancer-related 
death in 2014 and 2015 it was 77 (men) and 73 (women) [11]. 
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Figure 5: PDAC: Incidence and mortality. Estimated worldwide age-standardized incidence (A; 
[35]) and mortality (B; [38]) rates (2012). C: Absolute number of new cases in Germany (2003-14; 
modified from [23]). D: International incidence and mortality rates (1France: No data on incidence 
available; age-standardized per 100,000 residents; 2013-14; modified from [11]). 
 
1.2 Non-invasive imaging for diagnosis and monitoring 
Imaging is crucial for reliable diagnosis of several diseases, monitoring during therapy, and 
long-term follow-up after successful treatment. Available non-invasive imaging modalities 
include different ultrasound (US) techniques, computed tomography (CT), MRI, and positron 
emission tomography (PET), alone or in combination. The optimal imaging tool needs to be 
selected case-specific after careful consideration regarding resolution, acquisition time, 
utilization of contrast agents, availability, health condition of the patient, and potential risks 
from radiation load. 
Advantage of US is its wide availability in medical offices and high resolution of acquired 
images. However, US is highly dependent on the examiners skill level. CT uses X-rays, and 
offers good resolution after a short acquisition time, especially of solid structures like bones. 
For good soft tissue contrast, CT imaging requires contrast agents which might have side-
effects, especially in old patients or patients with co-morbidities like renal dysfunction. MRI 
provides high tissue resolution and contrast without radiation exposure. For specific 
questions, there are contrast agents available. Disadvantages are the long acquisition time 
and relatively high costs per scan. In PET/CT scans, radioactive tracers, such as 18F-
fluorodeoxyglucose (FDG), are detected upon accumulation. The tracers can be chosen 
depending of the target, for example FDG accumulates in metabolically active tissues, such 
as primary tumors and their metastases. Therefore, PET scans mostly involve whole-body 
imaging for metastasis identification in distant tissues. The PET signal then gets localized by 
superimpositioning of the PET scan data with the corresponding anatomical information from 
CT or MRI scans. Big advantage is the specificity of the tracer molecules, as they could be 
coupled to target-specific ligands. [7, 41, 42] 
1.2.1 Magnetic resonance imaging (MRI) 
Since the 1980s, MRI is used for diagnostic approaches and established as one of the 
imaging columns in modern medicine. Big advantages are the lack of ionizing radiation, 
excellent soft tissue contrast, high spatial resolution, slice-wise image acquisition of the 
region of interest (ROI) in any possible orientation, and hence the possibility for post-
processing into three-dimensional reconstructions (e.g. maximum intensity projections 
(MIP)) [43, 44]. With specific scan protocols and data analysis, morphological, metabolic, 
and functional information can be obtained. Figure 6 shows an exemplary T2w MR scan of a 
rat HCC tumor nodule and is an example to illustrate the good resolution in the µm range 
[45]. 
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Figure 6: T2w MRI scan of HCC tumor nodule in rat model [45]. 
Basic principle behind is the excitation of atomic nuclear spins 
(most commonly 1H or 13C) in the ROI by application of an 
external magnetic field and the subsequent detection of tissue-
specific relaxation time, the time the spins need to return to their 
starting orientation. That relaxation consists of longitudinal and transverse components, the 
relaxation time of the longitudinal component is T1, and T2 is the transverse relaxation time. 
[46] The relaxation times depend on the chemical and physical environments of water 
protons in tissue, the grades of freedom those molecules have. Thus, T1 and T2 relaxation 
time measurements help to understand water molecular dynamics in biologic systems which 
can be translated into anatomical tissue information [47]. Differences in the tissue 
microstructure are the basis of the contrast between normal and pathologic tissue, 
expressed in relaxation time shifts. Therefore, MRI scans provide for example information 
about inflammation, tumor malignancy, edemas, infarction, and ischemia [47]. 
1.2.1.1 Contrast agents 
The administration of contrast agents could further increase the contrast of the target 
structure, and hence could improve the diagnostic efficiency regarding detection sensitivity 
of (pathologically) altered tissues and lesions. Contrast agents for example accumulate in 
specific tissues, are not taken up by specific cells or structures, or are taken up in an altered 
pattern. The altered MRI signal detected in pre- and post-scans can help to clarify several 
clinical questions. The pioneering idea for the use of magnetic imaging probes with high 
magnetic moments, and their application for magnetically-guided targeting approaches can 
be dated back to the early 1960s and Freeman et al. [48]. In the late 1970s they were 
established for MRI due to their ability to shorten T2 relaxation times [49]. 
Widely utilized substances are paramagnetic gadolinium (Gd) formulations, which shorten T1 
relaxation time and T2-reducing superparamagnetic iron oxides (SPIOs). Clinically approved 
products include the SPIO formulations Resovist® (ferucarbotran; [50]) and Feridex®/ 
Endorem® (ferumoxides; [51]) for liver-specific contrast enhancement in the diagnosis of 
HCC [52, 53]. The SPIOs specifically accumulate in Kupffer cells and leave cancerous 
lesions bright amidst hypointense healthy liver tissue. Sinerem®/Combidex® (USPIO) was 
applied for the detection of metastatic lymph nodes, but was withdrawn from the market [54-
56]. Lumiren®/GastroMARK® is an oral ferumoxsil contrast agent for imaging of the gastro-
intestinal tract [56]. Eovist® (gadoxetate disodium) is a Gd preparations used in liver imaging 
[51]. Other Gd contrast agents are needed for MR-angiography and brain and spine 
imaging, examples are Gadovist® (gadobutrol; [51]), Magnevist® (Gd-DTPA; [50]), 
MultiHance® (gadobenate dimeglumine; [57]), and OmniScanTM (gadodiamide; [58]). 
ProHance® is a liposomal formulation of gadoteridol for brain and spine imaging [57]. 
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In general, MNPs possess ferri- or ferromagnetic properties which generate significant 
susceptibility effects resulting in strong T2 and T2* contrast. This made them ideal candidates 
to be examined as sensitive imaging probes in pre-clinical MR imaging approaches, for 
example in oncologic issues [59] and potential use for clinical approval processes. 
1.2.1.2 Sequence optimization and data evaluation 
Improvement of diagnosis for better and earlier detection of for example tumor lesions could 
improve the prognosis of cancer patients [60]. It also relies on development and optimization 
of application specific scan sequences. As experiments and studies can not be performed 
on patients, alternatives were needed. Tissue-mimicking phantoms can be equipped to 
possess close-to-in vivo properties and hence provide a convenient tool to improve the MRI 
scan sequences, to test radiofrequency coils, and to evaluate system performance [60]. In 
addition, phantoms could be used to elucidate variations between different MRI scanners 
and/or different field strengths (table 1 [47], and figure 29E+F). 
 
 
Table 1: Comparison of T1 and T2 relaxation times acquired at 3.0 and 1.5 T (table 1 from [47]). 
A second aspect is the first in vitro evaluation of newly developed contrast agent-loaded 
formulations regarding their imaging properties [4, 60-64]. Tissue-mimicking phantoms could 
be used to find out whether the content of imaging probe is high enough to result in a 
sufficient contrast over baseline tissue relaxation and to identify detection limits. Hence, they 
may help to reduce the extent of animal testing. Probably, relaxation data from in vitro 
samples embedded in phantoms could also provide the basis for quantitative analysis in 
according in vivo scans. 
 
 
 
Figure 7: Tissue-mimicking by 
Ni- and agarose-dependent T1 
and T2 modulation [65]. 
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Most common material in MRI phantom preparation is agarose [65-68]. General criteria for 
phantom components are chemical, physical and thermal stability, easy handling regarding 
plasticity in size and shape, and tolerability regarding ingredients (non-toxicity) at good 
availability and low price [60, 65]. The T2 relaxation is modulated by the agarose itself, the 
addition of superparamagnetic metals like nickel allows T1 relaxation adjustment [60, 65, 68]. 
Hence it is possible to obtain independently tune T1 and T2 relaxation values to mimick 
specific body tissues [65]. In figure 7, Christofferson et al. graphically demonstrated the 
influence of varying agarose concentrations on the T2 relaxation, and nickel-doping on the T1 
values [65]. Advantages of agarose gel phantoms are independency from magnetic flux 
density and temperature (within the acquisition range). Disadvantageous is that MR-effecting 
in vivo parameters like diffusion, flow, movement and susceptibility effects can not be taken 
into account [65]. 
1.2.2 Imaging of HCC 
Contrast agent-enhanced US of emerging HCC nodules presents highly vascularized areas 
within the surrounding tissue [69]. Further applied imaging modalities include CT, multi-
detector CT (MDCT), MRI scans, angiography of the abdominal blood vessels and organs, 
and FDG-PET/CT [14, 69]. In the arterial phase of contrast agent-enhanced MDCT and the 
arterial phase of gadolinium-enhanced T1-weighted MRI sequences, a HCC nodule also 
presents as hyperintense region due to the arterial flush in the highly vascularized tumor [69, 
70]. During the portal venous phase and the late arterial phase, the hyperintense MRI signal 
washes out, resulting in hypointense signals of cancerous tissue [14, 70, 71]. The 
administration of liver-specific contrast agents such as in bolus intravenously injected SPIOs 
enables for the detailed visualization of smaller lesions by dynamic (T2) MRI [14]. The effect 
of SPIOs on the acquired MR images is primarily the shortening of T2 relaxation times [72]. 
Such SPIOs are selectively taken up by the reticulo-endothelial system (RES), about 80 % of 
an injected dose is taken up by the liver Kupffer cells and 5 – 10 % by the spleen. Most HCC 
lesions do not have an intact RES, they appear bright among the hypointense liver 
parenchyma after SPIO uptake [72]. Whole-body FDG-PET/CT is another imaging modality 
that allows for the parallel detection of both, the primary tumor and, most importantly, distant 
metastases [73]. The FDG tracer administered for PET accumulates in highly proliferative 
tissue such as tumors. Combination of FDG-PET imaging with anatomical CT scanning 
allows for concrete localization of the glucose-active tumor nodules [41]. Cancer imaging has 
become a valuable and important tool for diagnosis and prediction of the tumorsʼ response to 
therapeutic approaches. On a molecular basis, HCC lesions are very heterogenous, both, 
intra- and inter-individually. The tumor nodules present a high grade of vascularity with 
activated angiogenesis and elevated expression of growth factors [69]. For histo-
pathological examination of unclear masses in the liver and to prove the diagnosis HCC, 
liver biopsies need to be taken. [17] 
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1.2.3 Imaging of PDAC 
Imaging plays a critical role in pancreatic cancer staging and the therapeutic decision 
process. The imaging modalities used to evaluate PDAC include CT, MDCT, MRI, different 
US modes, and FDG- / 18F-fluorothymidine (FLT-) PET/CT [7, 74]. CT, and especially MDCT, 
is the preferred imaging tool for PDAC staging due to its short acquisition time, the 
robustness, the excellent spatial resolution, and the option for contrast-enhanced imaging of 
the vasculature [7]. Primary PDACs show a peak enhancement in the late arterial phase (45 
– 50 seconds post i.v. contrast agent injection), potential hypodense liver metastases reach 
optimal enhancement in the portal venous phase after 70 seconds [75]. MRI principally 
provides the better soft tissue contrast compared to unenhanced CT imaging. Therefore MRI 
is especially valuable in patients with contraindication for intravenous contrast agent 
administration, and it provides flow sensitive sequenced and diffusion-weighted imaging [7]. 
In a recent study it could be shown that MRI improved a lot and thus presents comparable 
sensitivities and specifities to CT (MRI sensitivity 93 %, specificity 50–75 %; CT sensitivity 
87 %, specificity 63–75 %) [76, 77]. Transabdominal US is typically applied in the initial 
examination of abdominal pain or suspected obstructive jaundice but visualization of the 
pancreas might be difficult due to body habitus or bowel gas [7]. Endoscopic US (EUS), 
endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous transhepatic 
cholangiography (PTC) can help localize, identify and characterize the tumor lesion and 
support in the guidance during biopsies for histo-pathological tissue evaluation [5, 7, 74]. 
The sensitivity of EUS for tumors ≤ 2 cm is nearly 100 %, the specificity ≥ 95 % [7, 77]. 
Besides the role in identification and localization of the primary PDAC, in whole-body 
examinations FDG-PET/CT can help to detect additional distant metatstases beyond those 
which can be found applying conventional cross-sectional imaging of the abdomen, pelvis 
and chest [7, 78]. Detection of distant metastases in as resectable classified patients 
prevents unnecessary resection [42]. The new tracer FLT evaluates tumor proliferation and 
has the potential to be more specific than FDG-PET/CT [42]. Both PET tracer help to 
differentiate benign and malign pancreatic lesions in PET-CT scans, but the specificity of 
FLT-PET/CT is higher as benign lesions are FLT-uptake-negative with a specificity of 100 % 
compared to 85 – 97 % for FDG-PET/CT [42]. 
1.3 Therapeutic approaches 
The treatment of several diseases by classical therapies is not as efficient as it should be. 
After systemic administration, a big problem is the incomplete delivery of the therapeutic 
agents to the target tissue due to for example short circulation times, early inactivation or 
degradation in the blood and rapid clearance by immune cells. Off-site delivery and 
accumulation at for example liver and kidney could lead to tissue damage [49, 79]. Though, 
as previously mentioned, this clearance by macrophages of the hepatic RES is a wanted 
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feature when applying SPIO-based contrast agents for liver imaging, it has to be avoided 
when targeting other tissues. 
Targeted approaches are broadly examined to overcome the delivery issues and even 
reduce administered doses. New therapeutic approaches utilizing nanocarrier formulations 
and targeting strategies also open the field for new therapies. For example nucleic acid 
therapies rely on packing into shielding nanocarrier formulations. Targeted delivery could be 
enhanced by the assembly with MNPs and target cell-specific surface functionalization of the 
vehicle. 
1.3.1 State-of-the-art therapy of HCC 
HCC is often difficult to treat or even cure due to late diagnosis or the tumor localization 
within the liver. Most patients suffer from advanced tumors upon diagnosis and are only 
eligible to palliative treatments. For the fewer number of patients in earlier stages, possible 
curative treatments are surgical removal of the tumor mass, liver transplantation, or ablative 
techniques (radio frequency ablation (RFA), microwave ablation (MWA), irreversible 
electroporation (IRE) or ethanol injection). Palliative treatments include intra-arterial 
therapies, chemotherapy, radiation therapy (stereotactic radiation therapy) or combinations 
thereof. For patients with metastatic spread, the therapeutic options are restricted to 
palliative therapies [69]. To decide on the optimal therapeutic approach, each patient is 
staged according to the 8th edition of the TNM (tumor, node, metastases) Classification of 
malignant Tumors of 2016 [80], compiled in table 2. 
Liver transplantation is an option only for individuals of stable health condition and HCC 
lesion(s) meeting the Milan criteria: i.e. single lesion ≤ 5 cm, or up to three lesions ≤ 3 cm in 
diameter, each in the absence of tumor vascular invasion or evidence of extra-hepatic 
metastases [81]. The Milan criteria predict the risk of relapse and survival probability after 
liver transplantation. Among those patients eligible for transplantation, elevated AFP levels 
might indicated a higher risk for tumor relapse [82]. The resection of even large liver portions 
is tolerable depending on the remaining liver volume, as the liver has a high regenerative 
capacity. Another possibility is the combination of surgery with local ablation techniques 
(figure 8; [83]). Operating principle behind all ablation methods is the local destruction of all 
tumor cells. RFA utilizes a needle probe inserted into the tumor nodule, which then heats up 
by applying an alternating radiofrequency electrical current (figure 8A, [84]). In MWA, the 
thermal ablation results from electromagnetic energy focused onto the cancerous area [84]. 
For IRE, also needle probes are used, but in contrast to the thermal RFA approach, the 
tumor cell death is induced non-thermally using electrical energy to disrupt the cellular 
membrane integrity with subsequent cell death (figure 8B, [85]). Ablation techniques are 
generally indicated for treatment of small tumors (≤ 3 cm in diameter) and patients that 
cannot tolerate an operation. 
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Table 2: HCC TNM staging criteria. T (tumor), N (regional lymph nodes), M (distant metastases), 
and stage criteria of HCC (data from [36]). 
Intra-arterial therapies are the most frequently applied palliative options. The success of all 
intra-arterial approaches is based on the specific blood supply of hepatocellular carcinomas, 
which is provided almost exclusively by the hepatic artery whereas the healthy hepatic tissue 
is fed to 75 % by the portal venous system [86, 87]. Therapeutic agents (chemotherapy or β-
emitter) are directly delivered to the tumor by placing a catheter into the tumor-feeding 
artery. Thus, side-effects from off site delivery are strongly reduced. These techniques use 
X-ray imaging to monitor catheter placement and agent delivery into the tumor specific so-
called feeding-arteries. During the trans-arterial procedure, chemotherapy emulsions (TACE, 
DEB-TACE; figure 8C; [88]) or Yittrium-90 microspheres are administered. The only clinically 
approved systemic therapy in HCC is sorafenib [69, 89], but others like 5-fluorouracil, 
oxaliplatin, irinotecan, cetuximab, and avastin are in clinical trials [17]. 
 
 
Figure 8: HCC: Treatment options. A: Schematical setup of radiofrequency ablation (RFA) [83]. B: 
Schematical setup of irreversible electroporation (IRE). C: Schematical setup of trans-arterial 
chemoembolization (TACE) [88]. 
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1.3.2 State-of-the-art therapy of PDAC 
The treatment options for PDAC patients are very limited, mostly due to the diagnosis in 
already advanced stages, and the local invasion and distant spread of tumor lesions. After 
identification, tumors are staged resectable, borderline resectable, locally advanced, or 
metastatic to decide on the treatment approach. Table 3 summarizes TNM staging criteria 
for PDAC [80, 90]. In general, possible approaches include surgery, radiation therapy, 
chemotherapy and targeted therapy. 
 
 
Table 3: PDAC TNM staging criteria. T (tumor), N (regional lymph nodes), M (distant metastases), 
and stage criteria of PDAC (data from [36]). 
Chemotherapy and targeted therapy can be applied in a neo-adjuvant and/or adjuvant 
regimen [91]. For patients with small intestine or bile duct stenosis due to the tumor mass, 
that block might be relieved by mechanical widening of the stenosis or the insertion of stents 
during ERCP or PTC. The surgical approach includes partial or complete pancreatectomy. 
The goal is a complete resection, i.e. R0 resection with no residual tumor cells left in the 
patient. Surgery is an option for only about 20 % of individuals, as in most cases the cancer 
has already spread to other organs [4-6]. Neo-adjuvant chemotherapy has become an 
important approach, by which the tumor is downsized and thus made eligible for surgery. 
The surgical intervention is typically followed by radiation and chemotherapy, the adjuvant 
therapy. 
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Aim of radiation therapy is the destruction of tumor cells by high-energy X-rays or other 
particles, and its therapy regimen consists of several treatments in patient-specific 
schedules and doses. To exploit the radiosensitization, radiation therapy is often combined 
with chemotherapeutic treatments, also in patient-specific regimen cycles. 
Different regimens are available in the neo-adjuvant and adjuvant setting. The most common 
agents are Folfirinox® (a combination of fluorouracil (5-FU), irinotecan and oxaliplatin), 
gemcitabine (Gemzar®), or Nab-paclitaxel (Abraxane®). An agent for targeted therapy is 
erlotinib (Tarceva®). Erlotinib targets and blocks a cancer cell surface protein, the epidermal 
growth factor receptor (EGFR). It is always administered in combination with gemcitabine 
and is an option for advanced PDAC. All chemotherapeutics have unpleasant side-effects 
that indicate further palliative care. On the other hand, chemotherapeutic drugs could also 
improve the patient´s general condition, as they could relieve pain and improve digestion, 
appetite, weight loss, and weakness. [91] 
1.3.3 Targeted delivery 
Driving idea behind targeting approaches is to increase the efficiency of the therapeutic 
agent by localized delivery towards the region of interest, and depending on the nanocarrier 
formulation even the controlled release of its cargo. The reduction of off-site delivery and 
prevention of inactivation also reduces the amount of therapeutic agent that has to be 
administered. 
1.3.3.1 What does this mean for HCC and PDAC? 
For HCC and PDAC clear diagnostic and therapeutic limitations exist and there is high 
demand for clinically practicable solutions. Biggest obstacles remain diagnosis only in 
advanced cancer stages and the lack of functional and clinically approved therapies in those 
often non-resectable patients. 
To overcome diagnostic obstacles is difficult, as both cancer types show no clear symptoms 
in the early stages. A solution might be more frequent medical check-ups in risk patients and 
the usage of sensitive contrast agents that specifically target cancer cells. Though more 
frequent screenings would eventually lead to false positive diagnoses and as economic 
aspect that would mean higher costs for the health care system. 
State-of-the-art chemotherapeutic treatments are non-targeted and rely solely on 
accumulation at the targeted site via the natural so called enhanced permeability and 
retention (EPR) effect leading to extravasation of particles up to 400 nm through the leaky 
vasculature into the tumor interstitium due to the increased vessel permeability. 
Unfortunately, not all tumors and stages, and not all cancer patients exhibit the EPR effect at 
the same level, for several individuals it is only weak [92]. Due to this limitation and the 
patients-specific composition of the tumor interstitium the drug delivery rate is only low. 
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Issues on delivery efficiency can be approached with nanocarrier formulations. By specific 
functionalization, the loss of therapeutic agent before even reaching the target tissue can be 
reduced, its circulation time increased, the functionality upon delivery improved and side-
effects decreased. Another problem is the heterogeneity of the tumor lesions due to fibrosis. 
Tumor cell-specific targeting could help to improve the uptake into the cancer cells. 
The generation of theranostic formulations combining improved diagnostic agents and 
encapsulated/assembled therapeutic agents for immediate delivery is a promising strategy. 
Core component of such theranostics could be MNPs enabling parallel magnetic targeting 
and MRI monitoring of the circulating nanocarriers. 
For the development of new therapeutic approaches in HCC and PDAC there are different 
animal model systems available. There are two basic concepts of rodent models: on one 
hand, they are based on orthotopic tumor lesions of (human) cancer cell lines with relatively 
homogeneous cancer nodules. On the other hand, there are endogenous tumor models with 
more heterogeneous tumor lesions whose properties are closer to the human pathologic 
situation. Cancer is then evoked either by exposure of the animals to chemicals or genetic 
engineering of the mouse strains leading to tumor growth. For both cancers, at the Klinikum 
rechts der Isar there are several animal models established. 
1.3.3.2 Nanocarrier formulations 
A nanocarrier formulation is composed of a cargo such as a drug, nucleic acids or an 
imaging probe, and a structure to protect the cargo. Of course there can be more than one 
cargo assembled with one or more stabilizing components, and further modifications 
providing special features. Examples for nanocarrier formulations are viral vectors, non-viral 
vectors such as lipoplexes and polyplexes, and liposomes. 
On the diagnostic side, there are several pre-clinical studies on for example contrast agent-
loaded liposomes and nanogels [93] for MRI and fluorescence imaging [94]. The MRI 
contrast agent ProHance® is a clinically approved liposomal gadoteridol formulation for T1w 
imaging of brain, HCC, and spine [95]. 
Lipsomes are also successfully applied for the delivery of encapsulated doxorubicin (DOX) in 
a pharmaceutical called Caelyx®/Doxil® [96-99]. Though they are frequently used for tumor 
therapies, they are non-targeted. Hence, the drug delivery efficiency is limited and need to 
be improved. Doxil® therapy contributes to an extension of survival, but full recovery is 
seldom. In pre-clinical research, there are several approaches to prepare complexes loaded 
with nucleic acids, for example lipoplexes and polyplexes. Such assemblies are stabilizing 
and prevent from early inactivation of the nucleic acids by nucleases. Another widely utilized 
nanocarrier for nucleic acids are viruses, also known as viral vectors. The viral capsids can 
be loaded with additional cargos if necessary, such as imaging probes, and the viral genome 
can be genetically engineered. For longer circulation times, the surface could be modified 
with shielding organics such as the polymer PEG or with hyaluronic acid. 
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1.3.3.3 Strategy: Magnetic targeting 
The described nanocarrier systems can all be assembled with magnetic nanoparticles to 
form magnetic nanocarriers. That enables for two key features: magnetic targeting via 
magnetofection [100] and non-invasive monitoring in vivo by MRI [4]. 
Suitable core-shell type MNPs form stable complexes with different viral and non-viral 
particles by self-assembly [101-106] and they can be loaded into liposomes. The integration 
of MNPs in such nanocarrier formulations resulted in enhanced viral transduction and non-
viral transfection efficiency and transgene expression [100, 101, 103-114]. Furthermore, the 
complex formation with MNPs and shielding with organic molecules minimized the 
interaction with blood components and cells, and could prevent early inactivation of 
assembled structures like viruses or nucleic acids [103, 105, 110, 115]. The uptake of 
magnetic liposomes could also be enhanced in external magnetic fields. In figure 9, the 
magnetic nanocarrier systems investigated in this work are schematically presented. 
Transport to specific targets and controllability of the release of the cargo are two of the 
most avidly pursued goals in drug delivery research. The advantage in utilization of SPIOs is 
their ability to acquire net magnetic moment in the presence of an external magnetic field, 
but return to a non-magnetic state when the external magnet is removed [116]. This is of 
paramount importance when these particles are introduced into living systems because once 
the external magnetic field is removed, the magnetization disappears and thus, 
agglomeration and the possible embolization of capillary vessels could be avoided [116]. 
 
 
Figure 9: Schematical sketches of the magnetic nanocarrier systems investigated in this 
work. A: MNP-VP complex self-assembly. B: MNP-siRNA complex self-assembly. C: MNP-LPs. 
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The combination of therapeutic and contrast agents in one formulation resulted to the new 
class of “theranostics” – therapeutics and substances for diagnostics integrated in one multi-
functional formulation [49]. Some assemblies of MNPs with for example pharmaceuticals, 
viruses or nucleic acids could be applied as such theranostic formulations providing MRI 
contrast and the delivery of the therapeutic agent at the same time. 
1.3.3.3.1 Magnetic nanoparticles (MNPs) 
In the last decades, MNPs have been widely employed in the biomedical field, for example in 
cellular therapy, tissue repair, drug delivery, hyperthermia, biosensors, immunoassays, and 
magnetic separation [49, 116-120]. In oncology, they are utilized as clinically approved 
contrast agents in tumor detection [49, 121, 122], and in preclinical approaches in 
magnetically targeted delivery of magnetic nanocarriers [123-131]. Their broad applicability 
is based on the magnetic properties, the chemical stability, the biocompatibility, and the 
tunable size [49, 67, 79, 115, 120, 132, 133]. Great advantage of MNPs is their large specific 
surface relative to their small size [49, 79, 120]. After cell uptake, SPIOs are metabolized 
intracellularly in lysosomes into a soluble, non-superparamagnetic form of iron to become 
part of the normal iron pool in ferritin or haemoglobin [55, 134]. 
A MNP is comprised of an inorganic magnetic core with a biocompatible surface coating to 
stabilize the nanoparticle under physiological conditions and enable further application-
specific surface modifications with functional ligands for in vivo applications [135]. The 
synthesis of MNPs is possible in aqueous as well as organic phases [49]. Coating materials 
provide non-immunogenic and non-antigenic properties, could prevent opsonization, and 
give conjugation sites for example for nucleic acids and viral particles [49, 136]. Often used 
materials include polysaccharides like dextran, organic polymers like polyethylene glycol 
(PEG) and polyethylene imine (PEI), or inorganic molecules such as silica [49, 79, 137, 138]. 
Further moieties could enhance targeting and increase delivery efficiency, examples are 
bioactive molecules like ligands or receptors, peptides, antibodies, and small molecules like 
dyes [49, 137]. Figure 10 presents the schematical structure of the core-shell type MNPs 
PEI-Mag2 (figure 10A), SO-Mag6-11.5 (figure 10B), and the coating components PEIBr-25 
kDa, Zonyl® FSA, Zonyl® FSE and palmitoyl dextran PALD2 (figure 10C+D). 
Of course MNPs can be used not only in the field of nanocarriers, but offer broad variety of 
application possibilities besides the biomedical approaches [116]. Further application fields 
are as various as aeronautic, automotive industry, and storage devices [96, 103, 113, 115, 
132, 139-142]. 
 
Introduction 
 19 
 
Figure 10: Core-shell 
type MNPs and their 
coating components.  
A: PEI-Mag2 particle, 
the coating comprises 
32 mass% PEIBr and 68 
mass% Zonyl® FSA. B: 
Silica-iron oxide MNPs 
SO-Mag6-11.5, deco-
rated with PEIBr in a 
PEI-to-Fe w/w ratio of 
11.5 %. C: Structural 
formulas of PEIBr and 
the fluoro-surfactant 
Zonyl® FSA. D: PALD2-
Mag particles were 
stabilized using 
palmitoyldextran PALD2 
(32 palmitoyl groups per 
100 dextran units) and 
the anionic phosphate 
fluoro-surfactant Zonyl® 
FSE. 
 
1.3.3.3.2 Magnetofection 
Magnetofection is the technique of magnetically enhanced delivery of magnetic formulations 
into cells. It was invented independently in two groups back in the year 2000 for the delivery 
of small molecules into hard-to-transfect cells. The first references on the topic of 
magnetofection were conference abstracts by Mah et al. [143] and Plank et al. [144]. The 
contributions of Scherer et al. [114] on non-viral and viral magnetofection and Mah et al. 
[145] on recombinant adeno-associated virus delivery were among the first articles 
addressing the new technique. The sketches in figure 11 by Plank et al. schematically 
explain the principle of magnetofection in general (figure 11A; [146]), and for the delivery of 
nucleic acids in an in vitro set-up (figure 11B; [147]). 
 
Figure 11: General principle of magnetofection (A; [146]) and magnetofection for in vitro 
nucleic acid delivery (B; [147]) 
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Since the pioneering work in our group, this technique was broadly adapted for viral and 
non-viral transfection with DNA, mRNA and siRNA for example in gene silencing approaches 
[106, 147-149]. Nowadays, magnetofection is well established for the delivery of nucleic 
acids under the guidance of an external magnetic field into cells or tissue by association with 
for example PEI- or silica oxide-coated MNPs [111, 114, 143, 144, 150]. 
Great advantages over chemical enhancers are easy, non-invasive and effective 
applicability, without negative effects. Moreover, acceleration of the kinetic course of 
infection could be useful in avoiding nucleic acid inactivation and immune response [110]. 
The technique was already tested in in vivo approaches, for example feline fibrosarcomas 
could successfully be treated applying magnetofection for nucleic acid delivery [151]. 
Progress was also made in the field of aerosol guidance for the treatment of respiratory tract 
diseases. There, the external magnetic field-mediated guidance could increase the gene 
delivery from viral and non-viral vectors into the airway epithelium of specific regions of the 
lung ex vivo and in vivo [152-154]. 
1.3.3.3.3 Viral and non-viral vectors 
In the treatment of diseases like cancer, genetic disorders, and chronic and acute diseases, 
viral [155-157] and non-viral vector-mediated nucleic acid therapies [158] are rapidly 
developing approaches [159]. The assembly of vectors with MNPs is often based on 
electrostatic interactions [147]. Thus the composition of the MNP-coating could positively 
influence the association of nucleic acids with the magnetic carrier particles, as for example 
positively charged PEI facilitates assembly with negatively charged DNA and RNA into 
stable complexes. In addition, PEI protects the nucleic acids from degradation, enhances the 
cell uptake via endocytosis, and, inside the endosomes, it enhances the release of the 
complexes into the cytosol [62, 160-162]. Viral vectors as well as non-viral vectors could be 
tailored in their composition to the application-specific needs. 
1.3.3.3.3.1 Oncolytic viruses 
The National Cancer Institute at the National Institutes of Health, USA, defines an oncolytic 
virus as: “A type of virus that infects and lyses (breaks down) cancer cells but not normal 
cells. Oncolytic viruses can occur naturally, or could be made in the laboratory by changing 
other viruses. Certain oncolytic viruses are being studied in the treatment of cancer. They 
may make it easier to kill tumor cells with chemotherapy and radiation therapy.” 
Often utilized viruses are adenovirus (Ad), herpes simplex virus, Newcastle disease virus 
and vesicular stomatitis virus (VSV) [163, 164]. Important for efficient delivery of the 
oncolytic virus particles (VPs) is the assembly into shielded and stabilized formulations, for 
example with MNPs (figure 9A), especially when administered via the systemic route. 
Magnetic targeting could further increase local titers in the tumor. The utilization of MNPs for 
virus functionalization also enables for real-time monitoring of the VP delivery in vivo by MRI. 
Introduction 
 21 
Big advantage of oncolytic viruses is their specificity to tumor cells, it is very unlikely that 
they infect healthy tissue [155-157, 163, 164]. In addition, they can be genetically 
engineered to eliminate their pathogenicity without destroying their oncolytic potency, 
enhance their tumor specificity, and, eventually, to introduce additional application-specific 
needs [163, 165]. After induction of cancer cell death, new virus particles are released during 
lysis, and the pro-inflammatory microenvironment might also induce an anti-tumoral 
response of the immune system [164, 165]. When utilized as nucleic acid nanocarrier, 
another important aspect of viral vectors is their highly efficient transfection, which could not 
be achieved with non-viral formulations so far [159, 166]. All this makes oncolytic viruses 
versatile platforms for molecularly targeted tumor therapies, maybe even more promising 
than traditional approaches, as such therapy approaches not affected by the increasing 
problem of cancer cell resistance to chemotherapeutics [165]. 
 
 
Figure 12: Schematical virus structures: VSV (A; [167]) and Ad (B; [168]). 
1.3.3.3.3.1.1 Vesicular stomatitis virus (VSV) 
The vesicular stomatitis virus (figure 12A; [167]) is a negative-stranded RNA virus of the 
Rhabdoviridae family. It specifically replicates in type I interferon deficient cells, a 
characteristic of several cancer cell types (figure 13; [169]). Natural hosts of the virus are 
cattle, horses, pigs and insects in which VSV evokes symptoms comparable to foot and 
mouth disease [164]. 
VSV has been successfully used pre-clinically for the treatment of various cancers, including 
multifocal hepatocellular carcinoma lesions (HCC) in rat models [164, 170, 171]. One of its 
advantages is the short replication cycle, reaching high number of copies within 24 hours 
post infection, and thus the ability to reach high titers in the microenvironment of many 
cancers. Representative results of VSV treatment in rat HCC models in vivo are summarized 
in figure 14. A rat bearing multifocal HCC lesions was viro-embolized with VSV by hepatic 
artery infusion (figure 14A), and compared to control animals, a prolonged survival of treated 
rats could be achieved (figure 14B) [170].  
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Figure 13: Tumor cell-selective viral replication and oncolysis of VSV [63]. 
 
 
Figure 14: HCC viro-embolization with VSV [170] A: Representative picture of a rat liver with 
multifocal HCC lesions and the schematical representation of the hepatic arterial infusion procedure 
for administration of VSV. B: Rat survival after arterial VSV viro-embolization. 
1.3.3.3.3.1.2 Adenovirus (Ad) 
Adenoviruses were among the first viral gene vector systems, and due to their long history 
they are well established [163, 172]. The Adenoviridae family comprises more than 50 
different serotypes of human adenoviruses and multiple non-human serotypes [173]. The 
icosaedric virus capsid envelopes the double-strand virus DNA (figure 12B; [168]), which 
transcribes the ability to transduce both, quiescent and dividing cells, and in addition offers a 
high cloning capacity of up to 37 kb [174]. 
Adenoviral vectors are classified among the most powerful gene delivery systems [110], 
especially when assembled with MNPs for magneto-transduction approaches. That was 
shown to reduce immune system inactivation and enhance oncolytic potency [114, 175]. 
Besides the high capacity for modification, the big advantage of adenoviruses is their low 
oncogenic potential as compared to retro- and lentiviral vectors - they do not insert their 
genome into the target cell DNA [176]. Adenoviruses have been tested for the treatment of 
several cancer types [157, 177], and are used in several gene therapy trials. In China, it was 
approved for the treatment of head and neck cancer [178] and nasopharyngeal cancer [179] 
in 2005, and pre-clinically tested in glioblastoma und cervical tumors.  
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1.3.3.3.3.2 Non-viral formulations 
Gene therapy is an upcoming alternative to conventional treatments and opens options for 
previously hard-to-treat genetic and acquired diseases. Obstacle is the delivery of the 
sensitive nucleic acids to the target tissue without early inactivation in the circulatory system 
by nucleases. In the recent years, a lot of work was done on non-viral vectors loaded with 
plasmid DNA (pDNA) or (si)RNA for gene therapy applications [61, 112, 113, 132, 149, 166, 
180-182]. The spontaneous assembly of negatively charged nucleic acids with MNPs (figure 
9B) and surface modification with for example cationic lipids or polymers such as PEI 
resulted in biocompatible formulations for targeted delivery approaches [183] and high 
transfection efficiencies [182-184]. Examples for non-viral nanocarrier structures are 
lipoplexes, polyplexes and MNP-siRNA complexes [112, 180, 185]. Advantages over viral 
vectors are their safety, biocompatibility, adaptability and efficiency in large-scale production, 
size, gene-carrying capacity, specificity through functionalization with targeting ligands, low 
immunogenicity, stability, and sufficient release into the cytoplasm [159, 166].  
First in vitro and in vivo approaches on non-viral constructs loaded with nucleic acids and 
coupled to PEI-coated MNPs were performed in the early 2000s [114, 186-189]. Surface 
functionalization with targeting moieties in combination with magnetofection was 
revolutionizing regarding nucleic acid delivery. The magnetofection process is pretty fast and 
in in vitro experiments, a few minutes of incubation with a magnetic field applied were 
sufficient for successful transfection [132, 188, 189]. Successful transfection could easily be 
proven with nucleic acids coding for reporter genes. Often used reporter genes are 
(enhanced) green fluorescent protein ((e)GFP) [100, 112, 113, 180] and luciferase [111, 190] 
as there are several assays available. After successful proof-of-principle studies, Wu et al. 
used RNA interference (RNAi) successfully for target-specific nucleic acid delivery in a 
murine HCC model. They synthesized multifunctional carriers comprised of siRNA targeting 
human HCC cells, PEG- and PEI-coated MNPs for MRI contrast, and tripeptide arginine-
glycine-aspartic acid (RGD)-functionalization for specific targeting [4]. 
1.3.3.3.4 Magnetic liposomes 
Magnetic liposomes are predominantly examined in the field of liposomal drug delivery [191-
194]. As for all nanocarrier formulations, encapsulation helps to stabilize and shield 
therapeutic agents within the bloodstream to increase their efficacy and decrease side-
effects from off-target delivery [195].  
Structurally, liposomes consist of a lipid bilayer enclosing a liquid filled core, and thus 
provide binding sites for both, hydrophilic and lipophilic molecules, during synthesis. 
Lipophilic molecules can incorporate into the bilayer beneath the lipid chains [196], 
hydrophilic substances can be encapsulated into the aqueous core liquid [197, 198]. Further 
liposome functionalizations to increase the EPR-mediated accumulation at the target tissue 
include loading of MNPs, PEGylation of the surface lipids [92, 199], and coupling of target-
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specific moieties (figure 9C). Possible candidates are antibodies [191, 200, 201], the vitamin 
folic acid [96, 202-206] and the tripeptide RGD [4, 59, 186, 207-210]. Both, folic acid and 
RGD are potential targets in HCC and PDAC therapy as their pendants folate receptor and 
αvβ3 integrin receptor are up-regulated in tumor cells [4, 59, 96, 186, 202-210]. PEGylation of 
the surface lipids results in stealth liposomes with increased stability in the blood circulation 
and reduced uptake into the RES, preventing hepatic drug overload [92, 199]. Labeling of 
liposomes with MRI probes enables for real-time monitoring of (magnetically enhanced) 
accumulation at the target site, and hence estimation of delivered drug [63, 139, 211-214]. 
1.3.3.3.5 Hyperthermia 
Magnetic nanocarriers could also be utilized in therapeutic hyperthermia approaches [117-
119]. In hyperthermic treatments, the local temperature in cancerous tissue gets elevated by 
either external heating sources or within the target tissue starting from therapeutic agents. 
Aim is the temperature-induced irreparable damage or death of tumor cells [59, 215]. In 
addition, the tumor gets sensitized for parallel radio- or chemotherapy [216]. Therapeutic 
formulations for hyperthermia treatments include MNPs and thermosensitive liposomes [96, 
199, 217]. 
The delivery of therapeutic agents in hyperthermia approaches is based on the temperature-
induced enhancement of natural extravasation into tumor tissue due to increased vessel 
permeability. At normothermia conditions of up to 39 °C, the EPR allows extravasation of 
particles up to 100 nm, at hyperthermia conditions above 42 °C, the cut-off for enhanced 
extravasation increased up to 400 nm due [218-221]. Hyperthermia was also shown to 
increase the blood flow which additionally could lead to better accumulation [221], especially 
if further supported by magnetic targeting. Further elevation of the tissue temperature 
resulted in hemorrhage and stasis in examined vessels [219, 220]. 
Besides their capability as targeting agent, the MNPs could be exploited as heating source 
within the target region with an AMF applied [96, 199, 217, 222-224]. AMF for hyperthermia 
induction was found to even have a better penetration than HIFU, laser, radiofrequency or 
microwaves [225]. NanoTherm® by MagForce® is the first approved pharmaceutical 
formulation consisting of SPIOs with aminosilane coating for fine dispersion in water and 
long-term localization at the target site, allowing for repeated treatments. It is successfully 
applied in the treatment of glioblastomas. After administration, the patient is exposed to a 
local alternating magnetic field (AMF) the heat the particles [216]. 
Thermosensitive liposomes are specifically designed to release the encapsulated cargo at 
the lipid transition temperature Tm [96, 213, 226-228]. For potential in vivo approaches, 
release should start above 40 °C to prevent unspecific liberation [96, 193, 213, 222, 223, 
225, 228-232]. The addition of PEG lowered the transition temperature, and led to faster 
release at Tm, better stability below Tm and higher drug delivery, also farther from the vessels 
[221]. The clinically approved thermosensitve liposomes ThermoDOX® were evaluated in 
Introduction 
 25 
several clinical studies on HCC [233-237] and breast cancer [238-241]. Between 2008 and 
2017, there were several phase III studies on HCC, partly in combination with 
radiofrequency ablation [233-236]. 
 
1.4 Aim of the study 
Hepatocellular carcinoma and pancreatic ductal adenocarcinoma are severe tumors with 
high incidence and mortality rates. Both cancers do not present clear symptoms, and 
therefore are often diagnosed in advanced stages. By then, the tumors of many patients are 
not capable of resection anymore and palliative and adjuvant treatments are the therapies of 
choice. Especially in PDAC it is difficult to improve the diagnosis due to its status as silent 
disease, but HCC patients were mostly cirrhotic before the HCC developed. Improved 
diagnostic, ideally with parallel delivery of therapeutic agents, could enhance the therapeutic 
outcome. For PDAC, the main focus was set on the improvement of drug delivery to 
overcome the poor chemotherapeutic efficiency. In both cancers, tumor cell-specific 
nanocarriers could improve the non-invasive and non-radiation detection of distant 
metastasis. 
In this study, we aimed to develop nanocarrier formulations for three different therapeutic 
approaches: MNP-VP complexes with oncolytic viruses to specifically infect tumor cells, 
MNP-siRNA complexes in a proof-of-principle set-up for future gene-silencing approaches 
targeting oncogenes, and magnetic liposomes for targeted drug delivery and release. Core 
component of the magnetic nanocarrier formulations were iron oxide MNPs. The adjustability 
of surface composition, high surface area-to-volume ratio and magnetic moment made the 
chosen core-shell type MNPs ideal candidates for the assembly of nanocarrier formulations, 
magnetically enhanced delivery, magnetofection, and as MRI contrast probes. The latter 
allow parallel examination of MRI imaging properties due to SPIO-induced T2 signal 
attenuation after in vivo administration. Figure 15 schematically presents magnetic targeting 
of our nanocarrier systems in vivo in PDAC (figure 15A) and exemplary MRI scans of 
accumulated MNP-VP complexes in a HCC model (figure 15B). 
 
All in vitro experiments were performed in HCC and PDAC cell lines of human and rodent 
origin. The MNPs were previously synthesized in our lab, viruses were amplified specifically 
for this study. As all nanocarrier formulations were characterized for their potential 
transferability into clinical approaches, it was important to test them for potential toxicity in 
animal models. Thus, PALD2-Mag particles were examined in a mouse study. PEI-Mag and 
SO-Mag particles were previously used for pre-clinical approaches, the in vivo toxicity study 
was not repeated.  
 
MNP-VP complexes were tested in tumor therapy approaches to utilize the cancer cell-
specificity of oncolytic viruses, i.e. Ad and VSV, combined with MNP-based magnetic 
targeting of the formulation. In in vitro and in vivo experiments, the viral complexes were 
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analyzed for their oncolytic activity, virus delivery efficiency and possibility to non-invasively 
identify the formulation by MRI. Tissue-mimicking in vitro phantoms were prepared and 
characterized for quantification of MRI detection limits regarding the amount of MNPs 
needed for sufficient contrast, and to provide the basis for estimation of virus delivery 
efficiency in further in vivo approaches. Such MNP-VP complexes are a promising approach 
especially for the treatment of chemo-resistant tumor lesions in non-resectable patients as 
well as metastasis detection and treatment in very localized and target tissue-specific 
manner. 
 
MNP-siRNA complexes are an excellent formulation for the targeted delivery of nucleic 
acids. In this study, proof-of-principle experiments should show how they enable for the 
knock-down of reporter genes. In further pre-clinical approaches, the delivery of oncogene-
specific nucleic acids towards tumor cells could help to stop tumor expansion, again in a 
very localized approach due to the magnetic targeting. 
 
Magnetic liposomes provide various options for application-specific tailoring. To identify the 
optimal synthesis protocol for our liposomes, different methods were compared. They were 
loaded with chemotherapeutic drug, and MNPs for targeting and monitoring. The lipid bilayer 
was composed to release the cargo temperature-dependently and further surface 
functionalization with PEG and a RGD-like structure would stabilize the LPs and enhance 
tumor cell targeting and, thus, increase drug delivery efficiency. Stabilization of the MNP-
LPs, their biodistribution and ability for magnetic targeting were analyzed in proof-of-principle 
in vivo experiments. 
 
 
Figure 15: Schematical setup of magnetic targeting in gastro-intestinal cancers. A: Magnetic 
targeting of a systemically administered nanocarrier formulation in murine PDAC. B: Hypointense MRI 
signal due to MNP-accumulation in a rat HCC tumor nodule (red arrow) before (top) and after (bottom) 
magnetic targeting. 
 
Experimental 
 27 
2 EXPERIMENTAL  
2.1 Material 
2.1.1 Technical equipment 
1.5 T Achieva and 3.0 T Ingenia Philips Medical Systems, Best, the Netherlands 
Beckman DU 640 spectrophotometer Beckman Coulter Inc., Krefeld, Germany 
Infinite M1000Pro   Tecan Trading AG, Switzerland 
Malvern 3000 HS Zetasizer   Malvern Instruments Ltd, UK 
Microplate Scintillation &  Packard Instrument Co., Inc./Canberra Industries, & 
Luminescence Counter   Meriden, CT, USA 
Rotavapor (Rotary evaporator) Büchi Labortechnik GmbH, Essen, Germany  
Wallac 1420 VICTOR2   PerkinElmer, Waltham, MA, USA 
Zeiss Libra 120 Plus (TEM)  Carl Zeiss NTS GmbH, Oberkochen, Germany  
 
All analysis was done using MS Excel (Microsoft Corporation, Redmont, USA) and the graphs 
were generated with Prism (GraphPad Software, Inc., La Jolla, CA, USA). 
2.1.2 Reagents 
Agarose    Biozym, Oldendorf, Germany 
Isofluorane    VetOneTM, MWI, Meridian 
 
Control (non-sil.) siRNA (5 nm) Qiagen, Hilden, Germany 
GFP-22 siRNA (5 nm)   Qiagen, Hilden, Germany 
Luciferase GL3 siRNA (5 nm)  Qiagen, Hilden, Germany 
 
DPPC (1,2-dipalmitoyl-sn-glycero-  Avanti Polar Lipids, Inc., Alabaster, Alabama, USA 
 3-phosphocholine) 
DSPC (1,2-distearoyl-sn-glycero-  Avanti Polar Lipids, Inc., Alabaster, Alabama, USA 
 3-phosphocholine) 
  
If not declared differently, all other chemicals and reagents were purchased from Carl Roth, 
GmbH & Co. KG (Karlsruhe, Germany), Merck (Darmstadt, Germany), Sigma-Aldrich (Steinheim, 
Germany), or ThermoFisher Scientific (Darmstadt, Germany).  
2.1.3 Media 
Dulbecco´s Modified Eagle´s Medium (DMEM), Dulbecco´s phosphate-buffered saline (PBS) 
(with and w/o Mg2+, Ca2+), fetal calf serum (FCS) and L-glutamine were purchased from Gibco® 
Life Technologies, Darmstadt, Germany. Non-essential amino acids, penicillin/streptomycin and 
trypsin/EDTA (0.25%/0.02%) were bought from PAA Laboratories GmbH, Pasching, Austria. 
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2.1.4 Animals, cells, viruses and vectors 
Provided by Dr Altomonte (II. Med Clinic, Gastroenterology, RdI, TUM): 
Baby hamster kidney cells BHK-21 (American Type Culture Collection (ATCC), LGC Standards 
GmbH, Wesel, Germany) 
Buffalo rats (Harlan Winkelmann, Borchen, Germany) 
HuH-7 human hepatocellular carcinoma cell line 
Rat Morris hepatocellular carcinoma cells (McA-RH7777) (American Type Culture Collection  
(ATCC), LGC Standards GmbH, Wesel, Germany) 
Human liver carcinoma cell line HepG2 (HepG2 ATCC® HB-8065TM)  
rVSV-GFP 
 
Provided by Dr Heid (Diagnostic and Interventional Radiology, RdI, TUM): 
BL/6 CKp53lox mice (Ptf1αwt/Cre; Kraswt/LSL-G12D; p53fl/fl) 
 
Provided by Dr Mykhaylyk/Dr Holm (Experimental Oncology and Therapy Research, RdI, TUM): 
E1A mutant adenovirus dl520 
MDR human pancreatic carcinoma cells EPP85-181RDB 
Parental human pancreatic carcinoma cells EPP85-181P 
 
Provided by Dr Anton (Experimental Oncology and Therapy Research, RdI, TUM): 
LV-PGK-eGFP-Luc-fusion construct 
 
Provided by Dr Trajkovic-Arsic (II. Med Clinic, Gastroenterology, RdI, TUM): 
Murine pancreatic ductal adenocarcinoma primary cells from CKp53lox mice (Ptf1αwt/Cre; 
Kraswt/LSL-G12D; p53fl/fl) 
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2.2 Experimental 
In this thesis the development and characterization of three different nanocarrier systems, 
namely MNP-VP complexes, MNP-siRNA complexes and magnetic liposomes, is described. 
Essential component of all three nanocarrier systems are magnetic nanoparticles. Therefore, 
in the first section the synthesis of the different MNPs is described. The further experimental 
chapter is structured into three parts, each describing one nanocarrier system. 
2.2.1 MNPs 
Core−shell type iron oxide nanoparticles all consist of a magnetic iron core and different 
surface functionalizations. The composition of those surface modifications influences the 
charge of the MNPs. 
The magnetic core particles were synthesized by precipitation of the Fe(II)/Fe(III) hydroxide 
from aqueous solution, followed by transformation into magnetic iron oxide in an oxygen-free 
atmosphere [242]. The condensation of tetraethyl orthosilicate (TEOS) and 3-
(trihydroxysilyl)propylmethylphosphonate (THPMP) resulted in the SO-Mag5 particles 
comprising a surface coating of a silicon oxide layer with surface phosphonate groups 
(SiOx/phosphonate) [243]. 
For assembling with negatively charged nanostructures such as virus particles and nucleic 
acids, the SO-Mag5 nanoparticles were decorated with PEI. Surface modification at a PEI-
to-iron (w/w) ratio of 11.5 % formed the positively charged SO-Mag6-11.5 nanoparticles and 
further referred to as SO-Mag particles. The exact synthesis procedure was previously 
described in [115]. 
The positively PEI-Mag2 nanoparticles, further referred to as PEI-Mag particles, were 
generated by spontaneous adsorption of the fluorosurfactant lithium 3-[2-
(perfluoroalkyl)ethylthio]propionate (Zonyl® FSA) and 25-kDa branched polyethyleneimine 
(PEIBr-25 kDa) onto the iron oxide core particles as described previously in detail by [100, 
113, 243]. 
Negatively charged MNPs can be used for the inclusion in magnetic liposomes. The detailed 
synthesis of PALD2-Mag particles was described by [180]. Surface coating of those particles 
resulted from the spontaneous adsorption of the fluorosurfactant ammonium bis[2-
(perfluoroalkyl)ethyl]phosphate (Zonyl® FSE) and the palmitoyl dextran PALD2 [79, 180]. 
 
The synthesis of all MNPs was kindly performed by Dr Mykhaylyk, Group of Prof Plank, 
Department of Experimental Oncology and Therapy Research, Klinikum rechts der Isar der 
Technischen Universität München. 
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2.2.2 Magnetic nanocarriers 
2.2.2.1 MNP-VP complexes 
2.2.2.1.1 Cell culture 
The rat Morris hepatocellular carcinoma cells (McA-RH7777), further referred to as McA 
cells, and the baby hamster kidney cells BHK-21 cells were purchased from the American 
Type Culture Collection, and were cultured in Dulbeccoʼs modified Eagleʼs medium (DMEM; 
ATTC, Manassas, MA, USA) supplemented with 10 % heat-inactivated fetal calf serum (FCS), 
100 U mL−1 penicillin, and 100 µg mL−1 streptomycin. The MDR human pancreatic 
adenocarcinoma cells EPP85-181RDB, further referred to as RDB cells, were grown in 
DMEM supplemented with 10 % heat-inactivated FCS and 1 % 2 mM L-glutamine.  
The McA cells derive from a female Buffalo rat and show an epithelial morphology with 
loosely adherent growth, the RDB cell morphology is epithelial with adherent growth. All cell 
lines were spilt before reaching 100 % confluency. Briefly, the cell culture medium was 
aspirated and the cell monolayer was washed with pre-warmed PBS to remove any serum. 
Then pre-warmed trypsin/EDTA (0.25%/0.02%) was added and cell detachment was 
observed under the microscope (Carl Zeiss, Munich, Germany). Once the cells started to 
detach, warm culture medium containing serum was added to stop the trypsin reaction and 
the cells were split 1:4 to 1:6 into new cell culture dishes. 
All cell lines were cultured at 37 °C in a humidified atmosphere containing 5 % CO2. 
2.2.2.1.2 Adenovirus and vesicular stomatitis virus 
The E1A mutant adenovirus dl520, further referred to as Ad, was kindly provided by Dr Holm 
[244]. The Ad was expanded in 293 cells and purified by double cesium chloride (CsCl) 
gradient centrifugation, resulting in a virus stock containing 4.3 x 1012 VP/mL and 2.6 x 1011 
transforming units per mL. Briefly, the 293 cells were infected with adenovirus and harvested 
when full cytopathic effect was observed. Cells and medium were harvested and centrifuged, 
then the pellet was resuspended in a smaller volume of the supernatant and the solution 
underwent freeze-thaw-cycles. After another centrifugation, the virus-containing supernatant 
was transferred as top layer onto 1.34 g/ml CsCl overlaid with 1.43 g/ml CsCl and 
centrifuged. The lower band containing intact virus particles underwent a second 
ultracentrifuge spin in 1.34 g/ml CsCl solution. After desalting using a sephadex PD-10 
column, the purified virus stock could be stored at -80 °C [245]. To determine the physical 
virus particle titer, an aliquot of the virus stock was diluted 1 to 20 in Dulbeccoʼs phosphate 
buffered saline (PBS) that contained 0.1 % sodium dodecyl sulfate, mixed thoroughly for 2 
minutes and centrifuged at 8,000 g for 5 minutes [246]. The optical density (OD) at 260 nm 
was measured, and the physical virus titer was calculated, taking into account that an OD of 
1 corresponds to 1.1 x 1012 VP/mL [247]. Aliquots of the stock were stored at -80 °C.  
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Figure 16: Plaque assay of 
sucrose-gradient purified 
VSV-GFP. 
 
 
 
The rVSV-GFP, further referred to as VSV, was amplified on BHK-21 cells and the 
supernatant was purified by sucrose gradient centrifugation [170, 171]. Briefly, BHK-21 cells 
(90 % confluent) in 15 cm cell culture dishes were infected with VSV at a multiplicity of 
infection (MOI) of 0.0001 in OptiPRO SFM (ThermoFisher Scientific, Darmstadt, Germany), 
and 48 hours later the supernatant containing virus particles and floating cells was 
harvested. The cells were cleared by 10 minutes centrifugation at 1,500 rpm then the virus 
was pelleted by ultra-centrifugation for 1 hour at 25,000 rpm. The in PBS resuspended virus 
was layered on top of a 60 % / 30 % / 10 % sucrose gradient and purified by ultra-
centrifugation at 25,000 rpm for 1 hour. The band containing the virus was carefully collected 
with a syringe and 20-gauge needle, and aliquots of the virus stock were stored at -80 °C. 
This virus stock contained 6.6 x 109 pfu/mL as was determined by plaque assay. Briefly, the 
virus was serial diluted in PBS with 1 mM MgCl2 and CaCl2, then BHK-21 cells (90 % 
confluent) in 6-well plates were infected with the VSV dilutions for 1 hour. The three times 
rinsed cell layers were then overlayed with 0.9 % agarose in GMEM (ThermoFisher Scientific, 
Darmstadt, Germany), and further incubated at 37 °C for 48 hours. After 15 minutes crystal 
violet staining, the number of plaques could be counted and the titer calculated (average of 5 
plaques/10-9 dilution means the titer is 5 x 109 pfu/mL). Figure 16 shows exemplary 
photographs of VSV plaque assay plates. 
2.2.2.1.3 MNP-VP interaction 
The question to be answered was to find a formulation, which could help to facilitate the 
localization of the oncolytic virus particles in the tumor region after systemic administration. 
To prepare such formulation, first the virus particles were assembled with magnetic 
nanoparticles to enable magnetic targeting and real-time monitoring of the applied virus by 
MRI. Those complexes were examined for their physico-chemical properties to identify the 
best composition. After this first step, the magnetic viral complexes were tested in vitro on 
cancer cells to evaluate the cell infection efficacy and the oncolytic potential of the 
formulations. Two types of particles, namely SO-Mag6-11.5 and PEI-Mag2, both positively 
charged, and two types of cancer cell lines, namely McA hepatoma and RDB pancreatic 
cancer cells were examined to identify the complex type with the best oncolytic potential for 
each cell line. 
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2.2.2.1.3.1 Preparation of magnetic viral complexes 
Adenovirus complexes with MNPs were prepared as described previously by Tresilwised et 
al. [105]. Briefly, 1011 VP of the Ad diluted in 800 µL PBS were added to 200 µL of PEI-Mag2 
or SO-Mag6-11.5 MNPs in ddH2O containing 500 µg of Fe and mixed, resulting in an iron-to-
physical virus particle ratio of 5 fg Fe/VP. The resulting complexes will be further referred to 
as PEI-Mag-Ad and SO-Mag-Ad complexes. 
To prepare magnetic VSV complexes, equal volumes of ddH2O containing MNPs of 226.8 
µg iron and PBS containing 4.5 x 108 pfu or 2.3 x 108 pfu VSV were mixed in a final volume 
of 1,380 µL. The resulting ratios of MNP-to-virus were of 500 and 1,000 fg Fe/pfu, 
respectively, for PEI-Mag2 and SO-Mag6-11.5 particles, respectively. The resulting 
complexes will be further referred to as PEI-Mag-VSV and SO-Mag-VSV complexes. 
After an incubation period of 20 minutes at RT to allow complex assembly, the volume was 
adjusted with PBS and the freshly prepared complexes were used for characterization of the 
magnetic vectors, cell infection, phantom preparation, or in vivo experiments as described in 
the following sections.  
2.2.2.1.3.2 Titration and characterization of MNP-VP complexes 
To identify the optimal iron-to-virus ratio for the magnetic viral complexes, a fix amount of 
virus was incubated with increasing concentrations of iron. 
The titration for the adenovirus complexes was already performed by Tresilwised et al. and 
an optimal ratio of 5 fg Fe/pfu was determined [105]. 
TCID50 assays were performed to identify the optimal condition for the according VSV 
complexes. Therefore, 108 pfu/mL VSV were titrated with increasing amounts of PEI-Mag 
and SO-Mag, respectively, at iron doses per viral pfu ranging between 0-750 and 0-1,250 fg 
Fe/pfu VSV. To determine at which iron-to-virus ratio most of the virus was complexed with 
the MNPs, the mixtures of the magnetic and viral particles were allowed to assemble for 15 
minutes and subjected to gradient magnetic field to magnetically separate the magnetic 
fraction (MF) and the non-magnetic fraction (NMF). Both fractions were used for cell 
infection. Pure virus at a concentration of 108 pfu/mL served as positive control, just MNPs 
with the same iron concentration as used in the 500 fg Fe/pfu VSV sample as negative 
control. 
Those batches of fractions were serial diluted and used in quadrupels for infection of BHK-
21 cells (50 % confluent) in 96-well plates as shown in figure 23A. After 48 hours incubation, 
the TCID50 values were calculated with the Spearman & Kärber algorithm [248]. In addition 
both, the fresh complex preparation and the magnetic fraction after separation, were 
analyzed regarding their physico-chemical properties zeta potential and hydrodynamic 
diameter.  
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2.2.2.1.3.3 Magnetic cell labeling and infection with magnetic viral complexes 
The cells were grown in 75 cm2 cell culture flasks (Techno Plastic Products, Trasadingen, 
Switzerland) and loaded with MNPs or infected with magnetic viral complexes when they 
reached 70 to 80 % confluency (4 - 6 x 106 cells per flask). 25 and 10 pg Fe/cell either free 
MNPs or complexed with Ad or VSV were applied in cell culture medium to the RDB and 
McA cells, respectively. Adenoviral complexes were applied at MOIs of 120, VSV complexes 
at MOIs of 20 (PEI-Mag-VSV) and 10 (SO-Mag-VSV). For the magnetofection [100], the 
magnetic field was applied by incubating the flasks on a magnetic plate (field strength and 
gradient at the cell layer location of 70−250 mT and of 50−130 T/m, respectively, OZ 
Biosciences, Marseille, France) for 30 minutes in the case of the RDB cells [105] and 1 hour 
for the McA cells at 37 °C. Afterwards, the RDB cells were incubated for another 3 hours in 
the incubator without magnetic field. The now labeled cells were washed with PBS three 
times to remove any loosely-bound particles or complexes. Next, the cells were trypsinized 
with 0.25 % trypsin/0.02 % EDTA solution. After washing with PBS, the cells were fixed with 
BD CytofixTM (BD Biosciences, Heidelberg, Germany), washed three times with PBS and 
resuspended in PBS for use in cell characterization or phantom preparation.  
2.2.2.1.3.4 Analysis of the exogenic non-heme iron content 
The exogenic non-heme iron content of the magnetically (virus-)labeled cells was 
determined using a modified protocol of the Torrance and Bothwell method [100, 249]. 
Briefly, approximately 4 x 105 trypsinized cells were washed with PBS and pelleted. The in 
500 µL acid mixture of 3 M HCl and 0.6 M trichloracetic acid contained resuspended cells 
were incubated overnight at 65 °C. To remove cell debris, the samples were centrifuged 5 
minutes at 14,000 rpm and 50 µL of the clear supernatant were analyzed for the iron content 
by a colorimetric method with 1,10-phenanthroline. Therefore, the supernatant was mixed 
with 50 µL sterile water, 20 µL 10 % hydroxylamine-hydrochloride solution, 100 µL 
ammonium acetate buffer (25 g ammonium acetate and 70 ml glacial acetic acid with a total 
volume adjusted to 100 ml with ddH2O), and 50 µL 0.1 % 1,10-phenanthroline solution. After 
20 minutes reaction time, the OD was measured at 510 nm, the absorption maximum of the 
iron(II)-1,10-phenanthroline complex, in a Beckman DU 640 spectrophotometer (Beckman 
Coulter Inc., Krefeld, Germany). The iron content of the samples could be calculated using a 
calibration curve, determined from an iron stock solution (392,8 mg ammonium iron(II) 
sulfate hexahydrate, 2 mL concentrated H2SO4 and 10 mL ddH2O water, titrated with 0.05 N 
KMnO4 until a faint pink color persisted, followed by volume adjustment to 100 mL). Basal 
non-heme iron level determined in non-labeled cells was used as a reference. 
2.2.2.1.3.5 Sample preparation and transmission electron microscopy (TEM) 
For TEM analysis, about 105 labeled or infected cells were washed with PBS after 
trypsinization. Free MNP suspensions and free MNP-VP complexes, both containing about 
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the same amount of iron as applied to cells, and the cells were pelleted for 5 minutes at 
1,600 rpm in beam tubes and the (cell) pellets were fixed with 2.5 % glutaraldehyde in 0.1 M 
sodium cacodylate buffer pH 7.4 TEM fixation buffer (Electron Microscopy Sciences, Hatfield, 
USA) at 4 °C. The samples were then post-fixed in 2 % aqueous osmium tetraoxide [250], 
dehydrated in gradual ethanol (30 – 100 %) and propylene oxide, embedded in Epon and 
dried for 24 hours at 60 °C. Semithin sections were cut and stained with toluidine blue. 
Ultrathin sections of 50 nm were collected onto 200 mesh copper grids (Sigma-Aldrich, 
Steinheim, Germany), stained with uranyl acetate and lead citrate before examination by 
TEM (Zeiss Libra 120 Plus, Carl Zeiss NTS GmbH, Oberkochen, Germany). Pictures were 
acquired using a Slow Scan CCD-camera (Olympus Soft Imaging Solutions, Münster, 
Germany) and the iTEM software (Olympus Soft Imaging Solutions, Münster, Germany). 
2.2.2.1.3.6 Characterization of the oncolytic potential of MNP-VP complexes in vitro 
The RDB cells and McA cells were seeded in 96-well cell culture plates at 104 cells per well 
and incubated at 37 °C 24 hours prior to infection. The cell culture medium in each well was 
replaced with 150 µL of fresh culture medium containing 10 % FCS or 66.7 % FCS, then 50 
µL of virus or the magnetic viral complexes in serum free medium were added. The resulting 
medium was referred to as the infection medium with final FCS concentrations of 7.5 % or 
50 %. To define the concentration required for 50 % cell growth inhibition (IC50) for free virus 
or viral complexes, 2-to-1 serial dilutions of naked adenovirus ranging from 2.5 − 320 pfu/cell 
and from 0.625 − 80 pfu/cell for the MNP-Ad complexes, and MOIs of 0.005 - 10 for naked 
VSV and the MNP-VSV complexes were prepared, all in triplicates. If indicated, a magnetic 
field was applied by positioning the cell culture plates on a magnetic plate (OZ Biosciences, 
Marseille, France) for 30 minutes. No medium change was performed and the RDB and McA 
cells were incubated for 6 days and 24 hours, respectively. 
The survival of infected RDB cells was evaluated 6 days after infection using luciferase 
assay (37). Briefly, the cells, which stably express firefly luciferase, in all wells were washed 
with PBS and lysed with 100 µL of lysis buffer per well. After incubation for 15 − 20 minutes 
at RT, 50 µL of cell lysate were transferred to the respective well in a 96-well black flat-
bottom plate. Then, 100 µL of luciferin buffer (35 µM D-luciferin (Roche Diagnostics, 
Mannheim, Germany), 60 mM DTT, 10 mM magnesium sulfate, 1mM ATP, in 25 mM glycyl-
glycin-NaOH buffer, pH 7.8) were added. The chemiluminescence intensity was measured in 
counts per min (CPM) using a Microplate Scintillation & Luminescence Counter (Packard 
Instrument Co., Inc./Canberra Industries, Meriden, CT, USA). The non-infected cells were used 
as reference representing 100 % viable cells. For background measurements, 50 µL of lysis 
buffer and 100 µL of luciferin buffer were used. The cell survival was calculated according to 
the following equation: 
Cell survival (%) = 100 * (CPMinfected cells – CPMblank) / (CPMuninfected cells – CPMblank) 
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The viability of the McA cells was assessed 24 hours after infection by MTT assay, based on 
reduction of the MTT reagent into formazan by superoxide anion radicals produced in the 
mitochondrial respiratory chain [251, 252]. Briefly, infected cells were washed with PBS and 
100 µL of MTT solution (1 mg/mL MTT in 5 mg/mL glucose) were added per well. After 2 
hours incubation at 37 °C, viable cells formed formazan crystals, which were lysed with 100 
µL solubilization solution (10 % Triton X-100 in 0.1 N HCl in anhydrous isopropanol) over 
night, incubation at RT in the dark. The solved crystals, representing the respiration activity 
of the cells, were quantified using a Wallac 1420 VICTOR2 microplate reader at a 
wavelength of 590 nm. To evaluate the effect of free MNPs on the viability, control cells were 
treated with MNPs in the same concentration range and analyzed under the same 
conditions. Again non-infected cells were used as reference representing 100 % viable cells; 
the background was determined from 100 µL MTT solution with 100 µL solubilization 
solution. The acquired cell survival data were plotted against logarithms of the applied virus 
dose (pfu/cell) and were fitted using the “DoseResponse” function of OriginPro 9G software 
(OriginLab Corporation, Northampton, MA, USA) to calculate the needed doses of virus 
resulting in 50 % cell growth inhibition (IC50 values). 
2.2.2.1.3.7 Magnetophoretic mobility measurements 
 
Figure 17: Setup magneto-
phoretic mobility measure-
ments. Magnetic responsiveness 
in µm/sec (modified from [67]). 
To characterize the magnetic responsiveness of the 
magnetically labeled cells and the MNP-VP complexes, 
the time course of the decreasing turbidity of the 
suspensions when subjected to inhomogeneous 
magnetic fields was measured [180, 181]. Briefly, a 
gradient field was generated by positioning two 
mutually attracting packs of four quadrangular 
neodymium-iron-boron permanent magnets 
symmetrically on each side of a cuvette holder, parallel 
to a beam of light, for optical density measurements. 
The magnetic field between the magnets was measured 
with a Hall detector using a grid of step size 1 mm, and 
the average magnetic field and the resulting field gradient 
were calculated to be 0.213 T and 4 ± 2 T/m in the 
direction of the complex movement (figure 17).  
The complex and cell suspensions were diluted to 500 µL aliquots to achieve a starting OD = 
0.3–1 at the analytical wavelength of 610 nm for the labeled cells and 360 nm for the 
magnetic viral complexes. Optical cuvettes filled with these diluted suspensions were placed 
in a Beckman DU 640 spectrophotometer and the change in the optical density or turbidity 
was immediately recorded over 30 minutes. 
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2.2.2.1.4 Magnetic resonance imaging 
Long-term aim was to facilitate the real-time monitoring and localization of the systemically 
applied oncolytic virus complexes. To examine the MNP-VP complexes for their imaging 
properties, complexes and infected cells were prepared under the identified most effective 
conditions. Then tissue-mimicking agarose phantoms were prepared from those complexes 
as well as from infected cells, both with known iron concentrations and sample material 
homogenously dispersed in the gel. In addition, there were phantoms prepared with certain 
iron concentrations either as homogenously dispersed free or cell internalized MNPs in 
dilution series, and phantoms prepared with clotted sample material. 
2.2.2.1.4.1 Cell labeling and infection for phantom preparation 
For the MNP-VP complex phantoms (dispersed and clotted), the cells were infected and 
prepared as described under 2.2.2.1.3.3. 
For the MRI phantoms prepared from free MNPs and cells with internalized MNPs, 
described in figure 28, the cell labeling conditions were identified in saturation experiments. 
Therefore, McA and murine PDAC cells were magnetofected with increasing amounts of 
MNPs, and after non-heme iron quantification with 1,10-phenantroline, the 
internalized/associated iron was plotted against the applied iron. From the saturation curves 
100 pg Fe/cell was identified as good labeling condition. Then 511181 cells were seeded at 
a density of 46,667 cells per cm2 in a 75 cm2 dish, while McA cells were seeded at a density 
of 8 x 104 cells per cm2 in a 75 cm2 dish. 24 hours post cell seeding, 100 pg Fe/cell SO-
Mag6-11.5 particle suspension in cell culture medium was applied. Then, the cell culture 
flasks were placed on a plate magnet (OZ Biosciences, Marseille, France) for 30 minutes in 
the incubator. After the magnetofection, cells and MNPs were further incubated for 24 hours. 
The harvested cells were fixed and stored at 4 °C in PBS/0.5% NaN3 until usage as 
previously described. This procedure was performed analogous for all other cell lines, 
complexes, and the PEI-Mag particles and complexes. 
2.2.2.1.4.2 Preparation of calibration phantoms for MRI 
Calibration phantoms for MR imaging were prepared with free MNPs, free MNP-VP 
complexes, cells labeled with MNPs and cells infected with MNP-VP complexes, 
respectively, all homogeneously dispersed in agarose gel in 24-well plates [67, 115]. Briefly, 
according to Christoffersson et al. tissue-mimicking phantom material can be prepared by 
using different concentrations of nickel and agarose to modulate the relaxation times of the 
gel [65]. Increasing nickel(II) ion concentration shifts the T1 values to longer relaxation times, 
while increasing agarose concentration results in T2 relaxation time shortening. The gel 
phantom mimicking relaxivity of murine liver tissue (T1 = 550 ms and T2 = 48 ms; table 4) 
was prepared with 1.98 mM nickel(II) nitrate,  2.45 % agarose, and 0.5 % sodium azide for 
preservative purposes [253]. 
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Table 4: Relaxation times used for tissue-mimicking: T1 and T2 of different body tissues [47]. 
2-to-3 dilution series were prepared for all samples, in water for free MNPs, and in PBS for 
free MNP-VP complexes and magnetically labeled and infected cells. The maximal iron [in 
mM Fe/well] and cell [in cells/mL] concentrations present in well 1, as well as the respective 
cell labeling [in pg Fe/cell] and labeling efficiencies are summarized in table 5. To prove 
detectability of the MNP iron in surrounding liver tissue, and to exclude air artifacts during 
the MR image acquisition, the 12 wells between the sample wells and the cavities between 
the wells on both sides were filled with the described Ni-containing agarose gel. Figure 18A 
shows the schematical setup of the phantom plates. For the 11 sample wells and the 
reference well, gel with 1.5-fold higher concentrations of the nickel salt, agarose (Biozym, 
Oldendorf, Germany) and sodium azide was prepared and 3 mL of to 60 °C pre-warmed 
agarose gel were vortex-mixed with 1.5 mL sample in 15 mL falcon tubes to distribute the 
nanomaterial homogenously, and transferred into the designated well avoiding air bubbles. 
Well R contained only water/PBS mixed with this agarose gel and served as a reference well 
for background normalization. To identify potential relaxivity changes caused by the cell 
background, phantom plates with untreated, fixed cells were prepared. The phantom plates 
were allowed to cool down slowly to RT, and sealed with parafilm (Brand GmbH & Co. KG, 
Grafrath, Germany) to avoid evaporation of water during their storage at 4 °C.  
In addition to the phantoms with homogenously dispersed sample material, clot phantoms 
were prepared. Therefore, sample material was mixed to a total volume of 120 µL with 1 % 
alginate as coagulant agent, 40 mM CaCl2, and PBS/0.5 % NaN3. To identify optimal clotting 
conditions, per well 50 µL medium were mixed with 50 µL 2 % alginate and either transferred 
directly to the wells of a 96-well plate, or added to wells prepared with CaCl2 in increasing 
volumes ranging from 5 µL to 100 µL; to the wells prepared with the alginate mix, the same 
increasing volumes of CaCl2 were added (figure 18B, “Ca” means CaCl2 first, “P” means 
sample first). The clot forming was supported either by incubating the plate on a 37 °C 
ThermoMixer, or by using a hair dryer for heating. The geling process took about 15 
minutes, then the clots could be removed from the wells using a small curved spatula. 
Optimal clot formation was observed when 100 µL sample were added onto 20 µL CaCl2 
followed by short hair dryer heating and incubation for 15 minutes. 
Clots were prepared from free MNPs, MNP-VP complexes, and cells with internalized MNP(-
VPs). The gelled clots were transferred to a phantom plate prepared with 1.5 mL agarose in 
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the sample wells, placed in the middle on top of the hardened agarose, and covered with 
another 1.5 mL agarose gel (figure 18C). 
 
 
Figure 18: MRI phantom preparation. A: General scheme of MRI phantoms. B: Optimization of 
alginate clot formulation: best result for 0.017 M CaCl3 and 1 % alginate (P: sample first, CaCl3 added; 
Ca: CaCl3 first, sample added à 20 µl CaCl3 + 100 µl sample with 1 % alginate). C: From left to right: 
MNP(-VP) ± McA cells clots and the according phantoms (set-up, plate ± agarose cover, T2*w image 
(1.5 T Achieva, Philips Medical Systems, Best, the Netherlands)). 
 
 
Table 5: Phantom properties. Phantom plates with MNPs, magnetic viral complexes and 
magnetically labeled or infected cells. The maximal concentration in well 1 is diluted in a 2-to-3 
dilution series. 
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2.2.2.1.4.3 Magnetic resonance imaging 
The imaging experiments were performed on a clinical 1.5 T MRI system (1.5 T Achieva, 
Philips Medical Systems, Best, the Netherlands) and a clinical 3.0 T MRI system (3.0 T 
Ingenia, Philips Medical System, Best, the Netherlands) using the 8-channel SENSE head 
coil (Philips Medical Systems, Best, the Netherlands) for signal reception. The rectangular 
agarose phantom plates were centrally positioned on the head cushion of the coil. 
T2 and T2* maps of the calibration phantoms were measured using the following sequences 
on the 1.5 T MRI system: for T2 a multi-spin echo sequence with TR = 2,000 ms, TE = n x 4.9 
ms (n = 1…30), flip angle = 90 °, FOV = 160 x 88, resolution = 1 x 1 x 3 mm3, 3 slices of 3 
mm thickness with gap = 0 mm, scan time = 6:04 minutes and for T2* a multi-echo gradient 
echo sequence (FFE) with TR = 1000 ms, TE = 2.1 + n x 3.2 ms (n = 0…15), flip angle = 90 
°, FOV = 160 x 92, resolution = 1 x 1 x 3 mm3, 3 slices of 3 mm thickness with gap = 0 mm, 
scan time = 4:40 minutes. 
On the 3.0 T system the sequences were the following: for T2 a multi spin echo sequence 
with TR = 2,200 ms, TE = n x 6.0 ms (n = 1…30), flip angle = 90 °, FOV = 160 x 88, 
resolution = 1 x 1 x 2 mm3, 7 slices of 2 mm thickness with gap = 0 mm, NSA = 1, scan time 
= 5:47 minutes and for T2* a FFE with TR = 1500 ms, TE = 2.2 + n x 2.7 ms (n = 0…15), flip 
angle = 90 °, FOV = 160 x 92, resolution = 1 x 1 x 2 mm3, 7 slices of 2 mm thickness with 
gap = 0 mm, NSA = 2, scan time = 7:28 minutes. 
T2 maps were calculated from the multi-spin echo data using the standard MR scanner 
mono-exponential fitting routine. For the T2* maps, the complex data of the multi-gradient 
echo sequence were analyzed using the RelaxMapsTool (Philips PRIDE data evaluation 
software package, Philips Medical Systems, Best, the Netherlands). This tool calculates B0 
maps for all slices and – as a first order deviation from a mono-exponential signal decay – 
takes into account the sinus-shaped oscillation of the multi-echo signal induced by the 
through plane B0 gradient [254]. 
For analysis, circular ROIs were manually drawn for each well avoiding the rim region with 
partial volume effects and the mean (± standard deviation (SD)) R2 values were calculated 
from the T2 values. The R2* values of the manually drawn ROIs were extracted from the 
RelaxMapsTool. The mean R2 and R2* values ± SD were calculated over the three slices 
scanned in all phantoms and the mean values were plotted against the iron concentration to 
determine the corresponding transverse relaxivities (r2 and r2*, [mM-1 Fe s-1]) by linear 
regression. 
Mean basal relaxation rates at 0 µg Fe/mL were: R2max = 3.91 ± 5.77 s-1 and R2max* = 2.51 ± 
3.03 s-1 for untreated McA cells (maximal cell concentration of 1.91 x 106 cells/mL) and R2max 
= 1.74 ± 0.37 s-1 and R2max* = 5.07 ± 0.86 s-1 for untreated RDB cells (maximal cell 
concentration of 3.36 x 106 cells/mL). 
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2.2.2.1.5 In vivo targeting of SO-Mag-VSV complexes 
All procedures involving animals were approved and performed according to the guidelines 
of the Institutional Animal Care and Use Committee, and the local government. Six-week-old 
male Buffalo rats, weighing 200 g, were purchased from Harlan Winkelmann and housed in 
a specific pathogen-free environment under standard conditions. 106 McA cells suspended 
in 20 µL of DMEM were implanted orthotopically into the liver. After 10 days, the size of HCC 
nodules was determined by T2-weighted MRI scans to be 0.5–1 cm in diameter. 100 µL of 
complexes consisting of 107 pfu VSV and 10 µg iron in form of SO-Mag6-11.5 particles (ratio 
of 1,000 fg Fe/pfu of virus), or 107 pfu of naked VSV were injected intra-tumorally into the 
orthotopic HCC nodules in the presence of a magnet placed on the surface of the tumor 
nodule, opposite to the injection site. Magnets were left in place for 30 minutes after 
injection. To evaluate intra-tumoral virus titer and non-heme iron, animals were sacrificed 30 
minutes post infection with SO-Mag-VSV complexes or naked VSV and whole tumors were 
sampled. To quantify delivered VSV, TCID50 analysis was performed on BHK-21 cells with 
whole tumor extracts. In addition, tumors were processed for quantification of non-heme iron 
content. An additional group of animals was MR imaged at 24 hours post infection to 
visualize accumulated SO-Mag-VSV complexes. Subsequently, the animals were sacrificed, 
and tumor and liver sections were fixed overnight in 4 % PFA for histological and immuno-
histochemical analysis. That analysis was kindly performed by Dr Altomonte, II. Med. Clinic, 
Gastroenterology, Klinikum rechts der Isar der Technischen Universität München. 
2.2.2.2 MNP-siRNA complexes 
2.2.2.2.1 Cell Culture 
The rat Morris hepatocellular carcinoma cells (McA-RH7777), further referred to as McA 
cells, derive from a female Buffalo rat, and show an epithelial morphology with loosely 
adherent growth [255]. The human liver carcinoma cell line HepG2 is a perpetual cell line 
derived from the liver tissue of a 15-year-old Caucasian male who had a well-differentiated 
hepatocellular carcinoma. The morphology of HepG2 cells is epithelial and they grow 
adherent as monolayers and in small aggregates [256]. HuH-7 is a well differentiated 
hepatocyte-derived cellular carcinoma cell line that was originally taken from a liver tumor in 
a 57-year-old Japanese male. HuH-7 cells have an epithelial-like morphology and grow in 
2D monolayers [257]. The McA, HepG2 and HuH-7 cells were purchased from the American 
Type Culture Collection (LGC Standards GmbH, Wesel, Germany), and were kindly provided 
by Dr Altomonte. All three cell lines were cultured in DMEM supplemented with 10 % heat-
inactivated FCS, 100 U mL−1 penicillin, and 100 µg mL−1 streptomycin. The human 
pancreatic adenocarcinoma EPP85-181P cell line, further referred to as 181P cells, is the 
parental and not daunorubicin-resistant cell line of the MDR human pancreatic 
adenocarcinoma cells EPP85-181RDB (RDB cells) [258], which were used in the MNP-virus-
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complex experiments. The cell morphology is epithelial with adherent growth. The cells were 
kindly provided by Dr Mykhaylyk and were grown in DMEM supplemented with 10 % heat-
inactivated FCS and 1 % 2 mM L-glutamine. 
Recombinant cell lines stably expressing luciferase and GFP were McA LV PGKeGFPLuc, 
181P LV PGKeGFPLuc, HepG2 LV PGKeGFPLuc and HuH-7 LV PGKeGFPLuc. They could 
be cultured under identical conditions as the non-transfected control cells not expressing 
luciferase and GFP. 
All cell lines were cultured at 37 °C in a humidified atmosphere containing 5 % CO2 and spilt 
before reaching 100 % confluency. Briefly, the cell culture medium was aspirated and the 
cell monolayer was washed with pre-warmed PBS to remove serum. Pre-warmed trypsin/ 
EDTA (0.25%/0.02%) was added and cell detachment was observed under the microscope. 
Once the cells started detaching, warm culture medium containing serum was added to stop 
the trypsin reaction and the cells were split 1:4 to 1:6 into new cell culture dishes. 
2.2.2.2.2 Cell transduction for stable eGFP-Luc-fusion expression 
The magnetic siRNA complexes were developed as carrier system to protect the siRNA from 
early degradation, and in parallel to provide a tool to magnetically target the siRNA to the 
region of interest after systemic application. Before siRNA could be used for specific knock-
down of target genes, the carrier system itself needed to be tested for its functionality. 
Therefore, luciferase and GFP were chosen as convenient reporter genes in these proof-of-
principle experiments. As the cancer cells do not express the genes naturally, lentiviral cell 
transduction with an eGFP-Luc-fusion construct was performed on several cancer cell lines, 
and the cells were examined for stable expression of the reporter genes via luciferase 
assay, GFP assay and microscopy. 
2.2.2.2.2.1 Cell transduction with eGFP-Luc-fusion construct 
Chosen cells lines for transduction were HepG2, HuH-7 and McA cells, all hepatoma cell 
lines and the pancreatic adenocarcinoma cell line 181P. For the stable transduction of those 
cell lines, a lentiviral transfer vector (LV-PGK-eGFPLuc; Figure 19) expressing the eGFP-
luciferase fusion protein under the control of a phosphoglycerate kinase (PGK) promoter was 
chosen [259, 260]. CMS-5 cells served as internal control of the transduction. The positively 
transduced cell lines were named after the transduction construct: 181P LV PGKeGFPLuc, 
HepG2 LV PGKeGFPLuc, HuH-7 LV PGKeGFPLuc and McA LV PGKeGFPLuc, and further 
referred to as 181P eGFPLuc, HepG2 eGFPLuc, HuH-7 eGFPLuc and McA eGFPLuc. 
 
Figure 19: Lentiviral eGFP-Luc-fusion construct (LV PGKeGFPLuc) scheme under PGK 
promoter control. 
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The cell transduction experiments were kindly performed by Dr Anton, Department of 
Experimental Oncology and Therapy Research, now the Institute of Molecular Immunology 
and Experimental Oncology, Klinikum rechts der Isar der Technischen Universität München. 
2.2.2.2.2.2 Reporter gene expression analysis - proof of cell transduction 
To examine the cells for successful transduction, the expression of luciferase and GFP 
reporter genes could be assayed quantitatively. In addition, culture dishes with cell 
monolayers were qualitatively checked for GFP expression under the fluorescence 
microscope. 
2.2.2.2.2.3 Cell preparation 
All cell lines were cultivated as described in the cell culture section. For plating 96-well 
plates, the respective cells were harvested from T75 flasks and counted using a Neubauer 
counting chamber. Then the respective volume of cell suspension was transferred into a 
reagent reservoir containing cell culture medium and mixed well for equal distribution. 150 
µL of that cell suspension were transferred per well into flat-bottom clear-walled or clear-
bottom black-walled 96-well microplates using a multichannel pipette. The cell culture plates 
were incubated over night at 37 °C in a 5 % CO2 atmosphere incubator. 
All transduced cell lines were seeded in 96-well microplates at several densities ranging 
from 1 x 103 to 25 x 103 to identify the optimal conditions for the knock-down experiments. 
After 24 hours, the medium was replaced with fresh medium mocking the MNP-siRNA 
complex treatment in later experiments. 48 hours and 72 hours post-“transfection”, cell 
lysates were prepared for the quantitative assays. Therefore, the cell monolayers were 
washed with 150 µL PBS per well using a multichannel pipette. Then, 120 µL lysis buffer 
(0.1 % Triton X-100 in 250 mM Tris, pH 7.8) were added per well, incubated for 10 minutes 
at RT. The plates with lysed cells were then placed on ice in a covered box to prevent from 
GFP and protein degradation. 
To qualitatively control GFP expression, culture dishes with cell monolayers were checked 
for GFP expression under the fluorescence microscope. 
2.2.2.2.2.4 Luciferase assay 
For the quantification of the luciferase reporter gene expression in the prepared cell lysates, 
50 µL from each well were transferred into a new 96-well black flat-bottom microplate. Then, 
100 µL luciferin buffer (see 2.2.2.1.3.6.) were added per well and mixed properly with the cell 
lysate. The chemiluminescence intensity was measured immediately afterwards using a 
Tecan infinite M1000Pro microplate reader (Tecan Trading AG, Switzerland) and a count time 
of 0.20 minutes per well with background correction. 
For quantification of luciferase in the cell samples, a calibration curve had to be constructed. 
Therefore, in a new black-walled 96-well plate 50 µL lysis buffer were pipetted per well in 
Experimental 
 43 
columns 1 and 3, and 40 µL lysis buffer per well in columns 2 and 4. To well A1, 30 µL lysis 
buffer and 20 µL luciferase standard stock (0.1 mg/mL luciferase (Roche Diagnostics, 
Mannheim, Germany), 1 mg/mL BSA (bovine serum albumin) in 0.5 M Tris acetate buffer, pH 
7.5) were added. Then, 50 µL from A1 were transferred to B1, mixed well, pipetted from B1 
to C1, etc. down to H1. That dilution series was continued by pipetting 50 µL from H1 to A3, 
and continued in column 3 down to G3; H3 was a blank. Then 10 µL of each well were 
transferred from column 3 to 4, and from column 1 to 2. After addition of 100 µL luciferin 
buffer to the wells of columns 2 and 4, the chemiluminescence intensity was immediately 
measured as described above. To construct the calibration curve, the logarithm of luciferase 
content was plotted against the logarithm of the 
luminescence intensity (light units). Figure 20 shows 
the calibration curve acquired via preparing and 
measuring as described above. 
To calculate the actual amount of luciferase in the 
cell samples, an approximation function, the linear 
regression, was applied. 
 
Figure 20: Luciferase assay calibration curve. 
 
2.2.2.2.2.5 GFP assay 
For the quantification of the GFP reporter gene expression in the prepared cell lysates, 50 
µL from each well were transferred into a new 96-well clear-bottom black-walled microplate. 
Then 100 µL PBS were added per well and mixed with the cell lysate. The fluorescence 
intensity was measured immediately afterwards at excitation 485 nm / emission 535 nm 
using a Tecan infinite M1000Pro microplate reader and an acquisition time of 1.0 second per 
well.  
For quantification of GFP in the cell samples, a calibration curve had to be constructed. 
Therefore, 147 µL lysis buffer were pipetted in well A1, 50 µL lysis buffer  to all other wells 
A2 - A12  of a new 96-well clear bottom black-walled plate. Then, 3 µL GFP stock solution 
(500 ng GFP per µL PBS) were added and mixed properly. 100 µL were transferred from A1 
to A2, mixed well, 100 µL were transferred from A2 to A3, mixed, and so on down to A11. 
The surplus 100 µL from well A11 were discarded and A12 served as a blank. After addition 
of 100 µL PBS to each well of row A and mixing, the fluorescence intensity of GFP (485/535 
nm) was measured as described above. To construct a calibration curve, the measured 
fluorescence intensity was plotted as a function of GFP content per well. Using a linear 
regression of the calibration function, the GFP content in the cell lysate samples could be 
calculated. 
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2.2.2.2.3 MNP - siRNA - cell interaction 
By assembling magnetic siRNA complexes, it was aimed to construct a tool for siRNA 
delivery to a target region. The complexation with magnetic nanoparticles provided on one 
hand a stabilizer for systemic applicability and the formulation, and on the other hand allows 
for magnetic guidance and monitoring within the organism. In the following section, the 
complexes were examined for their knock-down capacity in first in vitro experiments.   
2.2.2.2.3.1 Cell preparation 
All cell lines were cultivated as described in the cell culture section. For plating 96-well 
plates, the respective cells were harvested from T75 flasks and counted using a Neubauer 
counting chamber. Then the respective volume of cell suspension for 104 cells per well was 
transferred into a reagent reservoir containing cell culture medium and mixed well for equal 
distribution. 150 µL of that cell suspension were transferred per well into a flat-bottom clear-
walled or clear-bottom black-walled 96-well microplate using a multichannel pipette. The cell 
culture plates were incubated over night at 37 °C in a 5 % CO2 atmosphere incubator. 
2.2.2.2.3.2 Preparation of magnetic siRNA complexes 
Magnetic siRNA complexes were prepared from PEI-Mag2 and SO-Mag5 magnetic 
nanoparticles, siRNAs to be tested were luciferase and GFP, non-coding siRNA served as 
negative control, and enhancer was Dreamfect Gold (DF-Gold; OZ Biosciences, Marseille, 
France). Maximal siRNA dose was 16 pg siRNA/cell, the Fe-to-siRNA ratio was 0.5:1, and 
the enhancer DF-Gold-to-siRNA ratio was 4:1. Analyzed cell lines were McA eGFPLuc, 
HepG2 eGFPLuc, HuH-7 eGFPLuc, 181P eGFPLuc and 181RDB Luc, all stably expressing 
the luciferase reporter gene. The siRNA was solved in H2O as indicated in the producers 
manual to reach final siRNA stock concentrations of 250 µg/µL. The MNPs were diluted with 
H2O to reach 0.1 µg/µL stocks, and DF-Gold was diluted to a 1 mg/mL stock. 
To prepare the transfection complexes, first siRNA dilutions of the coding and non-coding 
control siRNAs were prepared. In numbers, that means per plate (105 cells per well) 1.152 
µg siRNA (4.61 µL of the previously mentioned 250 µg/µL stock) were diluted in 273.02 µL 
medium without additives. 5.76 µL of the 0.1 µg/µL MNP stocks were mixed with 4.61 µL DF-
Gold and to a final volume of 10.37 µL. Those MNP-DF-Gold dilutions were mixed and the 
siRNA was added to this solution, mixed well and the 288 µL assembling liquid incubated for 
15 minutes at RT for complex assembly. During the incubation time, all wells B to D and F to 
H in the columns 1, 4 and 7 of a 96-well flat-bottom microplate were filled with 180 µL 
medium without additives for the 1-to-1 dilution series. The incubated complexes were filled 
up with medium to the final volume of 360 µL per plate, mixed, and 360 µL of the complex 
solutions were transferred to the wells A or E of the columns 1, 4 and 7 of each plate. 180 µL 
each were used for the dilutions series from wells A (E) down to wells D (H). The wells of 
column 10 A to G were prepared with plain medium without additives and medium w/o / 
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water instead of siRNA, enhancer and MNPs; the wells H stayed empty and served as 
background wells in the later luciferase and GFP assays. The plate design for luciferase 
silencing is presented in table 6 and all plates for the different cell lines were prepared 
analogous. 
 
 
Table 6: Color-coded plate design for preparation of magnetic siRNA complexes 
 
2.2.2.2.3.3 Knock-down via magnetofection 
The 96-well plates with 24 hours incubated cells were checked under the microscope for cell 
state and confluency, which should be about 40 to 50 %. The medium was replaced by 150 
µL fresh cell culture medium per well, then 50 µL of the respective transfection complex was 
transferred to the culture plate using a multichannel pipette. The treatment scheme was as 
follows: mixed dilutions of transfection complex prepared in column 1 of the complex 
preparation plate were transferred to the wells of columns 1, 2, and 3 (to test each 
composition and dilution of transfection complex in triplicate) of the cell culture plate. 50 µL 
from each well of column 4 of the complex preparation plate were transferred to columns 4, 
5 and 6 of the cell culture plate, and 50 µL from each well of column 7 of the complex 
preparation plate to columns 7, 8, and 9 of the cell culture plate. The rows A to G of the 
columns 10, 11, and 12 of the cell culture plate served as untreated control cells, row H as 
background. With that transfection scheme, 16, 8, 4 and 2 pg siRNA/well, respectively, were 
applied to cells in rows A (E), B (F), C (G), and D (H). For magnetofection, the cell culture 
plates were then placed on a plate magnet (OZ Biosciences, Marseille, France) for 30 minutes 
in an incubator to create at the cell layer location a permanent magnetic field with a field 
strength and gradient of 70–250 mT and 50–130 T/m, respectively. After 30 minutes, the 
magnet was removed and the cell culture plates were incubated for further 48/72 hours at 37 
°C until analysis of the gene silencing. 
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2.2.2.2.3.4 Reporter gene expression analysis 
2.2.2.2.3.4.1 Luciferase assay 
To quantify the luciferase reporter gene down-regulation, the luciferase expression was 
determined 48 and 72 hours after MNP-siRNA complex treatment. Therefore, luciferase 
assays were conducted in cell lysates as described in section 2.2.2.2.2.4. Either the data 
acquired from cell transfected with the non-coding siRNA, or cell lysates of non-transfected 
cells served as reference. 
To allow the results of the luciferase expression assays to be presented as weight luciferase 
per weight unit total protein, total protein content in lysate was determined, and the weight 
luciferase per weight unit total protein was calculated. Again, the results were normalized 
against the reference data of non-transfected cells. In order to get a dose–response curve, 
the results were plotted against time post-transfection or against the siRNA dose per well.  
2.2.2.2.3.4.2 Protein assay 
To correlate the amounts of luciferase and GFP protein, and present them as weight 
luciferase or GFP per weight unit total protein, the total protein of the cell lysate samples had 
to be determined. A flat-bottom 96-well plate was prepared with 150 µL ddH2O per well, then 
10 µL cell lysate were transferred using a multichannel pipette. After addition of 40 µL 
BioRad protein assay reagent (Bio-Rad Laboratories GmbH, Munich, Germany), the plates 
were mixed well with the pipette or placed on a shaker. Then the absorbance at 590 nm was 
measured using the Tecan infinite M1000Pro microplate reader, acquisition time was 0.1 
second per well. 
To calculate the protein amounts in the cell lysate samples, first a calibration curve had to be 
constructed. Therefore, row A of a new 96-well plate was prepared with 25 µL lysis buffer. 
Then 50 µL BSA stock solution (1.5 mg/ml BSA in PBS) was added to well A1 and after 
mixing well, 50 µL were transferred to A2, mixed well, and 50 µL transferred to A3 and so on 
down to A11; A12 was left as blank. Then 150 µL of water per well were added to another 
row, for example row B, and 10 µL per well were now transferred from row A to the 
corresponding well in row B. After addition of 40 µL BioRad protein assay reagent (Bio-Rad 
Laboratories GmbH, Munich, Germany) and well mixing, the absorbance at 590 nm was 
measured using the microplate reader as described above. The measured absorbance was 
plotted against the protein content per well to construct the calibration curve and again linear 
regression was used to derive the calibration function and therewith to calculate the protein 
content of the cell lysate samples. 
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2.2.2.3 Magnetic liposomes 
2.2.2.3.1 Pre-studies on the MNPs 
MNPs were tested for their characteristics in vitro and in vivo in the first part of this chapter. 
After the positive results in vitro and no adverse effects in the in vivo biodistribution and 
toxicity experiments, the liposome preparation was started. 
2.2.2.3.1.1 Cell culture 
Murine pancreatic ductal adenocarcinoma cells were extracted as primary cells from 
CKp53lox mice by Marija Trajkovic-Arsic, II. Med. Clinic, Gastroenterology, Klinikum rechts 
der Isar der Technischen Universität München, and were cultured in DMEM supplemented 
with 10% heat-inactivated FCS, 1 % non-essential amino acids, 100 U mL−1 penicillin, and 
100 µg mL−1 streptomycin. The cells were numbered after the animal they were extracted 
from; namely: 10078 (male), 10083 (male), 10088 (female), 10115 (male), 10123 (female), 
10124 (female), 10127 (female), 10135 (male), 511181, 511189, 511677, 512010, 530202. 
The rat Morris hepatocellular carcinoma cells (McA-RH7777), further referred to as McA 
cells, and the baby hamster kidney cells BHK-21 cells were purchased from the American 
Type Culture Collection, and were cultured in DMEM supplemented with 10 % heat-
inactivated FCS, 100 U mL−1 penicillin, and 100 µg mL−1 streptomycin. 
All cell lines were cultured at 37 °C in a humidified atmosphere containing 5 % CO2.  
2.2.2.3.1.2 MNP - cell interaction 
To identify and characterize the MNP-uptake behavior of the pancreatic and the hepatic 
carcinoma cells, all cell types were treated with different iron concentrations, and the cells 
were analyzed for the internalized iron, and the cytotoxicity of the applied MNPs was 
evaluated in cell viability assays. Several types of particles, namely SO-Mag6-11.5, PEI-
Mag2, PALD2-Mag1 and PALD2-Mag2 were examined to identify the particle type with the 
best properties. 
2.2.2.3.1.2.1 Saturation 
Pancreatic cells and McA cells were seeded at densities of 2 x 105 and 5 x 105 cells per well, 
respectively, in 6-well plates. 24 hours post seeding, the cell culture medium of each well 
was changed to a MNPs suspension. Therefore, MNPs were diluted in cell culture medium 
to the desired applied iron dose. A range of 5 – 80 µg Fe/mL was used for the 511181 cells 
and 12.5 – 100 µg Fe/mL for the hepatic cells, resulting in an applied iron dose of about 25 
to 400 pg Fe/cell in a 1-to-2 dilution series. After 24 hours incubation, the cells were washed 
with PBS, trypsinized using 0.25 % trypsin/0.02 % EDTA solution, and analyzed for the 
associated/internalized iron. To evaluate the optimal ratios of applied-to-internalized iron for 
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the different particles and cells, data of at least three saturation experiments were plotted as 
applied iron doses versus internalized iron. 
2.2.2.3.1.2.2 Analysis of the cell associated/internalized iron 
To quantify the cell associated/internalized exogenic non-heme iron in magnetically labeled 
cells, the analysis was performed as described in the first section 2.2.2.1.3.4. Briefly, 
approximately 2 x 105 trypsinized cells were washed with PBS and pelleted. The cell pellet 
was resuspended in 250-500 µL of an acid mixture containing 3 M HCl and 0.6 M 
trichloracetic acid. After overnight incubation at 65 °C, the samples were centrifuged, and 50 
µL of the clear supernatant was analyzed for its iron content by a colorimetric method with 
1,10-phenanthroline using a spectrophotometer [261]. Basal non-heme iron level determined 
in non-labeled cells was used as a reference.  
2.2.2.3.1.2.3 Cytotoxicity evaluation 
The cytotoxicity of the MNPs on cells was evaluated using the MTT assay which is based on 
reduction of the MTT reagent into formazan by superoxide anion radicals produced in the 
mitochondrial respiratory chain [262, 263] and described in section 2.2.2.1.3.6. Briefly, cells 
were washed with PBS 48 hours post-treatment, the supernatant was discarded and the 
cells were incubated for 1–2 hours in 100 µL of 1 mg/mL MTT solution. Afterwards, 100 µL 
solubilization solution were added and incubated at 37 °C, shaking overnight to dissolve the 
formazan crystals. Those solved crystals were quantified at 590 nm using a microplate 
reader. Non-treated cells served as a reference representing 100 % viable cells; the 
background was determined from 100 µL MTT solution with 100 µL solubilization solution. 
2.2.2.3.1.3 In vivo biodistribution and toxicity study 
As there were no detectable adverse effects of the magnetic nanoparticles in the in vitro 
tests, the particles were analyzed for their in vivo biodistribution and toxicity in mice.  
2.2.2.3.1.3.1 Animals 
The genetically engineered animals used in that experimental setup had a pancreas-specific 
deletion of p53 (p53lox). One group of animals was wt Kras/wt Cre, two other groups were 
heterozygous with either wt Kras/+/- Cre, or +/- Kras/wt Cre. Those three genotypes were 
not capable to develop invasive pancreas tumors. In addition, a fourth group of animals had 
a pancreas-specific activation of oncogenic KrasG12D and p48-Cre (+/- Kras and +/- Cre), 
and thus, those animals had the genetic prevalence to develop pancreatic tumors. At the 
day of the MNP injection, the animals were between 37 and 49 days (5 to 7 weeks) old, 
according to Trajkovic-Arsic et al. [209].The administered iron dose was 200 µg per animal 
via catheter tail vein injection (PALD2-Mag2 in 0.9 % NaCl, PALD2-Mag1 in 6 % HES buffer, 
maximal volume of 0.2 mL) under isofluorane anesthesia and temgesic analgetics. After the 
magnetic nanoparticle treatment, the animals were observed for 14 days regarding weight 
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development, general fitness and behavior, then they were sacrificed and tissue samples 
underwent histological and biochemical analysis for iron of the magnetic nanoparticles. 
Sampled tissues were liver, lung, spleen, kidney, pancreas/pancreatic tumor (tumor head 
and tumor tail), heart, testis/ovary, bone, and tail (injection site). An overview of all animals, 
their genotypes, and the sampled tissues is shown in the supplemental table 12. 
At all times, the animals were treated according to the guidelines of the local Animal Use 
and Care Committees, and following the welfare guidelines and GV-Solas [264-266]. The 
scoring sheet used for the daily animal evaluation is attached as supplemental table 13. 
2.2.2.3.1.3.2 Histology: Prussian Blue staining 
The tissue samples were fixed in formalin over night at 4 °C. The histological processing and 
evaluation of the tissue samples was kindly conducted by Dr Aichler, Research Unit 
Analytical Pathology, Institute of Pathology, Helmholtz Zentrum München, Neuherberg, 
Germany. 
2.2.2.3.1.3.3 Non-heme iron quantification 
The biochemical analysis for exogenic non-heme iron, the administered magnetic 
nanoparticles, was performed as described earlier. Briefly, between 20 and 100 mg tissue 
(sampled, weighed and stored at -80 °C) were thawed and cut with scissors into small 
pieces. Then the tissue was lysed with 500 µL of an acid mixture (3 M HCl and 0.6 M 
trichloracetic acid) overnight at 65 °C (18 to 20 hours). To remove debris, the samples were 
centrifuged 5 minutes at 14,000 rpm and 20 µL of the tissue extract were analyzed for the 
iron content by a colorimetric method with 1,10-phenanthroline. After 20 minutes reaction 
time, the OD was measured at 510 nm, the absorption maximum of the iron(II)-1,10-
phenanthroline complex, in a Beckman DU 640 spectrophotometer. The iron concentration 
in the tissue samples could be calculated using a calibration curve, determined from an iron 
stock solution. 
2.2.2.3.1.4 Target-protein expression integrins αv and β3 
Potential target for surface modification of the multifunctional liposomes was the tumor cell 
surface protein αvβ3 integrin. Therefore, the primary PDAC cell lines were screened for their 
αvβ3 integrin expression by Western blotting. The CKp53lox PDAC mice were analyzed for 
the integrin expression ex vivo by immuno-histolgical analysis of tumor tissue, and in vivo 
using MRI for tumor localization and intraoperative fluorescence imaging with the integrin-
specific contrast agent integrisense for visualization of αvβ3 integrin expressing tumor cells. 
2.2.2.3.1.4.1 Western blot in PDAC primary cell lysates 
For Western blot analysis, cells were washed with cold PBS and then removed from the 
culture flask using a cell scraper. After combining those harvested cells with the PBS wash-
off from the culture flask in a falcon tube, the cell suspension was centrifuged for 10 minutes 
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at 5,000 rpm and 4 °C. Then, the PBS supernatant was carefully removed and discarded. At 
that point, the cell pellets could be stored at -80 °C until further analysis. In case of freezing 
of the cells pellets, they were thawed on ice. Then the cell pellet was resuspended in 500 µl 
STEN lysis buffer (50 mM Tris-HCl, 2 mM EDTA, 1 % NP-40, pH 7.6) containing 1 protein-
inhibitor tablet/10 mL. After 10 minutes of lysis on ice, the tubes were centrifuged for 10 
minutes at 14,000 rpm and 4 °C to pellet the cell debris. The supernatant was transferred to 
new tubes and the Bradford (BCA) assay kit was used for determination of the protein 
content in the samples. Desired protein concentrations for Western blot analysis range 
between 50-80 µg protein in a 7 % SDS gel. Therefore, 40 µL BioRad Bradford reagent (Bio-
Rad Laboratories GmbH, Munich, Germany) per well were pipetted into a 96-well microplate. 
The standard was prepared as follows: 0, 1, 2, 3, 4 and 5 µL of the BSA standard solution (2 
mg/mL in NaCl) was pipetted in triplicates onto the Bradford reagent, then 2 µL lysis buffer 
were added, in the sample wells 2 µL cell lysate were added, and all wells were adjusted to 
200 µL final volume with H2O. The reaction incubated on a ThermoMixer at 400 rpm for 
about 45-60 minutes at 37 °C. Protein binding of the reagent dye Coomassie led to color-
changing from green to purple. The absorbance was analyzed at 570 nm using a microplate 
reader. According to the protein concentrations, the cell lysates (including the positive and 
negative control cell lysates) were diluted with STEN buffer to final protein amounts of 60 µg 
per sample per SDS gel and 14 µL Lämmli buffer were added per sample followed by boiling 
for 5 minutes. The prepared protein solutions could be stored at -80 °C over night.  
The samples were thawed, boiled again, vortexed and centrifuged. Then, either 23.4 µL 
sample or 15 µL marker were loaded per well on 7 % SDS gels, 15 µL Lämmli buffer served 
as loading control. The gels ran for about 3 hours at RT, blotting conditions were 150 mA per 
gel for 2 hours at 4 °C, and blocking was for 1 hour shaking in milk at RT. The primary 
antibodies (integrin αv in milk or integrin β3 in BSA) incubated over night shaking at 4 °C. 
Chosen antibodies were anti-integrin αV (T-20): sc-6618 goat polyclonal (Santa Cruz 
Biotechnology, Inc., Heidelberg, Germany) and anti-integrin beta 3 antibody [EPR2417Y] 
ab75872 rabbit monoclonal (abcam®, Cambridge, UK) and. 
The next day, the membranes were rinsed with PBS-T and the secondary antibodies (anti-
goat (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) or anti-rabbit (abcam®, Cambridge, 
UK)) were added. After rinsing of the membranes, they were developed with enhanced 
chemiluminescence Western blotting substrate, an enhanced luminol-based 
chemiluminescent substrate for the detection of horseradish peroxidase (HRP) on 
immunoblots. After 1 hour exposure, the blots were developed on X-ray films.  
2.2.2.3.1.4.2 MRI, intra-operative fluorescence imaging, and immuno-histology of 
CKp53lox PDAC mice 
MRI, intra-operative fluorescence imaging, and immunohistologic experiments were 
performed, and the results were kindly provided by Dr Trajkovic-Arsic, II. Med. Clinic, 
Gastroenterology, Klinikum rechts der Isar der Technischen Universität München. 
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2.2.2.3.2 Magnetic liposomes 
2.2.2.3.2.1 Liposome preparation 
To generate liposomes of about 100 nm in diameter, three different synthesis protocols were 
compared. For better stability in the blood circulation und targeting towards the RGD-ligand 
αvβ3 integrin receptor expressed on tumor cell surface in vivo, either PEGylated lipids or the 
new polymer P3C18 of 18 carbon atoms and 7 PEG chains were used. The arrow diagram of 
figure 21 displays the three synthesis methods, figure 22 shows the structure of the polymer 
P3C18 consisting of PEG 3 kDa with 6 lysine-serine-serine-C18 chains. 
 
Figure 21: Liposome synthesis protocols. A: Thin film hydration (TFH): lipids are heated to build a 
lipid film, then the lipid film is hydrated with a MNP solution and sonicated to form liposomes. B: 
Reverse phase evaporation (REV): lipids are mixed with MNPs and sonicated to form the primary 
emulsion that gets sonicated with more water to form the secondary emulsion. This emulsion is 
evaporation dried and hydrated to form liposomes. C: Injection method: not water but DMSO is the 
solvent of the MNPs, the MNPs are mixed with solved lipids, sonicated and injected into pre-warmed 
polymer solution under vigorous condition to form liposomes. MeOH is removed by rotary 
evaporation. In A, B and C, synthesis is followed by a clean up to remove unbound MNPs and solvent 
by dialysis or PD10 columns. Liposomes are stored at 4 °C after size optimization via extrusion. 
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Figure 22: Structure of the P3C18 polymer PEG3kDa with 6 lysine-serine-serine-C18 chains  
 
2.2.2.3.2.1.1 Thin film hydration (TFH) 
Liposome preparation via thin film hydration (TFH) was performed as described by Pradhan 
et al. [96]. Briefly, a lipid mix of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (MW = 
734.05 g/mol), cholesterol (MW = 386.66 g/mol), and a functionalized lipid, 1,2-distearoyl-sn-
glycerol-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] ammonium salt 
(DSPC-PEG2000) (MW = 2790.52 g/mol), were used in a molar ratio of 75:25:5. 11.2 mg total 
lipid (8.2 mg DPPC, 1.2 mg cholesterol and 1.8 mg DSPC-PEG2000) were solved in 1 mL 2:1 
CHCl3:MeOH and transferred into a round-bottom flask. The lipid suspension-containing 
flask was placed in the rotary evaporator (Rotavapor, Büchi Labortechnik GmbH, Essen, 
Germany), and the solvent was evaporated to get a dry lipid film on the flask wall at 40 °C. 
Optionally, the lipid film could be further dried using a lyophilizator. 1 mg iron in form of the 
palmitoyl dextran magnetic nanoparticles PALD2-Mag1 were suspended in a total volume of 
500 µL ddH2O and added to the lipid film. After 30 minutes lipid film hydration at 40 °C in the 
water bath, the emulsion was sonicated for 15 minutes. The liposome emulsion was then 
washed with 500 µL 0.9 % NaCl to precipitate unbound MNPs. After a centrifugation for 10 
minutes at 1,000 rpm and 4 °C, the liposome containing supernatant was transferred into a 
new tube and stored at 4 °C until further usage. 
2.2.2.3.2.1.2 Reverse phase evaporation (REV) 
For the liposome preparation via reverse phase evaporation (REV), the same lipid mix as for 
the TFH liposomes was used. The lipids (8.2 mg DPPC, 1.2 mg cholesterol and 1.8 mg 
DSPC-PEG2000) were solved in 500 µL 2:1 CHCl3:MeOH and transferred into a round-bottom 
flask. 1 mg iron in form of the palmitoyl dextran magnetic nanoparticles were suspended in a 
total volume of 500 µL ddH2O and added to the lipid mix. After 15 minutes of sonication, the 
same volume (1 mL) ddH2O was added to this primary emulsion followed by a second 
sonication step for 15 minutes leading to the secondary emulsion. Then the solvent was 
removed using a rotary evaporator at 40 °C. The brownish MNP-containing lipid film was 
then washed with 1 mL 0.9 % NaCl to precipitate unbound MNPs. After a centrifugation for 
10 minutes at 1,000 rpm and 4 °C, the liposome containing supernatant was transferred into 
a new tube and stored at 4 °C until further usage. 
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2.2.2.3.2.1.3 Injection method 
Using the injection method synthesis protocol, 10 mg total lipid DPPC:Chol 80:20 were 
solved in 1 mL DMSO:MeOH 3:2 at 650 rpm, 70 °C in the ThermoMixer. The polymer P3C18 
was solved in ddH2O at 10 mg/mL and vortex mixed, the molar ratio of the lipids was then 
DPPC:Chol:P3C18 80:20:5. The MNPs were stored in H2O, but before liposome synthesis, 
the medium had to be changed to DMSO. Therefore, palmitoyl dextran magnetic 
nanoparticles equivalent to 1 mg iron were centrifuged for 15 minutes at 14,000 rpm, then, 
the tube was placed on the magnetic rack for another up to 24 hours. After magnetic 
separation, the water was carefully removed and the MNPs were resuspended in 100 µL 
DMSO. For liposome synthesis, 2 mL ddH2O were heated to 60 °C in a round-bottom flask, 
then the flask was placed on a vortex mixer and fixed. The in DMSO suspended MNPs were 
sonicated shortly, then the lipids were added, and again the suspension was sonicated. The 
pre-heated polymer was then added to the water in the round-bottom flask, and then the 
lipid-MNP suspension was injected using a G23 needle, both under vigorous conditions on a 
vortex mixer. That vigorous condition allowed for liposome formation. After further vortex 
mixing and short sonication, the round-bottom flask was connected to a rotary evaporator, 
and the solvent was reduced to 1 mL at 60 °C. To remove the remaining DMSO, the 
liposomes were either purified through a PD10 Sephadex column, or the liposomes were 
dialyzed against ddH2O over night at 4 °C, stirring, using a Slide-A-Lyzer® 10 K Dialysis 
Cassette 10,000 MWCO. The column was first equilibrated with 4 volumes PBS, then, the 
liposome solution was loaded. To push the liposomes through, another volume PBS was 
layered on top, and the liposome-containing (brown) flow-through was collected in an 
eppendorf tube. The liposomes then underwent further analysis. After the overnight dialysis, 
the liposomes were extracted from the dialysis cassette and transferred to a round-bottom 
flask, placed on the rotary evaporator and the water was completely removed. The dry lipid 
film was then hydrated with PBS.  
2.2.2.3.2.2 Characterization of MNPs and magnetic liposomes 
As the planned administration route for magnetic liposomal nanocarriers was systemic 
injection followed by magnetic targeting towards the tissue of interest, the main goal was a 
good response of the liposome to external magnetic fields. In this section, the properties in 
magnetic fields and the physico-chemical properties were observed for particles and 
liposomes. 
2.2.2.3.2.2.1 Non-heme iron determination 
To quantify the liposomal iron content, biochemical analysis for exogenic non-heme iron was 
performed by the procedure described in section 2.2.2.1.3.4. Briefly, 20 µL liposome 
preparation were lysed with 200 µL concentrated HCl and 280 µl H2O overnight at 65 °C. 
Then the samples were centrifuged 5 minutes at 14,000 rpm, and 20 µL of the extract were 
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mixed with 860 µL sterile water, 20 µL 10 % hydroxylamine-hydrochloride solution, 200 µL 
ammonium acetate buffer (25 g ammonium acetate and 70 ml glacial acetic acid with a total 
volume adjusted to 100 ml with ddH2O), and 80 µL 0.1 % 1,10-phenanthroline solution. After 
20 minutes reaction time, the OD was measured at 510 nm, the absorption maximum of the 
iron(II)-1,10-phenanthroline complex. The iron concentration in the tissue samples could be 
calculated using a calibration curve, determined from an iron stock solution. 
2.2.2.3.2.2.2 Wavelength scan 
To visualize the magnetic particles with a spectrophotometer, first the absorption optimum 
had to be determined. Therefore, MNP suspensions in water underwent wavelength scans in 
the visible range, with absorptions between 280 and 800 nm. 350 nm was identified as good 
wavelength for further spectrophotometrical experiments. 
2.2.2.3.2.2.3 Magnetophoretic mobility 
The magnetophoretic mobility measurements were conducted as described in section 
2.2.2.1.3.7. for the magnetic viral complexes. Briefly, the magnetic liposomes were diluted to 
500 µL aliquots to achieve a starting OD = 0.3–1 at the analytical wavelength of 360 nm for 
the magnetic liposomes. A gradient field was generated and optical cuvettes filled with these 
diluted suspensions were placed in a Beckman DU 640 spectrophotometer, and the change 
in the turbidity was immediately recorded over 30 minutes. From the decrease in optical 
density under magnetic field, the average magnetic moment of the complexes and the 
number of associated magnetic nanoparticles could be calculated. 
2.2.2.3.2.2.4 Physico-chemical characterization 
Mean hydrodynamic diameter Dh and electrokinetic zeta potential ζ of the liposomes 
suspended in ddH2O were measured by photon correlation spectroscopy using a Malvern 
3000 HS Zetasizer.  
2.2.2.3.2.3 MNP-PTX liposome synthesis 
The drug-loaded magnetic liposomes were synthesized applying the TFH technique as 
described above. Briefly, a lipid mix of DPPC, cholesterol, and a PEG-functionalized 
molecule, either the lipid DSPC-PEG2000 or the polymer P3C18, at 80:20:5 was mixed with 5 
mg paclitaxel, and all was solved in 1 mL 2:1 CHCl3:MeOH. The PTX-lipid film was hydrated 
with 1 mg iron in PALD2-Mag1, suspended in 1 mL ddH2O. After 30 minutes lipid film 
hydration at 60 °C in the water bath, the emulsion was sonicated for 1 minutes, vortexed for 
1 minute and sonicated again. The liposome emulsion was then extruded through 400 nm, 
200 nm and 100 nm polycarbonate membranes with an extruder (both Avanti Polar Lipids, 
Inc., Alabaster, Alabama, USA), and over night dialyzed against ddH2O at 4 °C. Next day, the 
liposome solutions were sonicated for 5 minutes and 250 µL of each liposome solution were 
washed with 250 µL 0.9 % NaCl by 10 minutes centrifugation at 1,000 rpm and 4 °C.  
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2.2.2.3.2.4 Analysis of liposome functionality 
In this section, the functionality of the synthesized liposomes was analyzed regarding their 
thermosensitivity. Therefore, a calcein release assay was performed within a temperature 
range of 37 to 43 °C, either in PBS, or 50 % FCS in PBS with sampling every 15 minutes 
over a period of 60 minutes. In addition, it was tried to detect the binding of the 
chemotherapeutic drug paclitaxel to the magnetic nanoparticles. 
2.2.2.3.2.4.1 Thermosensitivity evaluation 
The calcein release assay was used to examine the thermosensitivity of the liposome 
formulation [96]. It was tested at which temperature the lipid shell started to get leaky, and 
released the content of the liposome. For detection of the release, the fluorescent calcein 
was encapsulated within the liposome, and its release was detected fluorometrically using a 
plate reader. Crucial for later administration in vivo was a melting temperature surely higher 
than 37 °C to prevent the liposomes from releasing their content before the external heat 
treatment at the target site. 
Three different lipid compositions and two different synthesis were tested for the 
thermosensitive decomposition of the liposomes. To reach the melting temperature Tm of 41 
°C analog to Pradhan et al. [96], the lipids DPPC and cholesterol were used in a 80:20 molar 
ratio, instead of DSPE-PEG the new P3C18 polymer was used at DPPC:chol:P3C18 = 80:20:5 
(= formulation a), total lipid concentration was 10 mg/mL. in the experiments of Tai et al. 
[225], the lipid composition DPPC:DSPC:chol = 10:5:3 weight ratio led to Tm of 40-42 °C. 
Desiring a similar melting temperature, the polymer P3C18 was used instead of the 
PEGylated lipid, and the according molar ratio of formulation b was DPPC:DSPC:chol:P3C18 
= 68.1:31.6:38.8:5 at 10 mg total lipid. In addition, a variation of Tai´s composition was 
tested as formulation b*: DPPC:DSPC:chol:P3C18 = 70:30:40:5.  
Using the injection method synthesis protocol, 10 mg total lipid of all three lipid compositions 
were solved in 1 mL DMSO:MeOH 3:2. To ease the solving, the individual lipids were solved 
in the DMSO:MeOH, then mixed in the desired composition, and the lipid mix was then 
heated to 60 °C for 10 minutes. The polymer P3C18 was solved in ddH2O at 10 mg/mL and 
also heated to 60 °C. As the liposomes were synthesized by the injection method, 2 mL 
ddH2O were heated to 60 °C in a round-bottom flask. The pre-heated polymer was added, 
and then the pre-heated lipids were injected using a G23 needle, both under vigorous 
conditions on a vortex mixer. After short sonication, the round-bottom flask was connected to 
a rotary evaporator and the solvent was reduced to 1-2 mL at 60 °C. To get rid of the 
remaining DMSO, the liposomes were dialyzed over night at 4 °C, stirring, against ddH2O 
using a Slide-A-Lyzer® 10 K Dialysis Cassette 10,000 MWCO. Next day, the liposomes were 
extracted from the dialysis cassette and transferred to a round-bottom flask, placed on the 
rotary evaporator and the water was completely removed. The dry lipid film was then 
hydrated with 1 mL sterile filtered calcein solution of 63 mM, pH 7.4. The resuspended 
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liposomes underwent several extrusion steps, each 11 times through 400 nm, 200 nm and 
100 nm. 
Preparing the liposomes via thin film hydration, 10 mg total lipids were solved in 
CHCl3:MeOH = 2:1 in a round-bottom flask, and the polymer in water was added. To get rid 
of the solvent, the rotary evaporator was used. The dried lipid film was then hydrated with 1 
mL 63 mM calcein (sterile filtered) at 60 °C for 15-20 minutes. The resuspension of the 
liposomes was again followed by extrusion, 11 times each through 400 nm, 200 nm and 100 
nm. The liposomes were dialyzed against water over night at 4 °C. The next day, the 
liposomes were transferred from the dialysis chamber into a new tube with a syringe. 
Having the two batches of liposomes prepared, the calcein assay was started. Therefore, 60 
µL liposomes were solved in 600 µL either PBS or 50 % FCS in PBS, and incubated at 37 
°C, 39 °C, 41 °C and 42 °C. 20 µL samples were taken after 0, 15, 30, 45 and 60 minutes 
incubation to quantify the released calcein over time in the suspension. The samples were 
transferred into 24-well plates with 2 mL PBS per well/48-well plates with 1 mL PBS per well, 
and the calcein fluorescence was detected at 485 nm excitation/520 nm emission (1 second 
and 0.1 seconds counting time for 24-well plate, 0.1 seconds for 48-well plate) using a 
Wallac 1420 VICTOR2 microplate reader (PerkinElmer, Waltham, MA, USA). 100 % release 
reference suspensions for data normalization were prepared by lysing 60 µL liposomes in 
600 µL 1 % Triton X-100 by vortexing 1 minute followed by 30 minutes incubation at 55 °C. 
The standard curve was prepared from sterile filtered 63 mM calcein in a dilution series in 
PBS, 50 % FCS in PBS and H2O; pure PBS and 50 % FCS in PBS served as background 
blanks.  
2.2.2.3.2.4.2 MNP functionalization 
In this experimental section it was tried to photometrically detect the paclitaxel (PTX) binding 
of the palmitoyl dextran magnetic nanoparticles. Paclitaxel was solved in DMSO at a stock 
concentration of 1 mg/mL and the magnetic nanoparticles were transferred from water to 
DMSO after magnetic separation for 3 hours and centrifugation for 5 min, 14,000 rpm. 900 
µL DMSO with 1 mg iron in from of magnetic nanoparticles were mixed with 200 µL of the 
PTX stock, sonicated for 5 minutes, and further incubated at 20 °C, 1,000 rpm on the 
ThermoMixer for 20 minutes. It was assumed that the particles were loaded with drug and 
therefore, the suspension was placed on the magnetic rack for 1 hour (4 hours) to separate 
the magnetic fraction from unbound drug. After an additional centrifugation at 14,000 rpm for 
5 minutes, the supernatant with unbound drug was carefully removed and the magnetic 
fraction with MNP-PTX complexes was resuspended in DMSO. Then both, magnetic and 
non-magnetic fraction, were analyzed from 200 to 800 nm using a Beckman 
spectrophotometer against pure DMSO as blank, dissolved PTX and pure MNPs served as 
controls. The samples were diluted with DMSO 1:10 and 1:100. 
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2.2.2.3.2.5 Magnetic liposomes in vivo 
To examine the biodistribution and magnetic targeting of the liposomes, in first in vivo pilot 
experiments anesthesized wildtype and tumor bearing PDAC mice were intravenously (tail 
vein) injected with magnetic liposomes (figure 23A). After sacrifice, tissue samples of the 
animals underwent histological and biochemical iron analysis. The arrow diagrams of figure 
23 show the timeline of the biodistribution (figure 23B) and targeting (figure 23C) 
experiments. 
 
Figure 23: MNP-LP in vivo targeting setup: i.v. liposome injection and magnetic targeting after 
laparotomy. A: Targeting setup. B: Experimental design LP2: wt mice for optimization of PB tissue 
staining, ± perfusion. C: Experimental design LP1: CKp53lox mice, ± magnetic targeting. 
2.2.2.3.2.5.1 Biodistribution 
2.2.2.3.2.5.1.1 Animals: Wildtype mice 
Two 3 months old wildtype mice were injected intravenously with magnetic liposomes in a 
concentration of 2.5 mg Fe per kg bodyweight in 100 µL NaCl per 20 g bodyweight under 
isofluorane anesthesia. The liposomes circulated for 1 hour, and as the wildtype animals had 
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no tumors, there was no magnetic targeting. Then the animals were sacrificed and samples 
were taken from the following tissues: pancreas, spleen, duodenum, kidney, heart and lung. 
The tissue samples were either fixed in 4 % PFA over night, 24 hours in sucrose at 4°C, or 
mounted in OCT for cryoslicing, the samples for non-heme iron determination were stored at 
-80 °C. 
At all times, the animals were treated according to the guidelines of the local Animal Use 
and Care Committees.  
2.2.2.3.2.5.1.2 Histology: Prussian blue staining 
The fixed tissue samples were sliced and 
mounted onto glass slides. Then, the dry samples 
could be stained using the Prussian blue staining 
to visualize the MNPs with a Kernechtrot tissue 
counterstaining. The 2 % iron stock solution (20 g 
potassium hexacyanoferrat(II)-trihydrate dis-
solved in 1 L ddH2O) and the 0.2 % Kernechtrot 
solution (2 g Kernechtrot, 50 g aluminiumsulfat ad 
1 L ddH2O), could be stored at 4 °C. The iron 
reagent for staining was prepared fresh every day 
with 2/3 iron stock solution and 1/3 1 % HCl. Table 
7 summarizes the staining protocol. 
Table 7: Prussian blue staining protocol. 
2.2.2.3.2.5.2 Magnetic targeting 
2.2.2.3.2.5.2.1 Animals: CKp53lox mice 
The genetically engineered animals used in that experimental setup had pancreas-specific 
activation of oncogenic KrasG12D and p48-Cre (+/- Kras and +/- Cre) and deletion of p53 
(p53lox), further referred to as CKp53lox mice, and therefore were capable to develop 
invasive pancreatic adenocarcinomas (PDAC). At the day of the magnetic liposome 
injection, the animals were 6 weeks old. To examine the magnetic targeting of the 
liposomes, PDAC mice were intravenously (tail vein) injected with magnetic liposomes under 
isofluorane anesthesia. Before liposome administration, the animals were divided into two 
groups. One group (n = 4) underwent magnetic targeting by an above the tumor site 
(pancreas tumor tail) fixed magnet for 1 hour post liposome injection, the other group (n = 3) 
served as control with free circulating liposomes without externally applied magnetic field. In 
addition, there were three control animals without liposome injection. The animals of the 
magnetic targeting group underwent a laparotomy for better access to the tumor region, 
figure 23C contains a picture of the experimental setup. As for the wildtype animals in the 
biodistribution experiment, liposomes were administered in concentrations of 2.5 mg Fe/kg 
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bodyweight in 100 µL sterile NaCl per 20 g bodyweight. In addition to the aesthesia, the 
animals got 50 µL Temgesic analgetics. After 1 hour of liposome circulation (and magnetic 
targeting), the animals were sacrificed, and tissue samples for histological and biochemical 
iron analysis were taken. Sampled tissues were liver, lung, spleen, kidney, 
pancreas/pancreatic tumor (tumor head and tumor tail), heart and blood. 
At all times, the animals were treated according to the guidelines of the local Animal Use 
and Care Committees.  
2.2.2.3.2.5.2.2 Histology: Prussian blue staining 
The fixed tissue samples were processed and stained as described in section 
2.2.2.3.2.5.1.2.  
2.2.2.3.2.5.2.3 Non-heme iron determination 
To quantify the liposomal iron in tissue samples, biochemical analysis for exogenic non-
heme iron was performed as described in section 2.2.2.3.1.3.3. Briefly, between 20 and 100 
mg tissue were cut with scissors into small pieces and lysed with 500 µL of an acid mixture 
overnight at 65 °C (18 to 20 hours). After removal of the cell debris, the samples were 
analyzed for the iron content by a colorimetric method with 1,10-phenanthroline at 510 nm in 
a Beckman DU 640 spectrophotometer. The iron concentration in the tissue samples could 
be calculated using a calibration curve, determined from an iron stock solution. 
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3 RESULTS 
The results section summarizes the outcome of all experiments conducted regarding the 
development and characterization of the different nanocarrier systems and their 
components. Again, first the magnetic nanoparticles are described, then the MNP-VP 
complexes, MNP-siRNA complexes, and magnetic liposomes. 
 
3.1 Magnetic nanoparticles 
The core−shell type iron oxide MNPs examined in the experiments of this dissertation were 
synthesized by precipitation of iron hydroxide from aqueous solution, followed by 
transformation into magnetite, and spontaneous adsorption of the surface structures/shell 
components. Those were a silicium oxide layer with surface phosphonate groups 
(SiOx/phosphonate) and PEI for SO-Mag nanoparticles, 25-kDa branched polyethyleneimine 
(PEIBr-25 kDa) for PEI-Mag nanoparticles, or palmitoyl dextran PALD2 for the PALD2-Mag 
particles. 
The selected MNPs exhibited similar core diameters of SO-Mag = 6.7 nm, PEI-Mag = 9.0 nm 
and PALD2-Mag1 = 4.0 nm. The saturation magnetization of the core material at RT was 94, 
62 and 62 Am2/kg(Fe), respectively, resulting in an average magnetic moment of the 
insulated particles of 8.7 x 10-20, 5.8 x 10-20 and 5.8 x 10-20 Am2 for the SO-Mag, PEI-Mag 
and PALD2-Mag1 MNPs, respectively [100, 267]. 
Decoration of SO-Mag MNPs with PEI resulted in SiOx/Phosphonate-PEI coating of 11.5 
w/w% PEI-to-iron [268] (shown schematically in figure 10B) with a silica coating width of 
approximately 1 nm and a higher mean Dh of 76 ± 27 nm, suggesting small aggregate 
formation. The average hydrodynamic diameter of the primary non-aggregated SO-Mag-5 
core nanoparticle without PEI-modification was Dh = 40 ± 14 nm in water (d = 6.8 nm), 
indicating there is no aggregate formation prior to surface modification [115]. 
Surface coating of PEI-Mag MNPs with a self-assembling layer comprising 32 mass% PEI 
and 68 mass% of the fluorosurfactant Zonyl® FSA (figure 10D) resulted in a mean 
hydrodynamic diameter Dh = 28 ± 2 nm. In addition, PEI coating led to a highly positive 
electrokinetic potential (ζ) for both MNPs of 40.4 ± 0.4 mV for SO-Mag and 55.0 ± 0.7 mV for 
PEI-Mag. The decreased potential of the SO-Mag particles compared to the PEI-Mag 
particles is due to the lower PEI content and the negatively charged surface phosphonate 
groups decorating the silica coating.  
The mean hydrated particle diameter of the with palmitoyl dextran (PALD2) decorated 
PALD2-Mag particles was Dh = 55 ± 11 nm, ranging between the other two particles. In 
contrast to the positively charged SO-Mag and PEI-Mag particles, the electrokinetic zeta 
potential of the PALD2-Mag particles in water was negative with ζ = -53.7 ± 12.1 mV due to 
the coating [180]. The physico-chemical properties of the MNPs are compiled in table 8. 
Results 
 61 
 
 
Table 8: Hydrodynamic diameter and electrokinetic potential. Dh and zeta potential of free MNPs, 
viral particles and their complexes. 
3.2 Magnetic nanocarriers 
3.2.1 MNP-VP complexes 
3.2.1.1 In vitro characterization of the MNP-VP complexes 
3.2.1.1.1 Physico-chemical properties 
The properties of the SO-Mag and PEI-Mag nanoparticles were described in the previous 
chapter, and the corresponding size values for naked virus particles were Dh = 123 ± 33 nm 
for adenovirus, and Dh = 175 ± 61 nm for VSV. Both viruses had negative zeta potentials 
in PBS: -9.1 ± 1.3 mV (Ad) and -11.8 ± 0.7 mV (VSV). This enabled the self-assembly of the 
positively charged MNPs and the negatively charged VPs by electrostatic interactions. 
Complex formation with PEI-Mag resulted in a net positive charge of the magnetic viral 
complexes (PEI-Mag-Ad ζ = 14.1 ± 2.2 mV and PEI-Mag-VSV ζ = 15.1 ± 0.8 mV, in PBS). 
Co-assembly of SO-Mag with Ad also resulted in a net positive charge (SO-Mag-Ad ζ = 13.6 
± 0.4 mV in PBS), while a net negative charge was detected with VSV (SO-Mag-VSV ζ = -
7.1 ± 0.8 mV in PBS). ζ and Dh measurements of the different MNP-VP complex 
suspensions showed neither free MNPs nor naked VPs (data not shown). As expected, 
MNP-VP complexes were larger compared to naked VPs, and larger for SO-Mag- compared 
to PEI-Mag-based complexes (PEI-Mag-Ad Dh = 271 ± 178 and PEI-Mag-VSV Dh = 514 ± 99 
nm; SO-Mag-Ad Dh = 609 ± 127 nm and SO-Mag-VSV Dh = 923 ± 120 nm). The latter 
results suggest aggregate formation of SO-Mag-VP complexes in PBS suspensions. Figure 
9A schematically presents the self-assembly of MNPs and VPs and the resulting magnetic 
viral complexes, and table 8 summarizes their physico-chemical properties. After that 
characterization, the magnetic viral complexes were tested in vitro in two cancer cell lines, 
McA hepatoma regarding the oncolytic effect of the VSV complexes, and RDB pancreatic 
cancer cells regarding the potential of the Ad complexes. 
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Figure 24: PEI-Mag2-VSV titration at different iron-to-virus ratios. A: Exemplary TCID50 assay of 
magnetic (MF) and non-magnetic fractions (NMF). B: TCID50 of the MNP-VSV complexes (nassay = 3, 
all samples in quadrupels). C: Physico-chemical characterization: Hydrodynamic diameter Dh and 
zeta potential of the MNP-VSV complexes (nassay = 3, all samples in quadrupels). 
3.2.1.1.2 Titration and characterization of magnetic viral complexes 
To identify the optimal iron-to-virus ratio for the magnetic viral complex assembly, virus 
particles were titrated with increasing amounts of MNPs. As this titration was already 
performed for the adenovirus complexes by Tresilwised et al. [105], and an optimal ratio of 5 
fg Fe/pfu was determined, it was conducted only for the MNP-VSV complexes. Exemplary 
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results of the VSV titration with PEI-Mag particles were summarized in figure 24. Figure 24A 
shows photographs of the TCID50 assay culture plates of magnetic and non-magnetic 
fractions of complex preparations, for better visibility in the photograph, the plates were left 
in the incubator after read-out until all medium was consumed by the healthy cells and the 
medium turned yellow due to pH changes. The medium of the wells with dead cells 
corresponding to high enough applied virus concentrations was still red. As expected, the 
medium of the reference wells on the right was used up as only MNPs and no virus were 
applied. In figure 24B, the TCID50 /mL values of the magnetic and non-magnetic fractions 
were plotted against the applied iron per pfu virus. The optimal binding condition 500 fg 
Fe/pfu VSV was identified, as there most of the virus was bound to the magnetic 
nanoparticles in the magnetic fraction relative to the non-magnetic fraction. For the SO-Mag-
VSV complexes, 1,000 fg Fe/pfu VSV was identified as optimal iron-to-virus ratio. The 
physico-chemical characterization was compiled in figure 24C, summarizing the according 
hydrodynamic diameters Dh and the electrokinetic zeta potentials over the applied iron per 
pfu virus.  
3.2.1.1.3 Highly efficient magnetic cell-labeling with MNPs and MNP-VP complexes 
To test cell-labeling efficiency of MNPs and MNP-VP complexes, two cell lines underwent 
magnetofection. Labeling with both, MNPs or MNP-VP complexes, resulted in high cellular 
iron loading (2.5 pg Fe/cell up to 17.3 pg Fe/cell upon application of 10 or 25 pg Fe/cell; 
table 5). No significant differences were detected between PEI-Mag and SO-Mag MNPs 
regarding that iron loading behavior. However, differences were evident between MNPs and 
magnetic viral complexes, and between the different cell lines employed: MNP labeling 
resulted in higher iron loading compared to MNP-VPs (45 – 69 % to 25 – 32 % labeling 
efficiency, respectively), and RDB cells showed a higher uptake than McA cells for free 
MNPs (69/64 % to 45/54 % labeling efficiency), but not for MNP-VP-complexes (table 5). To 
avoid false positive results from background contamination, non-labeled cells were also 
analyzed for their iron content, and neither cell line revealed detectable levels of exogenic 
non-heme iron. Based on the obtained iron loading data, an efficient internalization of the 
magnetic nanomaterial was suggested. 
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Figure 25: Self-assembly of MNP-VP complexes and their cell uptake. TEM of MNPs and MNP-
VP complexes (A, scale bar 100 nm) and TEM of cell internalized MNPs and complexes (B, scale bar 
500 nm). C: Microscopy of trypsinized labeled cells (scale bar 50 µm, Dcell (181RDB) = 16.5 ± 2.6 µm, 
Dcell (McA) = 16.3 ± 1.8 µm). The cell labelings are: PEI-Mag2-Ad in RDB: 3.9 pg Fe/cell; SO-Mag6-
12.5-Ad in RDB: 2.3 pg Fe/cell; SO-Mag6-11.5-VSV in McA: 0.5 pg Fe/cell. 
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3.2.1.1.4 TEM analysis of internalized MNPs and MNP-VP complexes 
To investigate the arrangement and aggregation of free and intracellular MNPs and MNP-VP 
complexes, as well as their intracellular localization, TEM was performed. Figure 25A shows 
TEM images of free MNPs and the according MNP-VP complexes for both types of VPs and 
MNPs. The suspended MNPs and MNP-VP complexes were mostly dispersed. Figure 25B 
compiles representative photomicrographs of the MNP and MNP-VP complex internalization 
in both cell lines. Naked MNPs mainly clustered in the cytoplasm, in the RDB cells in 
endosomes while in McA cells the particles are more dispersed in the cytoplasm (figure 25B, 
top row). In contrast to the free particles, MNP-VP complexes were localized exclusively in 
endosomes, independent from the cell type. Inside the endosomes, the magnetic and viral 
particles were arranged in a similar aggregate structure as the naked MNPs in the 
cytoplasm. 
3.2.1.1.5 Magnetophoretic mobility measurements of MNPs, MNP-VP complexes and 
labeled cells 
As expected, MNPs, MNP-VP complexes, and loaded cells were responsive to an externally 
applied magnetic field as indicated by a decrease in the relative OD of their suspensions 
under the magnetic field (figure 26). The decrease in OD of the magnetic samples was due 
to the accelerated clearance imparted by the magnetic properties, whereas unlabeled cells 
simply sediment over time. From these turbidity clearance curves, the average 
magnetophoretic mobility of MNP-VP complexes and MNP- or MNP-VP-labeled cells, and 
the average number of MNPs associated per complex or cell could be calculated (table 9). 
Such complexes comprise 2.2 x 104 PEI-Mag MNPs per virus particle for the complexes with 
VSV, and 2.6 x 104 MNPs per complex with Ad. The complexes with SO-Mag particles were 
larger and had more associated MNPs per complex (7.7 x 104 MNPs per VSV and 2.2 x 105 
MNPs per Ad). The mean hydrodynamic diameters of the MNP-VP complexes of about 500 
nm, 270 nm, 900 nm, and 600 nm (table 8), respectively, suggest that the complexes 
consisted of few physical virus particles surrounded with the evaluated number of MNPs. In 
addition to the information about the complex sizes and compositions, it could be evaluated 
how many naked and nanoassembled magnetic particles, respectively, were taken up by the 
cells. There was an uptake of 6.6 x 105 to 7.0 x 105 MNPs per McA cell (16.3 µm in 
diameter), and 8.4 x 105 to 8.7 x 105 free magnetic particles by the RDB cells (16.5 µm in 
diameter) (table 9). The McA cells were infected with 15 and 36 MNP-VSV complexes and 
the RDB cells were infected with about 5 and 19 adenoviral SO-Mag- and PEI-Mag-
complexes, respectively. The turbidity clearance time course under magnetic field 
application indicated an optimum of 30 minutes incubation time on the magnet (i.e. time 
needed for complete magnetic sedimentation) for the in vitro labeling and magnetofection 
experiments. 
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Figure 26: Magnetophoretic mobility 
of magnetic viral complexes and labeled 
and infected cells. Decrease of the 
normalized turbidity (D/D0) of 
representative suspensions of untreated 
cells (green), magnetic viral complexes 
free (blue) as well as cell internalized 
(purple), and cells with internalized 
magnetic nanoparticles (red) in an 
average magnetic field of B = 0.213 ± 
0.017 T with a magnetic field gradient of 
∇B = 4 ± 2 T/m. The left panel shows the 
data set for PEI-Mag particles, Ad and RDB cells, right panel the respective data for SO-Mag 
particles, VSV and McA cells. 
 
 
 
Table 9: Physico-chemical characteristics of magnetic viral complexes, MNP-labeled cells and 
viral complex infected cells. 
3.2.1.1.6 Characterization of the oncolytic potential of MNP-VP complexes in vitro 
Figures 27A and B and table 10A display the virus dose required for 50 % cell growth 
inhibition/oncolysis (IC50). The curves registered for the concentration-dependent oncolytic 
effect of magnetic complexes of VSV and Ad with both MNPs were significantly shifted to 
low applied virus doses relative to the dose-effect-curve of naked virus particles. Even 
without magnetic field induction, the magnetic complexes were 1.2- to 6-fold more efficient 
than the virus alone in terms of the IC50 values of the applied dose (figure 27C and table 
10A). The IC50 values of the MNP-VP complexes under magnetic field-guided infection at 7.5 
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% FCS were 1.6- and 2.5-fold lower for VSV, and 11.8- and 27.4-fold lower for Ad, 
respectively, than those of the naked virus, emphasizing the higher oncolytic activity of the 
MNP-VP complexes (figure 27C and table 10A). High serum concentration had a strong 
inhibitory effect on the oncolytic potency of the naked viruses, and some effect on the 
complexes when no magnetic field was applied. However, for the magnetic complexes, the 
magnetic field-influenced oncolytic potency-enhancing effect was about 10-fold and 2-fold for 
the adenoviral and VSV complexes, respectively (table 10B). This enhancement was true for 
low and high serum concentrations. The PEI-Mag-Ad complexes were hardly affected by 
serum in terms of the IC50. High serum had only limited inhibitory effect on the IC50 of the 
SO-Mag-Ad and magnetic VSV complexes. Thus, the in vitro results demonstrated 
enhancement of the oncolytic efficacy of the studied magnetic VSV and Ad complexes in 
McA and RDB cells at both, low and high serum concentrations. 
 
 
Figure 25: Oncolytic activity of the MNP-VP complexes at moderate and high FCS 
concentrations. McA (A) and RDB (B) cells were infected with naked virus or MNP-VP complexes at 
different virus doses under magnetic field application (+MF) for 30 minutes at FCS concentrations of 
7.5 % (left panels) and 50 % (right panels). Oncolytic activity of the viruses and their magnetic 
complexes was assessed by measuring cell viability 24 hours after infection of McA cells using the 
MTT assay and 6 days after infection of the RDB cells expressing firefly luciferase using luciferase 
assay and expressed as a percentage using the untreated cells as a reference (mean ± SD; n = 3). 
Cell viabilities after treatment with equivalent doses of free MNPs are given as references. Naked 
virus is plotted in black, SO-Mag particles and their complexes in blue and PEI-Mag particles and their 
complexes in red. Panel C represents enhancement of oncolytic activity of the virus due to 
assembling with magnetic nanoparticles calculated as IC50virus /IC50MNP-VP, where IC50virus and IC50MNP-VP 
are virus doses per cell required for 50 % cell growth inhibition/oncolysis after infection with virus or its 
magnetic complexes deduced from the dose-response curves registered after infection under 
magnetic field (+MF, data shown in figures A and B) or without magnetic field (no MF, data not 
shown) application and different FCS concentrations (grey bars: 7.5 % FCS, red bars: 50 % FCS). 
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Table 10: Oncolytic activity (IC50). A: Virus dose required for 50% cell growth inhibition/oncolysis 
(IC50) 24 hours after infection of McA cells with VSV vectors and 6 days after Infection of RDB cells 
with Ad vectors for the virus alone and its complexes with MNPs. Effect of the magnetic field and fetal 
calf serum (FCS) concentrations. B: Enhancement of oncolytic activity of magnetic virus complexes 
relative the virus alone. Effect of the magnetic field and fetal calf serum (FCS) concentrations. 
3.2.1.1.7 Quantitative MRI analysis 
MRI was performed to examine the visibility of the complexes under tissue-mimicking 
conditions, to determine the MR detection limit for the non-invasive monitoring of MNP and 
MNP-VP complexes, and to quantify the effect of cluster formation or intracellular 
compartmentalization on measured tissue relaxivities. 
The visual iron detection limit in the R2* maps was as low as 0.003 – 0.008 mM Fe, 
representing 0.76 x 105 labeled cells per mL at a loading of 2.5 pg iron per cell (SO-Mag-
VSV in McA cells), 0.24 x 105 labeled cells per mL at a loading of 6.7 pg iron per cell (PEI-
Mag-Ad in RDB cells), or 0.36 x 105 labeled cells per mL at a loading of 5.4 pg iron per cell 
(SO-Mag in McA cells). A MR detection limit could not be determined as all dilutions of the 
magnetic nanomaterial were clearly detectable above the background of mimicked liver 
tissue and untreated carcinoma cells, and therefore it was below 0.001 mM Fe, the lowest 
measured iron dilution.  
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Figure 28: MRI of exemplary liver-mimicking phantoms. Panels show (from left to right) a 
photograph of the phantom, a T2* echo image, and the respective R2* map. The phantoms are loaded 
with PEI-Mag2 (A), SO-Mag-VSV-complexes in McA cells (B), and untreated McA cells (C). All 
phantoms were prepared from a 2-to-3 dilution series of the magnetic nanomaterial in the wells 1-11 
and reference material in well R, on a 1.5 T Achieva MRI system. 
Figure 28 compiles image sets of exemplary phantoms with (a photograph of the plate,) a T2* 
echo image, and the corresponding R2* map. Figure 28A shows the phantom with 
homogenously dispersed PEI-Mag particles, panel 28B presents the phantom prepared with 
SO-Mag-VSV complexes internalized in McA cells, and the image set figure 28C shows the 
background phantom of untreated McA cells with no detectable iron signal. The fading brown 
color in the photograph, the black-to-grey signal increase and the red-to-blue signal 
transition in the R2* map in all three panels mirror the decrease of magnetic material. Both, 
the R2 and the R2* relaxation rates linearly increased with increasing iron concentrations in 
the range of 0.001 to 0.34 mM Fe of free, assembled, and intracellular MNPs. The measured 
R2 or R2* transverse relaxation rates and respective iron concentrations were plotted in figure 
28 for the 1.5 T (figures 29A and 29B) and 3 T (figures 29C and 29D) acquisition. 
The assembly of MNP-VP complexes and further cell internalization led to 47 - 97 % 
reduction of r2 and 14 - 82 % increase of r2* after internalization compared to free particles, 
which both yielded the highest r2 and lower r2* relaxivities. Cell internalization of free particles 
reduced the r2 relaxivities by 79 – 92 %, while the internalization of the corresponding MNP-
VP complexes reduced the r2 relaxivity in the same range (79 – 94 %), with the exception of 
the PEI-Mag-Ad complexes (47 %). In summary, the calculated r2* values were higher than r2 
values, and SO-Mag exhibited higher r2* relaxivities compared to PEI-Mag MNPs, while the 
r2 relaxivities were in the same range. Internalized or complexed MNPs yielded lower r2 
values compared to freely dispersed naked MNPs. In contrast, r2* relaxivities increased after 
nanoassembly and/or cell internalization. Our r2 relaxivities were between 10 and 286 mM-1 
Fe s-1, and therefore comparable to clinical contrast agents [269]. The r2* to r2 ratio after 
particle assembly and/or cell internalization compared to free, suspended particles was 
dramatically increased. The variation was 2- to 33-fold for PEI-Mag and 3- to 56-fold for SO-
Mag samples. Table 11 summarizes those r2 and r2* relaxivities, ratios of the complexed 
and/or internalized MNPs relative to the naked MNPs, iron loading per cell, and r2*/r2 ratios 
acquired on a 1.5 T clinical MRI system (corresponding 3.0 T MRI data in supplemental 
table 14). Figures 29E and 29F clearly demonstrates the comparability of data acquired 
either on a 1.5 T or a 3.0 T clinical MRI system. 
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Figure 29G shows the relaxivity plots for the data set of SO-Mag5 particles (from figure 9 of 
[115]), the magnetite core of the SO-Mag6-11.5 particles, and naked and cell internalized 
SO-Mag6-11.5 particles in McA cells and a primary murine PDAC cell line in liver tissue-
mimicking phantoms. The maximal iron concentration was 72 µg Fe/mL (1.3 µM Fe) for all 
three phantoms, free particles and labeled cells. 
 
 
 
Table 11: r2 and r2* relaxivities of the MNP assemblies. The table compiles the r2 and r2* relaxivity 
data of the free MNPs and all magnetic viral complex assemblies in liver-mimicking agarose 
phantoms, the ratios of the nanoassembly relaxivity normalized to the relaxivity of free MNPs 
(r2/r2(MNP) and r2*/r2*(MNP), respectively), and the r2* / r2 ratios. All measurements were performed 
using a clinical 1.5 T Achieva MRI system. 
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Figure 29: r2 and r2* relaxivity plots. A-D: 1.5 T (A-B) and 3 T(C-D), E-F: merge of the 1.5 and 3 T 
data. G: r2* plots of free and cell associated MNPs (SO-Mag5/SO-Mag6-11.5) acquired at 1.5 T (from 
figure 9 [115]). 
 
Figure 30B shows the corresponding saturation curves of SO-Mag particles in those two cell 
lines with internalized/associated iron plotted against the applied iron. The saturation curves 
of figure 30A show the results for both, SO-Mag and PEI-Mag particles in McA cells and 
three primary murine PDAC cell lines. Exogenic non-heme iron analysis elucidated SO-Mag 
particle loadings of 27 and 39 pg Fe/cell for 511181 and McA cells, respectively. Therefore, 
calibration phantoms for MR imaging were prepared with maximal final cell concentrations of 
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8.6 x 105 cells/mL in the 511181 cell PDAC phantom, and 6.2 x 105 cells/mL in the McA cell 
liver phantoms. 
Due to the MRI signal “blooming” effect it was not possible to quantitatively analyze the 
phantoms prepared with clotted MNP(-VP complexe)s, neither naked or cell internalized 
(figure 18C). The concentration of the sample material into a small alginate clot and 
embedding of that clots in agarose phantoms instead of homogenous dispersion of the 
sample in the whole volume agarose led to very high punctual iron concentrations and very 
strong hypointense signals. 
 
 
Figure 30: Saturation curves. 
 
3.2.1.2 In vivo targeting of SO-Mag-VSV complexes 
To test targeting and non-invasive detectability of MNP-VP in vivo, orthotopic HCC bearing 
rats were intra-tumorally injected with SO-Mag-VSV complexes in the presence of an 
external magnetic field. Anatomical T2-weighted MR imaging at 24 hours post injection 
clearly revealed intra-tumoral drop in signal intensity (figure 31A top). Regional histogram 
analysis of the hypointense parts graphically depicted the signal intensity shift of SO-Mag-
VSV complex-injected tumors in the lower signal range (figure 31A right). Histological 
analysis showed MNP-VP complex accumulation at the side of magnet placement (figure 
31B). Ex vivo analysis confirmed increased VSV titer and non-heme iron content of SO-Mag-
VSV complex-injected compared to naked VSV-injected tumors (figure 31C).  
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Figure 31: In vivo targeting of SO-Mag-VSV complexes. A: Pre- and 24 hour post-injection T2-
weighted anatomical MR images of orthotopic HCC after SO-Mag-VSV complex (top row) or naked 
VSV (bottom row) injection. The corresponding histograms (A, right) illustrate the signal loss after 
magnetic complex application in an emerging signal shoulder in the lower signal range. B: Overview 
(top) and high magnification micrographs of Prussian blue staining 24 hours after SO-Mag-VSV 
complex injection. The asterisk marks the injection site and the magnet was placed above the boxed 
area (top); scale bars 2,000 µm (top) and 500 µm (bottom), respectively. C: Intra-tumoral virus titer 
and non-heme iron of whole tumors sampled 30 minutes post infection with SO-Mag-VSV complexes 
(n=4, blue) and naked VSV (n=3, black). 
3.2.2 MNP-siRNA complexes 
Pre-clinical siRNA-based approaches were examined in various studies in the recent years. 
For in vivo applications, the siRNA needs to be enveloped with a carrier system to stabilize 
those small molecules and prevent from early degradation in the blood circulation. 
In our nanocarrier system, the siRNA was assembled with magnetic nanoparticles and an 
enhancer, which in parallel provides the opportunity to monitor and magnetically target the 
siRNA complexes after administration in future in vivo trials. The MNP-siRNA constructs 
were in vitro tested for their capability to down-regulate specific genes in cancer cells in a 
poof-of-principle study. Test systems for the knock-down experiments were stably luciferase 
and GFP expressing cell lines. SO-Mag and PEI-Mag particles were chosen as they easily 
assemble with negatively charged siRNA due to their own positive surface charge. 
3.2.2.1 Cell transduction for stable eGFP-Luc-fusion protein expression 
Selected pancreatic and hepatic cancer cell lines were transduced with the eGFP-luciferase-
fusion reporter gene construct, and were analyzed for their capability to express those new 
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proteins. First, the cells were checked for GFP expression qualitatively under the 
fluorescence microscope. Compared to the non-transduced cells on the left, all transduced 
cells exhibited fluorescence as the right column of the photograph panel in figure 32A shows 
clearly. For quantitative analysis, luciferase and GFP assays were performed, and the 
expression levels were measured after 48 and 72 hours at different cell seeding 
concentrations. The read out was plotted as chemiluminescence/fluorescence units in 
counts per second over the number of cells seeded to identify the cell density needed for 
reliable assay results. The first McA cell transduction did not work properly, therefore there 
were three batches of cells tested, cells of the first transduction (48 h and 72 h samples), 
“new” (same transduction conditions as before; 72 hours) and “double” transduced cells 
(underwent two sequential transductions; 72 hours). Those double-transduced cells were 
chosen for the further experiments, and from this point on referred to as McA eGFPLuc. For 
all other cell lines, the first transduction already resulted in positive GFP and luciferase 
expression. The luciferase and GFP expression levels varied between the different cell lines 
with the highest luciferase and GFP expression in the HuH-7 cells relative to the number of 
cells seeded. For the further knock-down experiments with MNP-siRNA complexes, and 
subsequent luciferase and protein assays, 104 cells per well, and 72 hours incubation after 
treatment were identified as optimal conditions. Figure 32B shows the calibration curves of 
luciferase plotted as chemiluminescence units over the luciferase concentration in ng/well. 
Those calibration curves were used for calculation of the cell expression levels via linear 
regression. 
 
Figure 32: Luciferase and GFP assay – proof of cell transduction with eGFP-Luc-fusion-
construct. Fluorescence/brightfield microscopy of LV PGKeGFPLuc-transduced vs. non-tranduced 
control cells and the according luciferase and GFP assay data (from left to right). 
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3.2.2.2 In vitro knock-down via magnetofection with MNP-siRNA complexes 
The down-regulation of luciferase expression after magnetofection with MNP-siRNA 
complexes is complied in figure 33. For all cells, the luciferase expression level of untreated 
cells corresponded to the data acquired from the luciferase assays presented in figure 33A. 
Analogous to the magnetic viral complexes, siRNA complexes of both magnetic 
nanoparticles, SO-Mag and PEI-Mag, were tested for their enhancing potential. To evaluate 
the enhancing effect of magnetofection using magnetic complexes instead of non-magnetic 
lipoplexes in those knock-down experiments, DF-siRNA lipoplexes were tested in parallel to 
the magnetic lipoplexes (red and blue curves), and the green curves in all graphs represent 
the data acquired for those reference lipoplexes. 
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Figure 33: siRNA knock-down via magnetofection. A: Absolute luciferase expression in pg per 
well of the different tested cell lines. B: Luciferase expression of siRNA-Luc transfected cells relative 
to the luciferase expression in with non-coding siRNA transfected negative control cells. C: Luciferase 
expression of transfected cells relative to untreated cells. D: Luciferase expression relative to the total 
protein. 
In all tested cell lines, transfection with PEI-Mag-siRNA complexes (red curves) resulted in 
higher down-regulation of the luciferase expression than with SO-Mag-siRNA complexes 
(blue curves). The down-regulative effect of the lipoplexes was a lot weaker than both 
magnetic complexes in all cell lines, especially in the 181RDB Luc cells. The graphs of figure 
33A present the total luciferase expression in pg per well. The expression levels were 
calculated from the chemiluminescence units detected using the calibration curve (figure 20). 
In addition to the absolute expression levels, the luciferase expression and more important 
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its down-regulation after transfection could be presented in two different ways depending on 
the reference values used. To derive the true down-regulation of the target protein 
expression, it might be better to use the values of the respective negative control siRNA 
complexes (figure 33B) rather than untreated cell data (figure 33C) as reference. But using 
untreated cells as reference allows to qualitatively evaluate the general effect of the 
transfection on the cells as even non-coding siRNA complexes led to slight down-regulation 
of the luciferase expression. Furthermore, in figure 33D the total amount of luciferase is 
presented graphically in ng luciferase per mg total protein. 
3.2.3 Magnetic liposomes 
3.2.3.1 Pre-studies on the MNPs 
The pre-studies were conducted to describe the in vitro and in vivo behavior of the palmitoyl 
dextran magnetic nanoparticles. They were characterized regarding their cell interaction and 
uptake, their MR imaging properties, and their toxicity in vitro in cancer cell lines and in vivo 
in mice.  
3.2.3.1.1 MNP – cell interaction 
The cell lines chosen for the in vitro tests were rat hepatic carcinoma cells and primary 
murine pancreatic adenocarcinoma cells as in both cancer types liposomal chemotherapy 
would be a convenient medication, and the rodent tumor models were established.  
3.2.3.1.1.1 MNP uptake and cytotoxicity evaluation 
To identify optimal labeling conditions, several primary murine PDAC cells and the rat HCC 
cell line McA were treated with increasing amounts of magnetic nanoparticles. Figure 34A of 
two exemplary cell lines shows photographs of pelleted labeled cells and micrographs of the 
corresponding MNP-loaded cell monolayers. The color of the cell pellets shifted from white 
to brown with increasing amounts of internalized iron particles (figure 34A, two top 
photographs, each from right 0 pg Fe/cell to left 400 pg Fe/cell). In the four picture sets 
below, the MNP aggregates could be identified in the magnification as clearly visible 
brownish spheres within the labeled cells but not in the non-treated reference cells of the 
according micrographs. Quantification of the exogenic iron was performed using a 
colorimetric method with 1,10-phenanthroline, and the saturation effect with MNPs at 
between 200 and 800 pg applied iron per cell was visualized by plotting the 
internalized/associated iron over the applied iron dose (figure 34B; magnification for the 
concentration range 0 – 400 pg Fe/cell for PALD2-Mag1). The plateau labeling 
concentrations ranged between 20 and 80 pg Fe/cell for the pancreatic and 125 pg Fe/cell 
for the hepatic cells in case of PALD2-Mag1, and 70 and 185 pg Fe/cell for the PALD2-Mag2 
nanoparticles in the pancreatic cells. To evaluate the cytotoxicity of the applied magnetic 
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nanoparticles on the cells, MTT assays were performed in that same iron concentration 
range; figure 34C summarizes those viability assay data. In the tested cell lines, the MNP 
treatment led to reduced cell viability in the 512010 and 530202 cells in a dosage range of 
25 – 800 pg Fe/cell applied iron with viabilities of 54.1 % (530202) and 52.1 ± 6.5 % 
(512010) at the highest applied iron dose of 800 pg Fe/cell. For the other tested cell lines, 
there were no strong adverse effects on cell viability with 73.8 ± 25.8 % for 511181 cells and 
84.7 ± 20.1 % for 511677 cells even at 800 pg Fe/cell. There was a first viability drop for all 
cell lines up to 25 pg Fe/cell (12.5 pg Fe/cell for 511181), then an increase, and then the 
viability was slowly decreasing again for all iron doses up to 800 pg Fe/cell (except for 
511677 with viability improvement between 400 and 800 pg Fe/cell treatment) as the graph 
and its magnification in figure 34C show. 
 
 
Figure 34: In vitro MNP-uptake and cytotoxicity evaluation: PALD2-Mag. A: Images of cells 
labeled with PALD2-Mag1: cell pellets in the top row and light microscopy of labeled cell monolayers 
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beyond, labeled and non-labeled cells both in sets with the two-fold magnification. B: Mean all 
saturation curves. C: MTT assay of PALD2-Mag1 particles in PDAC cell lines. 
3.2.3.1.2 In vivo biodistribution and toxicity study 
The in vitro MNP-uptake and cytotoxicity evaluation exhibited no adverse effects, so the 
particles were analyzed for their in vivo biodistribution and toxicity in mice. After intravenous 
administration of both types of magnetic palmitoyl functionalized nanoparticles, the mice 
were observed for 14 days regarding weight development, general fitness and behavior. 
Then they were sacrificed and tissue samples underwent histological and biochemical 
analysis for exogenic iron from the magnetic nanoparticles; figure 35 summarizes all 
analysis results of both treatment groups (PALD2-Mag1 and PALD2-Mag2). The weight 
development was plotted for both MNPs as weight over age for female and male animals in 
figure 35A (PALD2-Mag1 male n = 6, PALD2-Mag1 female n = 7, PALD2-Mag2 male n = 4, 
PALD2-Mag2 female n = 10). All animals presented a healthy gain of weight; the weight of 
the PALD2-Mag2 injected female animals was slightly higher as they were 10 days older 
than the PALD2-Mag1 injected females (supplemental table 12). Regarding the weight 
development and the scoring of general fitness and behavior, no impact of the MNP 
treatment was suggested as the animals showed no signs of health alteration such as 
cachexia, reduced mobility or behavioral changes. For the histological (figure 35C) and 
biochemical (figure 35B) evaluation sampled tissues were liver, lung, spleen, kidney, 
pancreas/pancreatic tumor (tumor head and tumor tail), heart, testis/ovary, bone and tail 
(injection site). In figure 35B the quantitative analysis of the Prussian blue stained tissue 
area (left) was compared with the biochemical analysis for non-heme tissue iron (right), both 
plotted for all sampled tissues and averaged over all animals per treatment group and sex 
analogous to figure 35A (exogenic iron quantification: control male n = 6, control female n = 
10, PALD2-Mag2 male n = 4, PALD2-Mag2 female n = 10; Prussian blue: control male n = 7, 
control female n = 11, PALD2-Mag1 male n = 8, PALD2-Mag1 female n = 11, PALD2-Mag2 
male n = 4, PALD2-Mag2 female n = 10). Figure 35C compiles exemplary histology results 
of liver, lung, spleen, kidney and pancreas samples in PALD2-Mag2-injected mice versus 
the untreated control, both in female and male mice. In the liver samples of treated (97 %) as 
well as untreated (19 %) animals, positive iron staining was mainly detectable in the 
periportal zone of the liver lobule. In detail, iron was found in the sinusoidal cells in most 
cases but also in single hepatocytes. Eosinophilic crystals which stained positive for iron 
were found in the lung tissue samples of 85 % of the treated animals. These crystals were 
needle-shaped and were present in the cytoplasm of alveolar macrophages as well as free-
lying within alveoli. Positive staining for iron was also found in alveolar cells, but there were 
no pathological findings in the lungs. Hemosiderin is an iron-positive pigment derived from 
erythrocytes. The presence of hemosiderin in the spleen is considered normal and can be 
seen in macrophages mainly in the red pulp but also in the white pulp, so the staining is also 
not necessarily related to the MNP administration as the staining was found in 100 % of the 
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treated and 81 % of the untreated animals spleen tissue samples. The iron particles stained 
in the kidney samples of 52 % of the treated animals were mainly found in the glomeruli and 
tubules of the cortex region. In the pancreas of 32 % of the treated animals, iron particles 
were mainly found in endothelial cells of the vessels as well as in the interstitium between 
acinus cells. In 16 % of the treated animals there were iron positive pancreatic lymphnodes, 
while the pancreatic tissue was iron-negative. In PDAC samples positive iron staining was 
localized focally in the tumor stroma. 
 
 
Figure 35: MNP biodistribution and toxicity in vivo: PALD2-Mag. PALD2-Mag1 (200 µg in 200 µL 
NaCl) and PALD2-Mag2 (200 µg Fe in 100/200 µL NaCl). A: Weight development after MNP 
administration. B: Prussian Blue are/all tissue area [%] vs. non-heme iron quantification [µg Fe/g 
tissue] with non-heme iron determination. C: Exemplary Prussian blue stained tissue samples, bar 50 
µm. Control male: n=6, Control female: n=10, PALD2-Mag2 male: n=4, PALD2-Mag2 female: n=10; 
Prussian Blue staining: Control male: n=7, Control female: n=11, PALD2-Mag1 male: n=8, PALD2-
Mag1 female: n=11, PALD2-Mag2 male: n=4, PALD2-Mag2 female: n=10; Weight development: 
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PALD2-Mag1 male: n=6, PALD2-Mag1 female: n=7, PALD2-Mag2 male dark: n=4, PALD2-Mag2 
female 7w light: n=4, PALD2-Mag2 female 5.5w dark: n=6. 
Positive staining for iron was mainly found in the interstitial cells of the heart of 39 % of the 
treated animals. Some ovary samples of female treated (57 %) as well as untreated (22 %) 
animals showed positive staining for iron particles in the ovarial stroma, whereas no specific 
staining could be found in the testis samples. By nature, most absorbed iron is utilized in 
bone marrow for erythropoiesis. A few animals, treated (72 %) and untreated (7 %), showed 
focal iron positive staining in the periosteum of the inspected bone sample. In a few treated 
animals (21 %) the tail vein showed a positive iron staining because of the intravenous 
administration of the MNPs via a tail vein catheter. The only pathological findings were areas 
of focal inflammation and/or microgranuloma and/or focal necrosis in many liver tissue 
samples of treated (85 %) and untreated (69 %) animals with which can be a common 
finding in BL/6 mice, and the pancreatic tumors, fibrotic tissue and focal areas of 
inflammation in the pancreas samples of PDAC positive mice. Over all other tissues there 
were no pathological findings.  
3.2.3.1.3 Target-protein expression: integrins αv and β3 
 
Figure 36: Target-protein expression in PDAC. A: Western blot of primary murine pancreatic 
cancer cell lines for integrin β3 and integrin αϖ. B: Magnetic resonance (left, middle) and intraoperative 
fluorescence imaging (right) in a PDAC-bearing mouse: The bright abdominal MR signal on the 
coronal slice in the T2 echo after 30 ms (left) as well as the T2 map (middle) and the αϖβ3-expressing 
tissue labeled with IntegriSense® (right) mark the tumor. C: Immunostaining of integrin β3 (brown) in 
murine pancreatic tissue around the vessels of a wildtype mouse (left) and throughout the whole 
tumor of a tumor mouse (right). Images from B and C kindly provided by Dr Trajkovic-Arsic 
The tumor cell surface protein αvβ3 integrin receptor was chosen as potential target structure 
and its expression on the primary PDAC cell lines was proven qualitatively by Western 
blotting. Figure 36A shows blots for the integrins αv and β3 in the PDAC cell lysates and a 
positive control lysate. Unfortunately, the antibody of the loading control Hsp90 did not work 
properly, but as it was only a qualitative expression control and no quantitative analysis, the 
Results 
 82 
assay was not repeated. The T2 echo MR image (36B left) of a PDAC bearing mouse and 
the corresponding T2 map (36B middle) of the anatomy scan enabled the localization of the 
tumor for the intraoperative fluorescence imaging (36B right). The binding of the αvβ3 
integrin-targeting contrast agent IntegriSense® 680 resulted in a bright signal of the tumor. 
The ex vivo immunostaining in figure 36C shows the normal expression of β3 integrin 
(brownish) around the vessels of a healthy wt mouse compared to the expression throughout 
the whole tumor tissue in a CKp53lox PDAC mouse. The data of figures 36B and C were 
kindly provided by Dr Trajkovic-Arsic, II. Med. Clinic, Gastroenterology, Klinikum rechts der 
Isar der Technischen Universität München. Detailed results are presented in Trajkovic-Arsic 
et al. [209]. 
3.2.3.2 Magnetic liposomes 
3.2.3.2.1 Liposome synthesis and characterization 
Liposomes were synthesized using three different protocols: thin film hydration, reverse 
phase hydration, and the injection method. Desired liposome size was about 100 nm in 
diameter, and the surface should be PEG-functionalized for stabilization, either as lipid 
moiety or using the polymer P3C18. Advantage of the polymer was its capability to bind αvβ3 
integrins, expressed specifically on tumor cells. Figure 37 compiles exemplary results of the 
palmitoyl dextran MNP and MNP-LP characterization. The optimal wavelength for 
photometrical analysis was examined in wavelength scans of the magnetic nanoparticles. 
For both PALD2-Mag particles, 350 nm was determined as appropriate (37A of an 
exemplary PALD2-Mag1 scan). In figure 37B, the decrease of turbidity was plotted over time 
for magnetic TFH liposomes consisting of DPPC:Chol:DSPE-PEG2000 at 80:20:5 prepared 
with PALD2-Mag1 particles versus naked PALD2-Mag1 particles. The schematic explains 
magnetophoretic mobility as the liposome migration towards the magnets on both sides, and 
thus the clearance of the suspension in the cuvette, detected as signal decrease. Liposomes 
synthesized following the injection method protocol met those criteria with 119 ± 57 nm 
(100.1 nm in one respective measurement, figure 37C) in diameter and a slightly anionic 
zeta potential of - 10 ± 6 mV (ζ  = -9.96 mV, 36C) after magnetic separation, as did the TFH 
liposomes with Dh = 92 ± 65 nm and an anionic ζ of - 55 ± 8 mV. Exemplary zetasizer 
measurements of the physico-chemical properties of magnetic liposomes, size and charge, 
are presented in figure 37C. The left graphs show the size (upper graph) and the zeta 
potential (bottom graph) of the magnetic fraction, and the right two graphs present the 
corresponding data of the non-magnetic fraction. Those exemplary injection method 
liposomes were prepared from DPPC:Chol:P3C18 at 80:20:5 and PALD2-Mag1 particles. A 
negative charge ζ  of -9.96 mV and the size of 100.1 nm indicated, that the injection method 
could be technique of choice for preparation of magnetic liposomes as size and charge meet 
the set criteria, as well as the TFH liposomes did with similar values (data not shown). The 
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magnetic separation into magnetic and non-magnetic fraction helped to remove bigger non-
magnetic liposomes, only a very small fraction of 2.2 % was left in the MNP-LP fraction and 
could be removed via extrusion. Figure 37D compiles phase contrast and fluorescence 
microscopic images of liposomes synthesized by the injection method and with P3C18 
polymer (20 % of it conjugated with atto550 fluorescence dye) in 40-fold magnification. The 
micrographs nicely show the behavior of the magnetic liposomes before (figure 37D left) and 
after (figure 37D right) an external magnetic field was applied, the magnetic liposomes 
instantly moved towards the magnet. 
 
 
 
Figure 37: MNP and MNP-LP characterization. A: Wavelength scan of PALD2-Mag1.                    
B: Magnetophoretic mobility measurement: exemplary TFH liposomes of DPPC:cholesterol:DSPE-
PEG2000 80:20:5 with PALD2-Mag1 and naked PALD2-Mag1 particles at λ = 350 nm. C: Physico-
chemical characterization of exemplary injection method liposomes: measurement data of size by 
intensity and charge. D: Microscopy of liposomes: phase contrast and fluorescence mode in 40-fold 
magnification. 
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3.2.3.2.2 Thermosensitive LPs 
Advantage of a liposomal formulation is the possibility to choose the lipids according to the 
application specific needs. In this study, the lipid shell formulation allowed for targeted 
release of the liposomes content triggered by temperature. When the liposomal solution was 
heated up above a specific temperature, the thermosensitive lipid layer started to get leaky 
and released the encapsulated liquid. Depending on the chosen lipid composition, that 
melting temperature Tm could be tuned. For this test, three different lipid compositions with 
proposed melting temperatures ranging between 39 and 42 °C were analyzed. The 
liposomes were filled with a calcein solution whose release could be quantified 
fluorometrically in the surrounding medium (PBS/50% FCS in PBS). To identify the specific 
wavelength for such quantification, first a wavelength scan was performed, and 496 nm was 
identified as calcein absorption maximum (figure 38A). Measurement of the standard curves 
in different media revealed that both, PBS and 50 % FCS in PBS could be used (figure 38A), 
whereby the FCS solution is closer to in vivo conditions. In addition, the extinction 
coefficients εcalcein in the different media were determined to be εcalcein(PBS) = 2,801 cm-1M-1,  
εcalcein(50 % FCS) = 2,932 cm-1M-1 and εcalcein(H2O) = 2,567 cm-1M-1 (figure 38A). Figure 38B 
summarizes calcein release assay data for two different liposome synthesis protocols, TFH 
(top graphs) and injection method (bottom graphs), and two different media, PBS (on the 
left) and the more physiological 50 % FCS in PBS (on the right). For all temperatures, the 
calcein release in % was plotted over time (temperature color code legend on the right; for 
all: circles represent lipid preparation a, squares composition b, and triangles lipid mix b*). 
Figure 44 in the supplement presents the release data for both types of liposomes in 
separate graphs for each temperature. Lowest incubation temperature was body 
temperature 37 °C to prove that none of the calcein would be released directly after an in 
vivo application before even reaching the target region, the other incubation temperatures 
were 39 °C, 41 °C and 42 °C, and the release was calculated relative to the 100 % release 
control samples lysed with Triton X-100. In general, the assay worked only for the TFH 
liposomes. For the liposomes synthesized using the injection method, the temperature-
dependent calcein release could not be shown properly. In PBS, the best calcein release 
levels from the TFH liposomes over all temperatures were gained for composition a, the 
DPPC:Chol:P3C18 liposomes. Melting temperature with high release levels above 50 % 
already after 15 minutes was Tm = 42 °C, at 41 °C the release started after 30 min and at 39 
°C it started after 45 minutes. For the two other lipid compositions, the temperature response 
pattern was the same but the release levels were lower. In 50 % FCS in PBS, the release 
levels and timing were comparable for all three lipid compositions, also with about 50 % 
release after 15 minutes exposure to 42 °C, 30 minutes to 41 °C and 45 minutes to 39 °C. 
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Incubation at increased temperatures revealed no clear calcein release from the injection 
liposomes for all three lipid compositions and in both media.  
 
Figure 38: Calcein release assay of thermosensitive liposomes.	   A: Calcein wavelength scan, 
standard curves and determination of extinction coefficient. B: Calcein release assay of TFH 
liposomes and injection method liposomes in PBS and 50% FCS. 
 
3.2.3.2.3 Drug loaded MNP-LPs 
3.2.3.2.3.1 MNP-PTX liposomes 
Liposomes co-loaded with the chemotherapeutic drug paclitaxel (PTX) and the PALD2-Mag1 
nanoparticles were synthesized following the TFH protocol. Figure 39 compiles the 
appearance of those liposomes prepared with PEGylated lipid vs. the polymer P3C18, drug 
loaded and without PTX, and before and after dialysis and magnetic separation. The 
liposomes prepared with the polymer were perfectly magnetically separable as it can be 
seen on the right picture of figure 39D. 
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Figure 39: Liposome synthesis and processing: TFH liposomes comprising 
DPPC:cholesterol:DSPE-PEG2000 80:20:5 or DPPC:cholesterol:P3 C18 80:20:5 and loaded with 
PALD2-Mag1 (and PTX). A: freshly synthesized MNP-LPs. B: freshly synthesized magnetic 
liposomes co-loaded with PTX. C: MNP-PTX-liposomes after ON dialysis against ddH2O, 4 °C.         
D: magnetic separation of both types of MNP-PTX-liposomes. 
3.2.3.2.3.2 MNP functionalization 
For further functionalization of the liposomes, the chemotherapeutic drug paclitaxel (PTX) 
should be encapsulated into the liposomes. Therefore, the positively charged magnetic 
nanoparticles were complexed with the PTX and binding should be quantified using the 
photometer. First, the absorption maxima of both, MNPs and PTX, were determined. In 
addition, the magnetic and the non-magnetic fractions of drug-loaded MNPs underwent 
wavelength scans. Unfortunately both, MNPs and PTX showed an absorption peak at 275 
nm, therefore it was not possible to reliably quantify the coupling of PTX to the MNPs 
photometrically. In figure 40, the absorption was plotted over the wavelength, and all 
samples, the free components as well as the drug-loaded complexes and the unbound drug 
in the non-magnetic fraction, show high absorption at 275 nm. From the close proximity of 
the free MNP-curve and the MNP-PTX magnetic fraction curve and the high values of the 
non-magnetic fraction it could be assumed that only a small amount of drug had bound to 
the particles. 
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Figure 40: MNP functionalization with 
PTX. 
 
 
 
 
 
 
3.2.3.2.4 In vivo evaluation of MNP-LPs 
3.2.3.2.4.1 Biodistribution 
 
 
Figure 41: MNP-LPs in vivo in wildtype mice. A: T2* dynamic MRI scans pre- and post-injection of 
magnetic liposomes (1.5 T clinical MRI system). The left image in both datasets is the anatomy scan 
to identify the iron accumulating hypointense tissue in the right images as liver. The histograms in the 
bottom row plot the signal drop over time after liposome injection for slices 1(, 2 and 3). B: Prussian 
blue staining of liver tissue for ferric iron and the corresponding 5x-fold magnification of stained iron 
particles, probably in Kupffer cells, bar 50 µm. 
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In the biodistribution experiment, wildtype mice were treated with magnetic liposomes. The 
liposomes were administered intravenously via tailvein catheter, and meanwhile the liver of 
the animal was real-time monitored applying MRI. Figure 41A shows pre- and post-injection 
liver T2* scan image sets in the top row, and in the bottom row the according histograms 
plotting T2* relaxation rates over time, the left graph for slice 1, marked with liposome 
injection and start of saturation, and the right graph compiling the subsequent acquisition of 
the slices 1, 2 and 3. The right anatomy scans in the top row image sets helped to localize 
the liver. The scan sequence protocol used for acquisition of the right images was sensitive 
for iron-containing magnetic contrast agents, and thus clearly showed a signal decrease in 
the liver after magnetic liposome injection. The graphs mirror that signal drop throughout the 
tissue slices. The histological localization of the magnetic nanoparticles was facilitated by 
Prussian blue staining of the tissue ferric iron in the liver samples. Figure 41B shows an 
exemplary micrograph and its magnification wherein the MNPs could be identified as blue 
spots within the liver tissue. 
3.2.3.2.4.2 Magnetic targeting 
In contrast to the biodistribution experiment, not wildtype but pancreatic tumor-bearing mice 
were used in this study, and there was no MRI-facilitated monitoring of the animals due to 
the experimental setup with external magnets. Again, the mice were anesthesized using 
isoflurane, and the liposomes were administered via tailvein catheters. Then, in one group 
the magnetic liposomes were targeted towards the pancreatic tumors using an external 
magnetic field. Therefore, the magnets were fixed above the tumor region. After 1 hour of 
liposome circulation (and targeting in the magnetic targeting group), the animals were 
sacrificed and tissue samples were taken. Those samples underwent histological and 
biochemical analysis. Figure 42A compiles exemplary micrographs of the Prussian blue 
staining for magnetic nanoparticles in several tissues for all treatment groups (liposome + 
magnet (top row); liposome, no magnet (middle row); control (no liposome or magnet, 
bottom row). As expected, there was some positive staining in liver and spleen. Kidney and 
pancreas showed no positive staining, but in the tumor tissue of all liposome-treated animals 
(with and without additional magnetic targeting) some positive staining could be identified. 
Figure 42B shows exemplary micrographs of a liposome-treated mouse (no magnet) in a 
lower magnification, showing the positive staining in liver, spleen and tumor tissue more 
clear. In the histogram of figure 42C, the results of the corresponding non-heme iron 
analysis were plotted as µg iron per gram tissue for all sampled tissues. That biochemical 
iron analysis mirrors the histological results with relative high levels in spleen and liver, and 
elevated iron levels in pancreatic tumor compared to healthy pancreatic tissue. 
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Figure 42: MNP-LPs in vivo in CKp53lox PDAC mouse model: LPs i.v. ± 1h magnet. A: 
Exemplary Prussian blue staining micrographs of several tissues over both treatment groups and 
control animals, bar 50 µm. B: Exemplary Prussian blue staining micrographs (liver, spleen and 
pancreatic tumor) of liposome-treated mouse in lower magnification. Iron could nicely be localized in 
the pancreatic tumor tissue (right micrograph), the positive staining in the spleen (middle) is most 
probably not due to the liposome treatment but could be found in all animals. The liver section shows 
some positive staining for iron, but from the biodistribution experiment in wildtype mice a little more 
was expected. Probably it was washed out already as the liposomes circulated for 1 hour prior to 
sacrifice and the contrast-agent effect of the liposomes was MR imaged in real-time acquisition. C: 
Non-heme iron determination: biochemical tissue-iron quantification from sampled tissues 
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4 DISCUSSION 
4.1 Magnetic nanoparticles 
The differences in the mean hydrodynamic diameters and specific magnetization of the 
selected core−shell type iron oxide MNPs resulted in different magnetic moments of the 
cores. The differences in the electrokinetic potentials were mainly due to the surface 
compositions. Small average hydrodynamic diameters of the PEI-Mag particles indicate 
single particles in aqueous suspension. Whereas the SO-Mag particles with the larger 
average hydrodynamic diameters suggest particle aggregation into small assemblies due to 
increased magnetic dipole-dipole interactions [103, 105]. The hydrodynamic diameter of the 
PALD2-Mag nanoparticles ranked between the PEI-Mag and SO-Mag particles [113]. 
The MNPs (PEI-Mag and SO-Mag) selected for viral and siRNA complexes both comprised 
branched PEI in their coating, and were therefore highly positively charged when suspended 
in water. Such PEI-stabilized particles were eligible for association with negatively charged 
VPs and siRNA, respectively, into efficient complexes at (virus-)specific and -optimized iron-
to-virus and iron-to-siRNA ratios, respectively, resulting in high cell labeling and 
magnetofection efficacies [103, 141, 270]. The self-assembly into stable MNP-VP or MNP-
siRNA complexes was of predominantly electrostatic nature. Such self-assembly is known to 
modify the magnetic behavior relative to that of isolated particles and often happens in liquid 
medium [271]. 
In contrast to SO-Mag and PEI-Mag particles, PALD2-Mag particles exhibit negative 
electrokinetic potential and are therefore especially suitable for the integration in liposomal 
formulations [96, 272] or lipoplexes [113], but they were also successfully used for viral [102] 
and non-viral siRNA complexes [100, 112, 180]. 
 
4.2 Magnetic nanocarriers 
4.2.1 MNP-VP complexes 
The central questions when developing oncolytic virus therapies are: What happens with the 
virus after administration? And is it possible to localize the oncolytic virus at the tumor site 
and therefore enhance its oncolytic potential? – The coupling of virus particles to magnetic 
nanoparticles is one possible approach to address both issues. The viral complexes can be 
monitored after administration via MRI, and targeting towards the region of interest applying 
an external magnetic field increases delivery efficiency. 
This section discusses on the physico-chemical and imaging characteristics of the selected 
MNPs and derived complexes with Ad and VSV, and their in vitro and in vivo evaluation 
regarding oncolytic activity and tissue virus titer. PEI-Mag2 and SO-Mag6-11.5 particles 
possessed highly positive electrokinetic potentials, enabling self-assembly based mainly on 
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electrostatic interaction with negatively charged VPs. TEM was used to visualize complex 
and cluster formation of free magnetic material and upon cellular uptake. Quantitative MRI of 
gel phantoms revealed decreased r2 and increased r2* values upon complexation and 
clusterization. First in vivo application of VSV-based MNP-VP complexes demonstrated their 
targeting and imaging properties. 
 
In many studies, MNP-VP complexes were used for the targeted delivery of nucleic acids to 
target tissues, and to utilize the uptake-enhancing effect of magneto-transduction in an 
external magnetic field [101, 145, 270, 273-278]. The physico-chemical properties of our 
MNP-Ad complexes were consistent with earlier studies on such complexes by Tresilwised 
et al. [103, 105]. Comparing the electrokinetic potential, magnetophoretic mobility and 
magnetic moment of our adenoviral complexes with lentiviral complexes with PEI-Mag and 
SO-Mag particles [102], the data for the PEI-Mag-Ad complexes were in the same range, 
whereas the SO-Mag-Ad complex data exhibited higher values in our study, indicative of 
aggregation as already postulated [139]. Using MNP-Ad complexes and applying 
magnetofection could successfully help overcome the transduction resistance in skeletal 
muscle cells compared to naked virus [277]. 
Besides the self-assembly of our MNP-VP complexes, also surface moieties could be used 
for complexation. Pandori et al. developed a method for coupling of adenoviral vectors to 
silica microbeads via streptavidin and its ligand biotin. No negative effects on the infectivity 
after conjugation of adenovirus virions to solid silica microbeads or paramagnetic 
microparticles via biotin-(strept)avidin interaction could be detected. On the contrary, the 
combination of those streptavidin-coated MNPs, biotinylated adenovirus and magnetic force 
resulted in high infection rates under magnetically controlled conditions [273]. We were the 
first group to couple VSV to MNPs for magnetically guided delivery and monitoring of the 
oncolytic virus particles. Regarding size and charge, the MNP-VSV complexes were within 
the same size range as the MNP-Ad complexes. 
 
Analogous to Trueck et al., we identified the optimal MNP-to-VP ratio for complex formation 
by titration of a fixed amount of VPs with increasing amounts of MNPs [102]. They analyzed 
the bound amount of virus by lentiviral capsid protein quantification from the non-magnetic 
supernatants by ELISA, whereas we quantified the remaining virus particles using TCID50 
assays. In addition to the supernatant analysis, we also analyzed the virus content in the 
magnetic fraction. The optimal iron-to-virus ratio identified for the PEI-VSV complexes was 
500 fg Fe/VP which was comparable to the lentiviral PEI-Mag complexes with 300 fg Fe/VP 
[102], although Wenzel et al. performed their experiments with PEI-Mag-LV complexes 
comprising only 40 fg Fe/VP [101]. Their titration experiments affirmed our choice to utilize 
electrostatic interactions between MNPs and VPs for self-assembly. There was a clear 
better binding efficiency of negatively charged lentivirus particles to positively charged MNPs 
[102]. 
 
Discussion 
 92 
As expected, MNPs and MNP-VP complexes both displayed high cell labeling and infection 
efficiencies with the magnetofection method applied [100]. The magnetic cell labeling with 
and without an externally applied magnetic field was previously tested in RDB cells [103, 
105], and within this work tested in McA cells [115, 139]. The total labeling was between 2.5 
and 5.4 pg Fe/cell in McA cells, and 6.7 and 17.3 pg Fe/cell in RDB cells after application of 
10 and 25 pg Fe/cell, respectively, indicating that the labeling efficiencies ranged between 
25 % and 69 % [139] and 39 % under higher applied iron doses of SO-Mag particles in McA 
cells [115]. 
The high transduction rates with the MNP-VP complexes could be explained by the surface 
modification of both magnetic particles with PEI, as this component is known to stimulate cell 
internalization of the complexes [102]. During complex assembly, it enhances the binding of 
VPs to MNPs leading to a high amount of viral particles per magnetic complex [102]. 
In addition, the magnetofection-mediated MNP-VP complex uptake is more efficient and 
faster than the uptake of naked adenovirus via coxsackie and adenovirus receptor (CAR)-
mediated endocytosis [276]. In detail, the entry of both, wildtype and recombinant 
adenovirus, into cells comprises a two-step sequence involving different membrane proteins: 
a high-affinity primary receptor, the CAR, that mediates the attachment of virus to the cell 
surface, and lower-affinity secondary receptors (αvβ3 and αvβ5 integrins) that allow 
internalization of the viral particles [279]. Additionally supportive are high expression levels 
of αvβ3 integrins on the surface of several tumor cell types including HCC and PDAC [209, 
280-283]. Also, magnetofection utilizes the natural uptake pathway of endocytosis, resulting 
in high post-transfection cell viability [148]. 
 
The localization and aggregation state of MNPs and MNP-VP complexes after cell 
internalization, as well as their appearance in suspended form was elucidated by 
transmission electron microscopy. TEM images revealed that MNPs were most probably 
arranged in layers around the VPs due to predominantly electrostatic interactions and 
magnetic dipole-dipole interaction between the particles as shown earlier [105, 139]. A 
similar corona of multiple MNPs surrounding a VP has previously proven as effective 
defense against virus neutralizing antibodies [103]. On the TEM photomicrographs of naked 
MNPs and MNP-VP, both samples were more or less dispersed, and single self-assembled 
complexes could easily be identified. 
As expected [284], the cell-internalized complexes were encapsulated in endosomes, 
whereas the free MNPs were mostly clustered within the cytoplasm and only few in 
endosomes. Cytoplasmic localization [285, 286] and endosomal encapsulation [287] of the 
internalized MNPs was also observed in other experiments with MNP-labeled cells. We 
assume that the compartmentalization, clusterization and distribution of MNPs and MNP-VP 
complexes in cells depended on the uptake mechanism. From the TEM photomicrographs, 
we speculate that the uptake of complexes was not receptor mediated, and therefore, cell-
bound complexes were most probably endocytosed. In contrast, naked MNPs might have 
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been taken up directly into the cytoplasm and aggregated there. In earlier studies, cell 
uptake and transfection with enclosed plasmid DNA of magnetic lipoplexes was very 
efficient. The sizes of these lipoplexes were comparable or bigger than our complexes, but 
also the bigger lipoplexes of about 2 micron were efficiently internalized [113]. Others found 
the larger complex size even advantageous for good internalization and transfection [288-
290] which could not be confirmed by Sanchez-Antequera et al. [113]. In contrast to the 
cytoplasmic localization of MNPs in our study, others found iron oxide particles to be 
localized intracellularly primarily in the tubular lysosomal compartment [291, 292]. Sun et al. 
identified the non-facilitated endocytosis of small particles into human hepatocellular liver 
carcinoma cells from TEM images [293]. Chemically modified dextran-coated iron oxide 
particles were internalized through receptor-mediated endocytosis into highly specialized 
cells such as hepatocytes [294, 295] or pancreatic acinar cells [296]. 
 
In vitro infection experiments have shown that exposure of the MNP-VP complexes to 50 % 
FCS resulted in considerable inhibition of the oncolytic activity of the naked virus, for both, 
VSV and Ad. In contrast, the oncolytic potency was not dramatically altered after assembling 
with selected MNPs at optimal iron-to-virus ratios and remained high even at high serum 
concentration for viral complexes with both, VSV and Ad (table 10 and figure 27). The 
stability of MNP-VP complexes in the presence of high serum concentration could also be 
shown for lentiviral complexes when utilizing the same MNPs chosen in this study [101, 
102]. Our findings promised enhancement of oncolytic potency due to assembling with 
MNPs, especially under application of a magnetic field. 
 
In addition to their physico-chemical properties Dh and ζ, the selected core-shell MNPs and 
their optimized self-assembled complexes with VPs were characterized for their magnetic 
responsiveness in applied magnetic fields [180, 181]. This step is crucial to ensure that the 
magnetic moment of such complexes is high enough for magnetic targeting even under 
physiological flow stress [102]. 
Therefore, the turbidity clearance curves were plotted and extrapolated to calculate the 
magnetophoretic mobility and the number of associated MNPs per VP applying the method 
by Wilhelm et al. [297]. The results were comparable to those of previous studies on MNP-
VP complexes [103, 105]. Flow experiments of Wenzel et al. and Trueck et al. revealed the 
magnetic moment of SO-Mag-LV complexes to be higher than that of PEI-Mag-LV 
complexes. Solely their SO-Mag-LV complexes could successfully internalize into 
endothelial cells [101, 102]. Therefore, in cell replacement experiments in an ex vivo murine 
aorta model, endothelial cells were transduced with MNP-LV complexes and loaded with 
SO-Mag5 particles for higher a magnetic moment of the cells. Such approach could be used 
for the combination of nucleic acid transfer and cell replacement or seeding of cells on 
cellular grafts in patients suffering from vascular disease. Lentiviral complexes with other 
MNPs were tested for in vitro transduction efficiency in several endothelial cell lines and ex 
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vivo under non-permissive conditions (hydrodynamic forces, shear stress induced by blood 
flow) in an aorta model and regarding targeting and transduction capacity in an injured 
common carotid artery model in vivo [106]. Another application of lentiviral vectors is the 
gene delivery into airway epithelium using polycation-coated iron oxide NPs non-covalently 
bound to LV particles. In vitro magneto-transduction with GFP as reporter gene led to high 
transduction efficiency of MNP-LV complexes compared to naked LV [298]. Such 
approaches are also an option for our MNP-Ad complexes. The most important application 
of our MNP-VSV complexes would lie in the treatment of HCC. 
 
Non-invasive MRI is a very important monitoring and diagnosis tool as clinical MRI scanners 
providing 1.5 to 3.0 T are capable of µm resolution in soft tissue imaging [43]. SPIOs have 
proven as negative MRI contrast agents in vitro, and will be used in in vivo labeling and 
tracking experiments, but challenging remains the quantification [64]. From first our 
experiments we knew that the selected core-shell type SO-Mag MNPs showed excellent r2 
and r2* relaxivities, both free and cell-internalized [115]. To further determine the efficacy of 
naked and cell-internalized MNP-VP complexes as contrast agents for MRI, and to identify 
the detection limit of iron in the different assemblies, tissue-mimicking MRI phantoms with 
homogeneously distributed nanomaterial were prepared. 
Although Kuhlpeter et al. found no differences in the R2 and R2* effect comparing low 
quantities of highly iron-loaded cells and high quantities of low iron-loaded cells with 
comparable average iron concentrations per sample [211], we decided to use comparable 
iron loadings and cell numbers per concentration. Also because Hardy and Henkelman 
predicted a difference from numerical simulations, i.e. smaller particles in a larger number 
should be more efficient than larger particles in a smaller number [299]. Therefore, to identify 
the detection limit we prepared phantoms from cells with similar iron loadings and phantoms 
with the respective amounts of naked MNPs and complexes. All samples were diluted and 
homogenously distributed and embedded in the agarose gel phantoms. 
The linear increase of the R2 and R2* relaxation rates with increasing iron concentrations is in 
concordance with previous findings for iron oxides [67, 115, 300, 301]. The chosen baseline 
relaxation mimicked by the phantom [211] was that of normal liver tissue, as HCC and PDAC 
develop in and often metastasize to the liver, respectively. That should enable the transfer of 
the in vitro iron quantification data to in vivo studies. 
Our r2 relaxivities (10 to 286 mM-1 Fe s-1) were within the range or even higher than those of 
clinically used contrast agents which range between 10 – 150 mM-1 Fe s-1 [269] with for 
example 60 mM-1 Fe s-1 for Combidex®/Sinerem®, 98.3 mM-1 Fe s-1 for Feridex® and 151.0 
mM-1 Fe s-1 for Resovist® [55]. The r2* relaxivities calculated from our phantoms 
measurements were higher than the r2 relaxivities, as it was shown by Shapiro et al. and 
Kuhlpeter et al. with significant r2 relaxivity reduction and r2* relaxivity amplification upon 
aggregation, the assembly of MNP-VP complexes and/or further cell internalization [211, 
269], always compared to the relaxivities of the respective amount naked MNPs. Perez et al. 
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also found the T2 signal intensity to decrease upon nanoassembly of herpes simplex or 
adenovirus particles and MNPs labeled with virus-specific antibodies [302, 303]. Others, too, 
saw reduced r2 relaxation rates relative to free particles induced by the intracellular iron 
particle clusterization [211, 285-287, 304, 305]. As reported by others [304], the r2* to r2 ratio 
after particle assembly and/or cell internalization compared to free, suspended particles was 
dramatically increased, especially for the SO-Mag samples (PEI-Mag: 2- to 33-fold, SO-Mag: 
3- to 56-fold). These variations in r2 and r2* relaxivity could be explained by the restricted 
diffusion of water-protons. The lower r2 relaxivities were in concordance with the motional 
narrowing effect [306], the effect of restricted water/proton diffusion after 
compartmentalization [305] and reduced proton relaxation [287]. It was induced by the 
clusterization of MNPs around VPs and/or intracellular compartmentalization. The increased 
diffusion distance of protons along intracellularly clustered MNPs decreased the r2 
relaxivities and increased the r2* relaxivities. In addition, the relatively small field 
inhomogenities induced by small free MNPs in the nanometer range, are potentiated in 
clustered particles of viral complexes and intracellular aggregates that occur in the high nm 
or µm range. Both factors lead to incoherent spin dephasing, and the outer-sphere relaxation 
theory could be applied to explain the r2 relaxivity drop [285]. The static dephasing regime 
theory says that large compartmental magnetic moments produce a strong enough outer-
sphere dipolar field so that diffusion has a minimal effect on the MR signal decay, and this 
decay is unaffected by details of the compact magnetic aggregate shape [304, 307]. Hence 
the aggregation state directly modulated the intracellular relaxivity of the cell and complex 
samples in comparison to free MNPs dispersed in agarose gel. Therefore, r2 is influenced by 
the concentration and the assembly state of the MNPs, r2* is mainly sensitive towards the 
iron concentration, and thus R2*-weighted acquisition was assumed to be the potentially 
most sensitive method to identify the presence of iron-oxide particles and labeled cells [211, 
304]. Therefore, the increased r2* relaxivity of MNP-VP complexes should further enhance 
their non-invasive detectability by MRI. Differences in R2* and r2* between the two particles 
could be explained by Dh-dependent higher diffusion restriction in SO-Mag MNPs as they 
tend to aggregate, even in the dispersed state [103]. 
Leung et al. also analyzed clustered, MNP-labeled cells for their T2 relaxation times. Their 
“blooming” effect of MRI signals [182] was comparable to the signal effects we detected in 
our MRI phantoms of clotted MNPs, MNP-VP complexes, and labeled/infected cells thereof 
in the high iron-load samples (figure 18C). Such blooming of hypointense signals whose 
sizes overran the physical sizes of the samples was also observed in the phantom 
measurements of Pouponneau et al. with a 1.5 T clinical MRI scanner. For their T2*w image 
acquisition they concentrated microcarriers and iron-cobalt-NPs at the bottom of 1.5 mL 
tubes, covered the samples with 2 % agarose gel containing manganese(II) chloride hydrate 
to mimic the relaxation properties of liver tissue, and embedded the tubes in the same 
agarose gel [308]. 
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In general, the local concentration of a contrast agent required for signal detection is a 
limiting factor in its application [132]. In our in vitro liver mimicking phantoms, iron 
concentrations as low as 3 – 8 µM per 105 labeled cells/mL agarose gel were visually 
detectable above the phantom background with sufficient image contrast [139]. Hence the 
detection was more sensitive compared to previous results (25 µM Fe for SO-Mag particles 
[115] and 21 µM Fe for NDT-Mag1 particles [67]; 1.5 T MRI) or the detection limit of for 
example 106 Endorem®-labeled cells per mL gelantin at comparable cell iron loading (25 pg 
Fe/cell   448 µM iron, 3.0 T clinical MRI system) [309]. Our detection limit was within the 
same range as small iron oxide particles (Dh = 17.1 ± 0.9 nm) prepared by Weissleder et al. 
with 2 µM Fe in evenly distributed (5 x 106 cells/mL) or pelleted (105 in 20 µL) cells in 2 % 
agarose gel using a 1.5 T MRI system [292]. Focusing on the determined relaxivities, our 
phantom measurements were comparative. The r2 relaxivity of our virus-complex-labeled 
McA cells with 2.5 pg Fe/cell was 55 mM-1 Fe s-1 (1.5 T MRI), Estapor® labeled neutrophils 
with 2 pg Fe/cell had a r2 relaxivity of 74 mM-1 Fe s-1 (4.0 T MRI) [310]. 
In our measurements, we could show that the data acquired from phantom scans at 1.5 and 
3 T clinical MRI systems were comparable. Field strength independency for T2 relaxation 
times with alterations less than 5 % was also shown by Tofts et al. for their Ni-doped 
agarose gel phantoms with MRI systems from 0.5 to 2.0 T [68]. Stanisz et al. had constant 
data for their comparative measurements from 1.5 to 3 T [47], which is consistent with the 
magnetic field-independent T2 relaxation times observed by Bottomley et al. [311], whereas 
De Bazelaire et al. found the T2 relaxation times to be generally lower at 3.0 T than at 1.5 T 
with tissue-dependent variations in the magnitude of change [312]. 
In future in vivo studies, in particular on viral cancer therapy, such tissue-mimicking 
phantoms could be used in preliminary in vitro tests and applied for the non-invasive 
quantification of exogenic iron from magnetic nanoassemblies by MRI in vivo. For example 
for calibration in studies on orthotopic McA tumor nodules in rats, the described phantoms 
could be used, as this model lacks the underlying liver damage of the human condition and 
the surrounding liver tissue is relatively homogenous [20]. Thereby it should be taken into 
account that such phantoms do not exactly represent the in vivo heterogeneity of human 
HCC. Most HCC patients also suffer from liver cirrhosis, therefore acquired images show 
different signal patterns compared to healthy individuals and between the different patients 
[14, 69]. Pathologic liver tissue is not homogenous throughout, there might be fibrotic 
strands, which result in MR signal drop or void due to the restricted diffusion [313]. Also, 
natural iron content of the livers of patients with varying clinical backgrounds is diverse and 
could lead to different baseline relaxivities. Thus, ideally for each patient, specific phantoms 
with the individual baseline relaxivity would be an option for correct quantification of 
delivered MNP-VP complexes. Calibration measurements should be performed using 
phantoms prepared from cells with internalized complexes rather than from complexes alone 
or naked particles, as this is more close to the cell internalized situation in vivo. 
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In general, all four complex derivates assembled in this study were suitable for in vivo 
applications regarding their size as small vessels typically have a diameter of 7 µm [314]. 
We chose the SO-Mag-VSV complexes in orthotopic HCC liver lesion bearing Buffalo rats. In 
this proof-of-principle study we could show the in vivo applicability of the magnetic viral 
complexes regarding detection and virus delivery. 
Tumor bearing rats were injected with either naked VSV or SO-Mag-VSV complexes and 
after 30 minutes of magnetic targeting, the virus titer in MNP-VSV complex treated animals 
was higher than the titers in animals treated with naked virus. 24 hours after infection, there 
was still a clearly detectable iron-induced MRI signal loss in the tumor lesions of SO-Mag-
VSV complex treated animals, whereas the naked VSV-treated control animal showed no 
signal alteration in their tumors. The same effect of enhanced oncolytic potential of the MNP-
VP complexes over naked virus was shown in in vivo experiments on local application of the 
magnetic complexes of the oncolytic adenovirus in a murine tumor model [103]. 
4.2.2 MNP-siRNA complexes 
Pre-clinical siRNA-based approaches were examined in various studies in the recent years. 
In our nanocarrier system, the siRNA was assembled with an enhancer and magnetic 
nanoparticles, which in parallel enable magnetic targeting and monitoring of the complexes 
after administration in future in vivo applications. In this study, the MNP-siRNA constructs 
were tested for their capability to down-regulate specific genes in cancer cells in a poof-of-
principle study in vitro. Test systems for the knock-down experiments were stably luciferase 
and GFP expressing cell lines. SO-Mag and PEI-Mag particles were chosen as they easily 
assemble with negatively charged siRNA due to their own positive surface charge. 
Non-viral vectors are an interesting and thoroughly tested approach for targeted nucleic acid 
delivery. In several studies, non-viral nanocarriers were loaded with plasmid DNA (pDNA) or 
(si)RNA for therapeutic applications [61, 112, 113, 132, 149, 166, 180-182]. Again, magnetic 
nanoparticles were the core structure facilitating magnetic targeting, and hence contributing 
to transfection enhancement. In addition, they provided stabilization for the sensitive nucleic 
acids. As our selected core-shell type MNPs, in other studies the MNPs were mostly coated 
with cationic polymers or peptides for better binding of the negatively charged DNA and RNA 
molecules via electrostatic interaction [132, 274]. PEI was a widely used molecule [61, 100, 
113, 132, 166] and was also chosen for the surface functionalization of PEI-Mag and SO-
Mag particles [115, 315]. Another exploited feature of PEI was the capability to promote 
endocytosis of particles resulting in rapid and efficient transfection [184], also in HCC cells 
[182]. The influence of sedimentation and magnetofection on the endocytosis was tested in 
various cell lines with PEI-coated SPIO-pDNA complexes. Huth et al. could show that 
endocytosis is not influenced directly by the magnetic field, but indirectly as it accelerates 
the sedimentation onto the cell surface, and thereby enhances the endocytic uptake taking 
place via clathrin-dependent and caveolae-mediated endocytosis [316]. 
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Our study and many others were first proof-of-principle experiments on the capability of the 
new carrier systems to efficiently deliver nucleic acids to a target tissue [100, 112, 180]. 
There, a convenient marker for successful transfection is the expression of reporter genes 
[67, 100, 112, 113, 189]. We chose the widely used reporter genes firefly luciferase and the 
(e)GFP as there are various reporter assays available. Luciferase can easily be quantified 
for example applying luciferase assay for quantitative analysis either after transfection as 
reporter gene [113] or as target in knock-down experiments [100, 112, 180]. In ex vivo and in 
vivo studies, the luciferase expression can be monitored based on its intrinsic capability for 
bioluminescence imaging [111, 190] with subsequent histo-pathologic luciferase staining. 
Techniques to quantify the GFP expression in vitro and ex vivo are for example GFP assay, 
FACS and fluorescence microscopy [112], in vivo, it could serve as an intrinsic fluorescent 
probe for fluorescence imaging [182]. 
Human (HepG2 and HuH-7) and rodent (McA-RH7777) HCC, and human PDAC (EPP85-
181P and EPP85-181RDB) cell lines were analyzed in vitro for the capability to be 
transfected with MNP-siRNA complexes to down-regulate the expression of previously 
inserted firefly luciferase and eGFP reporter genes. A lentiviral vector with the luciferase-
GFP-fusion construct was chosen for this transduction and resulted in stable expression of 
both proof-of-principle target proteins. 
 
Utilizing magnetic siRNA complexes, we could show strong luciferase down-regulation after 
magnetofection compared to non-magnetic DF-Gold-siRNA lipoplexes. The successful 
knock-down was in concordance with previous results on MNP-siRNA complexes. 
Mykhaylyk et al. assembled magnetic siRNA complexes following the same protocol, and 
tested them in vitro in different cell lines [112, 180]. The magnetic MNP-siRNA complexes 
with the enhancer DF-Gold were most efficient for transfection experiments exposed to 
external magnetic fields. Sanchez-Antequera et al. used (magnetic) firefly luciferase pDNA-
loaded complexes for transfection of Jurkat T cells, and compared the transfection 
efficiencies of magnetofection and lipofection [113]. Again, the luciferase expression 
enhancement was better for magnetic MNP-DF-Gold-siRNA complexes compared to DF-
Gold-siRNA lipoplexes. Magnetofection allowed for pDNA delivery to primary mouse 
embryonic fibroblasts and porcine fetal fibroblasts even at low doses of nucleic acid per cell 
bound in magnetic complexes with SO-Mag5 and PEI-Mag2 [150]. Zhao et al. analyzed 
MNPs with PEI-coating and surface-bound pDNA on morphology, assembling structure and 
nucleic acid delivery abilities regarding transfection efficiency, as the MNPs increase DNA 
concentration and prevent DNA from degradation at low toxicity. They found the MNP-to-
DNA ratio to be crucial for the transfection efficiency in mammalian somatic cells [317]. 
 
There were several studies using nucleic acid-MNP complexes in HCC cell lines such as 
HepG2 cells in vitro and in vivo in xenograft models for reporter gene expression [182, 186, 
190], as gene silencing has significant therapeutic promise for the genetic treatment of HCC 
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[4]. The MNPs one hand enabled for magnetic targeting and on the other hand for in vivo 
monitoring of the nanocarrier formulation after administration [4, 182]. Next step after such 
proof-of-principle experiments would be the replacement of the reporter genes by 
application-specific target genes. In HCC and PDAC therapy, a potential target gene for 
therapeutic knock-down approaches is the octamer-binding transcription factor 4 (OCT4). 
This factor is associated with the self-renewal and differentiation of cancer stem cells and 
hence is crucial for the progression of several cancer types [318-320]. Its involvement in the 
tumorigenesis, proliferation and invasion of pancreatic and hepatic cancer cells was shown 
in several studies based on elevated expression levels compared non-cancerous cells [318, 
319, 321, 322]. In HCC, its function is based on a positive feedback loop with the oncogene 
c-JUN [323], in PDAC with AKT pathway-mediated proliferating cell nuclear antigen (PCNA) 
and matrix-metalloproteinase-2 (MMP-2) expression [318]. The knock-down of OCT4 could 
inhibit the proliferation and invasion for example in the human HCC cell line Hep-G2 [323] 
and human PDAC cells Panc-1 [318]. 
4.2.3 Magnetic liposomes 
Magnetic liposomes are the third nanocarrier formulation for targeted delivery examined in 
this study. Liposomal formulations are especially eligible for the delivery of drugs to a target 
tissue. In clinical approaches, the stabilization of the (free) therapeutic agent within the 
bloodstream for longer circulation times, targeted delivery to the destined tissue, and the 
prevention of early inactivation or degradation before even reaching the region of interest are 
driving forces [195]. Functionalized liposomes were examined to address those issues, 
delivery efficacy can be increased, and toxic side-effects decreased [195]. Consisting of a 
lipid bilayer enclosing a liquid filled core, during synthesis a liposome provides binding sites 
for both, hydrophilic and hydrophobic molecules. Hydrophobic molecules can incorporate 
into the lipid bilayer beneath the lipid chains, hydrophilic substances can be encapsulated 
into the aqueous core liquid [197]. 
Three different protocols, thin film hydration [96, 208], reverse phase hydration [191], and 
the injection method, were used to synthesize our magnetic liposomes which all had an 
aqueous core. The additional inclusion of SPIOs made our liposomal formulation suitable for 
magnetic targeting and as MRI-visible probe as it was previously shown by others [4]. To 
support the magnetically targeted delivery, our MNP-LPs were functionalized with tumor cell-
binding surface moieties binding the αvβ3 integrin receptor as ligand. The αvβ3 integrin 
receptor, an angiogenesis marker, is up-regulated in PDAC and HCC, and in its expression 
level often correlated to the tumor grade [4, 59, 208-210]. Surface PEGylation can increase 
liposomal stability in the circulatory system in vivo. The inclusion of the polymer P3C18 into 
the lipid bilayer provided both, PEG groups and an αvβ3 integrin-binding motif. To fully exploit 
the potential of the targetable MNP-LPs, they had to be loaded with a chemotherapeutic 
drug for targeted delivery. The encapsulated drug, PTX in our case, thus would be shielded 
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from clearance and stabilized for longer circulation times. Hence the efficacy after targeted 
delivery could be increased, off-site delivery decreased [195]. Local hyperthermia was 
evaluated for the treatment of cancer cells [59]. Designing the lipid composition of the drug-
loaded MNP-LP accordingly, a controllable temperature-dependent release of the liposomal 
core liquid could further increase the specificity of the formulation and enable local liberation 
of the cargo. To determine the lipid transition temperature of our liposome formulations, the 
calcein release assay was our method of choice [96, 227, 324-327]. 
 
First step in our study was to analyze the MNP-cell interaction. Therefore, several primary 
murine PDAC cell lines and the rat HCC cell line McA were treated with naked PALD2-Mag 
particles and exposed to an external magnetic field. The cells were then analyzed regarding 
cell labeling capacity and iron saturation behavior. MTT viability tests were performed to 
clarify the effect of increasing iron loads. The obtained good labeling capacities at low 
toxicity were comparable to the results obtained analyzing PEI decorated SO-Mag particles 
[115] and provided the basis for further experiments. 
 
Thus after those promising in vitro tests, the MNPs were tested for their toxicity and 
biodistribution in vivo in mice. The animals were intravenously injected with PALD2-Mag 
particles, and after 14 days of careful observation regarding behavioral or physiological 
changes, the animals were sacrificed. Tissue samples from various organs underwent 
quantitative iron analysis and histological Prussian blue staining. 
There were no major MNP-treatment-related alterations. Solely, a few treated animals 
accumulated iron particles in the tail vein at the injection site, probably due to too fast 
injection. As expected the PDAC-positive mice had pancreatic tumors, fibrotic tissue and 
focal areas of inflammation in the pancreas samples. Even without targeting, some of those 
mice accumulated MNPs in their pancreatic cancer nodules. Nearly all liver samples (treated 
and control animals) showed areas of focal inflammation and/or microgranuloma and/or 
focal necrosis, a common finding in BL/6 mice. Almost all animals in the treatment and a fifth 
in the control group had slightly elevated iron levels in the biochemical and histological liver 
tissue analysis, but without pathological tissue changes. The accumulation of SPIOs in the 
liver was expected as this uptake is widely exploited when utilizing the particles as MRI 
contrast agents, later-on the SPIOs would have been metabolized into a soluble, non-
paramagnetic form of iron that become part of the normal iron pool [52, 55]. In spleen 
samples, hemosiderin derived from erythrocytes is considered normal in both, red and white 
pulp, so the positive staining for iron is also not necessarily treatment-related, and was found 
in all treated and almost all untreated animals. Yang et al., too, found high levels of Prussian 
blue-positive cells in the liver and spleen samples of MNP-treated mice when they sacrificed 
the animals 48 hours post-injection [328]. Eosinophilic crystals, which stained positive for 
iron, were found in the lung tissue samples. These needle-shaped crystals were found in the 
cytoplasm of alveolar macrophages as well as free-lying within alveoli, again a structure 
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mainly found in mouse strains on a BL/6 background. It is discussed if they are representing 
eosinophilic granules at various stages of degeneration [329] or hemoglobin breakdown 
following uptake by macrophages [330]. Positive staining for iron was also found in lung 
alveolar cells, and glomeruli and tubules of the kidney cortex region, of our samples, but 
there were no pathological findings. Besides the positive staining in spleen and liver, there 
were also a few animals with scattered iron-positive cells in lung and kidney tissue samples 
of Yang et al. [328]. 
Summarizing this biodistribution and toxicity experiment, there were no pathological findings 
induced by the administered iron particles in the tissue analysis. All animals showed a 
healthy gain of weight and there were no behavioral changes of the animals indicating no 
MNP-related (negative) side-effects. 
 
The cell surface receptor integrin αvβ3 is an angiogenesis marker expressed on activated 
endothelial cells of new vessels. It is up-regulated in newly synthesized tumor blood vessels 
and crucial for tumor metastasis [187]. This, and the expression on tumor cells of various 
cancers such as PDAC and HCC made it a very interesting binding molecule for targeted 
delivery of diagnostic probes and drugs [209, 280-283]. In liver cancer, its expression is 
limited to HCC cells with very rare expression on healthy hepatocytes [4, 187], the same 
pattern could be shown in PDAC patients [209]. Hence the liposomes in our study carried an 
αvβ3 integrin-binding molecule. 
To prove the existence of the integrins αv and β3 on the surface of the chosen primary 
murine PDAC cell lines, the expression of these target structures was tested by Western 
blotting. As described previously [209], we found the integrin β3 expression to be higher than 
the integrin αv expression. 
An established αvβ3-binding molecule is the tripeptide RGD that can be coupled to the 
liposome surface for tumor targeting [4, 186, 207, 208, 331-333]. In our MNP-LPs, the RGD-
like αvβ3 integrin receptor binding motif lysine-serine-serine-C18 (LSS-C18) was integrated in 
the P3C18 polymer and included into the lipid bilayer of the liposome. Their surface was 
modified with 6 such LSS-C18 chains and 7 PEGs per polymer molecule. The polymer chains 
surrounded the liposome in a bow-like manner, and in vivo the PEG molecules in the P3C18 
polymer coating would shield the liposomes to prevent from early RES-phagocytosis. That 
probably could increase the circulation time 2- to 3-fold for target tissue delivery via EPR 
[198]. Caldorera-Moore et al. postulated the αvβ3 integrin to be an optimal targeting ligand for 
their theranostic liposomes loaded with an imaging probe and a drug. Hence, the surface 
was modified with an RGD peptide [334], a setup comparable to our magnetic liposome 
design. Additional coating of the liposome with PEI could optimize the cellular uptake as it 
was shown for RGD motif-containing peptides [132, 335]. Conjugation of the RGD peptide 
onto PEI enabled targeting for liposomal luciferase pDNA delivery in vitro into HepG2 cells 
[186] or siRNA to the human HCC cell line Bel-7402 in an in vivo nude mouse xenograft 
model [4].  
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After the preliminary experiments regarding the tolerability of the PALD2-Mag particles in 
vitro and in vivo, and the proof of αvβ3 integrin receptor expression in the chosen cancer cell 
lines, magnetic liposomes were synthesized and examined using three different protocols. 
Most common technique for liposome synthesis used in the literature is the thin film 
hydration [96, 193, 208, 213, 214, 223, 225, 325, 336-339]. Another protocol is the reverse 
phase hydration [191, 222, 232, 340]. The third technique, the injection method, was 
developed in our lab. 
The size of our magnetic liposomes was around 100 nm to exploit the EPR effect applicable 
for particles smaller than 200 nm [341]. The commercially available and clinically used 
liposomal doxorubicin-loaded formulation Caelyx®/Doxil® has a size of 86 ± 1 nm, being 
slightly smaller than we intended our liposomes to be [96-98]. 100 nm as optimal liposome 
size was supported by Kono et al.s finding of better accumulation at the tumor site for 
liposomes of around 100 nm in diameter rather than for 50 nm liposomes [229]. 
As the magnetic liposomes would be utilized for magnetic targeting, their responsiveness in 
external magnetic fields had to be ensured. Hence for characterization of the MNP-LPs, the 
optimal wavelength for photometrical analysis of the PALD2-Mag particles and formulations 
encapsulating them had to be identified. Analogous to the SO-Mag and PEI-Mag particles 
[115, 139, 180], an analytical wavelength of 350 nm was determined from wavelength scans 
[112]. Then the magnetophoretic mobility of the liposomes was tested in the same setup as 
the magnetic viral complexes [105, 112, 113, 139, 342]. The detected magnetic 
sedimentation behavior of the MNP-LPs was comparable to the data of magnetic lipoplexes 
of Sanchez-Antequera et al. [113], the very slow sedimentation of naked, suspended MNPs 
was comparable to that of the MNP-VP complexes with the lowest virus load of Tresilwised 
et al. [105] and the PALD2-Mag-siRNA complexes of Mykhaylyk et al. [112]. In addition, the 
influence of an external magnetic field on a suspension of magnetic liposomes was 
visualized under the microscope. MNP-LPs were prepared with atto550 fluorescent dye 
coupled to 20 % of the deployed P3C18 polymer. The magnet was placed besides the sample 
slide and the liposomes immediately started moving towards it and accumulated at the air-
liquid-interface next to the magnet. The same behavior was observed by Pradhan et al. 
[272]. Those results strongly suggested the capability of our magnetic liposomes to be used 
as vehicle for magnetic drug targeting approaches. 
 
Besides the possibility to magnetically alter the MNP-LP distribution and accumulation in 
vivo after administration, the MNPs themselves could serve as contrast agents for non-
invasive monitoring via MRI. There were several studies deploying liposome encapsulated 
MNPs as imaging probes in T2 and T2* imaging to real-time follow their localization [4, 191, 
343, 344]. In in vivo experiments on the biodistribution of non-targeted MNP-LPs, we could 
show the accumulation of non-targeted liposomes in the liver tissue of wildtype mice by T2* 
MR imaging and the results correlated with the corresponding Prussian blue staining 
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histology. As expected [63, 139, 211], they accumulated in the liver and led to hypointense 
signal in T2* dynamic MRI scans. 
In a second in vivo approach on the magnetic targeting of MNP-LPs, we could show the 
accumulation of the liposomes in endogenous pancreatic tumors, though there was no 
further improvement between the magnetically targeted and the non-targeted liposome 
control groups. Compared to the first non-targeted biodistribution experiment, there was less 
accumulation in the livers indicating an overall successful targeting towards the PDAC within 
the circulation time (1 hour) at reduced unspecific liver uptake. For example Wu et al. could 
also successfully target their magnetic liposomes towards HCC xenograft lesions [4]. 
Babinkova et al. were among the first applying MRI probe-labeled liposomes for real-time 
monitoring in vivo. They were able to show their accumulation at the target site and that 
success encouraged further magnetic targeting approaches to increase the amount of 
accumulated nanocarriers [212]. 
Without stabilizing PEG, magnetic liposomes were metabolized by cells of the mononuclear 
phagocyte system and accumulated in liver, spleen and bone marrow. There, they were 
used for tumor detection, especially in liver diseases [345]. Inclusion of PEGylated lipids 
such as DSPE-PEG2000 prevented opsonization via “mushroom brush boundary”-formation 
[346, 347]. Yang et al. PEGylated their MNP-LPs for reduced liver macrophage 
phagocytosis, confirmed by less T2 signal reduction in the liver, and thus prolonged 
circulation times to provide a higher chance of target binding, [224]. In in vitro and in vivo 
PDAC models of human Panc-1 cells and xenograft tumors in mice, USPIO-loaded LPs 
were successfully applied as contrast probes in MRI [191]. Besides the utilization of SPIOs, 
Gd-chelates are applied as contrast agent in several studies on pre-clinical liposomes [206, 
207, 213, 214, 229, 230, 324, 348]. Lorenzato et al. tested dually functionalized liposomes 
loaded with USPIOs and Gd-chelates for MR-guided focused US and hyperthermia-induced 
drug release [231]. Recently, Martinez-Gonzalez et al. found SPIONs to be less toxic than 
Gd-DTPA [231], nevertheless liposomes loaded with gadolinium were widely used for T1 
weighted imaging and accumulation monitoring in vivo [214]. 
 
To further improve the (magnetic) liposome properties for clinical demands, lipids can be 
selected to form thermosensitive lipid bilayers. This makes the LPs eligible in hyperthermia 
applications. Hyperthermic treatment of tumor lesions is a common therapeutic approach as 
the heating of tumor cells was shown to induce cell death [59] and to increase the vessel 
permeability for increased EPR-mediated drug delivery [221]. Thermosensitive liposomes 
release their load at the target site after local temperature increase, and by that increase 
drug delivery efficiency and reduce side-effects from drug release at non-target tissues. 
A convenient approach to prove the temperature-dependent release of the core liquid is the 
encapsulation of a fluorescent probe [225]. Due to its water solubility, for example calcein 
could be loaded into the liposomes during synthesis, and its liberation detected fluometrically 
[96, 227, 324-327]. In our calcein release assay, tested aspects were the comparison of 
Discussion 
 104 
different lipid compositions and determination of the respective lipid transition temperatures 
Tm., calcein release in the presence of serum, and different synthesis protocols. Therefore, 
liposomal suspensions were incubated at the chosen temperatures and samples were taken 
in 15-minute-intervals at different incubation temperatures ranging from 37 to 42 °C. 
We determined the lipid transition temperature to be 42 °C for all three lipid compositions a, 
b and b*. Though for lipid formulation b, we expected Tm to be 41 °C analogue to Tai et al. 
[225]. Most probably the temperature shifted due to the P3C18 polymer in the liposome 
bilayer that was used instead of the PEGylated lipid. The presence of FCS had only minor 
influence on the calcein release. Whereas the preparation technique emerged as crucial, 
calcein encapsulation was not successful applying the injection method. The calcein release 
from TFH liposomes started after 60 minutes incubation time at 37 °C, which should allow 
circulating LPs to reach the target region in in vivo approaches. At higher incubation 
temperatures, the release started earlier: Per 1 °C increased temperature, released calcein 
could be detected 15 minutes earlier. Calcein release beginning between 37 and 39 °C after 
60 and 45 minutes incubation, respectively, was in concordance with results on similar 
liposomal preparations [324]. 
An overall aim in thermosensitive LPs was to tune the drug release above 40 °C to prevent 
unspecific liberation before reaching the target region [96, 193, 213, 222, 223, 225, 228-
232]. With Tm values above 40 °C in all tested formulations, we could meet this criteria. In 
vivo, the fast and controlled release of encapsulated substances at the target site could be 
facilitated by local hyperthermia treatments for example via external water baths, heat pads, 
near-infrared laser pulsed or pulsed high-intensity focused ultrasound (HIFU) [226]. Even if 
the release would start 1-2 °C below Tm as shown by Kong et al. [349], there would be only 
little drug leakage after administration in vivo, as normal body temperature lies between 36 
and 37 °C. 
ThermoDOX® is a clinically approved, thermosensitive formulation of DOX loaded 
liposomes. In several clinical trials, is was tested for application in (metastatic) HCC [233-
237], partly in combination with RFA, and breast cancer patients [238-241]. Transition 
temperature of the preparation consisting of DPPC:MSPC:PEG at 86.5:9.7:3.8 is Tm = 41.3 
°C, therefore it is suitable for mild hyperthermia treatment at 41 – 42 °C [221]. In general, 
thermosensitivity could be tuned by including DPPC and cholesterol with transition 
temperatures of Tm = 41.5 – 41.6 °C (peak 38 – 42 °C) for DPPC [96, 221] and Tm = 39.7 °C 
(peak 36 – 48 °C) for cholesterol [96]. Other possible lipids are DSPE-PEG with Tm = 41.3 
°C (37 – 49 °C), DSPE-PEG-folate with Tm = 41.1 °C (37 – 49 °C) [96], HSPC with Tm = 54 
°C [208] and DSPC with a Tm of 43 – 45 °C [350]. The addition of PEG lowered the transition 
temperature, and led to faster release at Tm, better stability below Tm and higher drug 
delivery, also farther from the vessels [221]. There also seemed to be an inverse correlation 
of the phase transition temperature of the main lipid component and the toxicity of the 
formulation [198].  
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To obtain therapeutic liposomes, (chemotherapeutic) drugs can be incorporated during 
liposome synthesis. Commercially examined and approved options for drug-loading into 
liposomes were paclitaxel (EndoTAGTM [351]) and doxorubicin (Caelyx®/Doxil® [99]), but both 
are non-targeted formulations relying on tumor cell delivery via the EPR effect. Hydrophilic 
drugs can be loaded into the liposomes during synthesis by solving them in the liquid phase, 
hydrophobic drugs need either to be modified to hydrophilic pro-drugs or partition into the 
lipid bilayer during synthesis. An example for hydrophilic pro-drugs are 4-(N)-acyl-
gemcitabine derivates [352, 353]. PTX is water-soluble and could directly be encapsulated 
during liposome synthesis [204, 354, 355]. For the lipophilic drug DOX, gradient 
encapsulation led to better drug retention in the liposome [198]. We decided to use paclitaxel 
as chemotherapeutic drug, as the EndoTAGTM liposomes were examined in a controlled 
phase II clinical trial with advanced PDAC patients in a combination approach with 
gemcitabine. Löhr et al. could show reduced side-effects and improved survival of the patient 
cohort [351]. We received best qualitative results for MNP-LPs loaded with paclitaxel in a 
1:33 PTX:lipid molar ratio. EndoTAGTM liposomes are prepared at 1:32 PTX:lipid molar ratio 
[351], comparable to our PTX-loaded MNP-LPs. In other pre-clinical studies on PTX-loaded 
liposomes, the drug content varied between up to 1:3 PTX:lipid [356], 1:5 [223], 1:20 [357], 
1:30 [358] and 1:33 [204, 354, 355], to 1:40 [359, 360], 4 mol% [361] and only 1 % w/w 
[362]. Our PTX-loaded MNP-LPs were synthesized from DPPC/Chol/ P3C18 applying the 
TFH method and proven to be stable for at least two weeks at 4 °C after qualitative 
storability monitoring. The loading of MNPs with PTX before loading both components into 
the liposomes could not be shown properly. Cholesterol was included in the lipid mix in DOX 
liposomes, as the absence of cholesterol was found to lead to destabilization and toxicity, 
whereas increasing acyl-chain length and saturation enhanced the drug encapsulation 
capacity [198]. 
Generally, drug-loaded MNP-LPs are an interesting formulation. Zhang et al. postulated 
greater potency over just drug-loaded liposomes based on a more gradual and less abrupt 
drug release due to the iron oxide core from their in vivo data on a breast cancer model 
[363]. Due to the shift of emphasis during this thesis project, that formulation was not tested 
in vitro or in vivo for its anti-tumoral efficiency. 
 
Taking together the examined functionalization possibilities of MNP-LP formulations, applied 
in vivo they enable for the MRI-guided visualization of biodistribution and delivery, supportive 
magnetic targeting by external magnetic fields, enhanced binding at the target tissue due to 
the αvβ3 integrin receptor binding motif, and temperature-induced drug release from 
thermosensitive liposomes at mild hyperthermia of 42 °C. Similar approaches led to 
successful studies in vitro and tumor specific targeted delivery in vivo in rodent HCC and 
PDAC models [213, 214, 226, 229, 230, 343, 350]. 
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5 CONCLUSION and OUTLOOK 
This work on three different types of magnetic nanocarriers, namely MNP-VP complexes, 
MNP-siRNA complexes and magnetic liposomes, was done to identify and examine the 
potential of each formulation in diagnosis and therapy of gastro-intestinal cancers, especially 
HCC and PDAC. Core component of all magnetic nanocarriers were MNPs. The magnetic 
moment and high surface area-to-volume ratio made the chosen core-shell type iron oxide 
MNPs ideal candidates for nanocarrier assembly, and as imaging probe for non-invasive and 
real-time monitoring of the formulation via MRI. 
 
Summarizing, it can be said that the variety of carrier formulations equipped with different 
properties allow for the application in various clinical questions, as each holds specific 
advantages. 
The approach to treat tumors with oncolytic viruses is still limited by the inactivation of virus 
particles in the circulatory system. The delivery efficiency could greatly be enhanced by 
assembly with magnetic nanoparticles and magnetic targeting towards the region of interest. 
MNP-VP complexes have shown efficient transfection rates and oncolytic activity in in vitro 
assays with HCC and PDAC cell lines. Tissue-mimicking in vitro phantoms of free and cell-
internalized MNP-VP complexes revealed excellent MRI properties for very sensitive 
imaging in future in vivo therapy monitoring. The agarose phantoms could serve as tool to 
optimize scan protocols and to evaluate nanocarrier concentrations needed for sufficient 
imaging contrast in in vivo applications. In vivo, the viral vectors were magnetically 
targetable towards orthotopic HCC lesions after intra-hepatic injection, and followed by 
successful virus replication within the tumor cells. In further approaches, the MNP-VP 
complexes could be shielded for example with organic structures to achieve a stable 
formulation for intra-arterial or systemic intravenous administration. Thereby, the diagnosis 
and treatment of metastases could be improved over the state-of-the-art therapy. 
 
Non-viral magnetic complexes with nucleic acids were successfully applied for gene 
silencing in in vitro model cancer cell lines, and have the potential for nucleic acid therapy 
approaches in clinical questions when loaded with target-specific nucleic acids. The packing 
of nucleic acids with MNPs and eventual further functionalization of those assemblies again 
shields the sensitive nucleic acids from early degradation and enables for targeted delivery. 
Examined MNP-siRNA complexes successfully could be applied for knock-down 
experiments in (primary) HCC and PDAC cell lines in vitro. Analogue to the formulations in 
those proof-of-principle experiments, MNP-siRNA complexes for oncogene down-regulation 
could be assembled in future experiments. Potential target gene in the therapy of HCC and 
PDAC is the octamer-binding transcription factor 4 (OCT4). 
 
Magnetic liposomes can be loaded with drugs and synthesized to carry surface binding sites 
required for target tissue-specific delivery. Such nanocarrier formulations allow for long 
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circulation times, utilizing local accumulation via the EPR effect in tumor tissue. Additional 
accumulation is facilitated by the surface moieties binding to target cells and magnetic 
targeting. The therapeutic cargo can be released from the thermosensitive liposomes by 
exposure to local hyperthermia. 
Naked MNPs and magnetic liposomes were tested in vitro and in vivo regarding their 
biodistribution, toxicity and targeting capability. No pathologic MNP-induced tissue 
alterations could be detected among the treated wildtype and endogenous PDAC-bearing 
model mice. Thermosensitive PTX-loaded MNP-LPs, partly functionalized with a αvβ3 integrin 
receptor binding motif, were characterized for their physico-chemical properties. They had 
the desired size of about 100 nm in diameter, and their surface was PEG-functionalized for 
stabilization, either as lipid moiety or from the polymer P3C18, which was incorporated in the 
lipid bilayer. Advantage of the polymer was its capability to bind αvβ3 integrins, expressed on 
HCC and PDAC cells. Thermosensitive LPs are capable of temperature-dependent release 
of encapsulated drugs with good local controllability. Tm of our tested liposomes was 42 °C, 
a temperature clinically used in mild hyperthermia treatment regimes. The release at 
temperatures below Tm started only after long circulation times, giving tolerable time 
windows for sufficient accumulation at the target site in vivo. In further experiments, the anti-
tumoral efficiency of drug-loaded MNP-LPs has to be examined in detail in vitro and in vivo. 
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6 SUPPLEMENT 
 
Figure 43: Cancer mortality rates in the European Union (per 100,000 with age adjusted to the 
European standard; 2011-13). A: HCC, B: PDAC (modified from [9-11]) 
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Figure 44: Calcein release assay of thermosensitive liposomes. Calcein release assay of TFH 
(left column) and injection method (right column) liposomes in PBS and 50% FCS plotted as calcein 
release versus time for all temperatures. 
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Table 12: MNPs in vivo: genetic background of the treated mice and experimental setup. 
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Table 13: Scoresheet for evaluation of the animals in in vivo studies. 
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Table 14: r2 and r2* relaxivities of the MNP assemblies. Analogue to table 11, this table compiles 
the r2 and r2* relaxivity data in liver-mimicking agarose phantoms, the ratios of the nanoassembly 
relaxivity normalized to the relaxivity of free MNPs (r2/r2(MNP) and r2*/r2*(MNP), respectively), and the 
r2* / r2 ratios. All measurements were performed using a clinical 3.0 T Ingenia MRI system. 
Sample 
 
PEI-Mag2 SO-Mag6-11.5 
r2 ratio  r2*  ratio  r2*/r2  r2 ratio  r2*  ratio  r2*/r2  
[mM-1 
Fe s-1]  [%]  
[mM-1 
Fe s-1]  [%]  
[mM-1 
Fe s-1]  [%]  
[mM-1  
Fe s-1]  [%]  
MNP  238 ± 11 100 476 ± 58 100 2.0 274 ± 10 100 857 ± 12 100 3.1 
MNP 
in McA 
55 ± 5 
23 
584 ± 17 
123 10.6 
37 ± 3 
14 
788 ± 12 
92 21.3 (4.5 pg 
Fe/cell) 
(4.5 pg 
Fe/cell) 
(5.4 pg 
Fe/cell) 
(5.4 pg 
Fe/cell) 
MNP-VSV 
MNP-VSV  
in McA 
23 ± 3 
10 
518 ± 8 
109 22.5 
57 ± 2 
21 
1494 ± 42 
174 26.2 (3.2 pg 
Fe/cell) 
(3.2 pg 
Fe/cell) 
(2.5 pg 
Fe/cell) 
(2.5 pg 
Fe/cell) 
MNP 
in RDB 
19 ± 1 
8 
560 ± 23 
118 29.5 
38 ± 2 
14 
1203 ± 118 
140 31.7 (17.3 pg 
Fe/cell) 
(17.3 pg 
Fe/cell) 
(15.9 pg 
Fe/cell) 
(15.9 pg 
Fe/cell) 
MNP-Ad 124 ± 13 52 542 ± 19 114 4.4 18 ± 2 7 1004 ± 32 117 55.8 
MNP-Ad  
in RDB 
21 ± 3 
9 
757 ± 22 
159 36.0 
8 ± 6 
3 
412 ± 26 
48 51.5 (6.7 pg 
Fe/cell) 
(6.7 pg 
Fe/cell) 
(7.4 pg 
Fe/cell) 
(7.4 pg 
Fe/cell) 
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